{"PMC5492287": [["BackgroundCoccidiosis is a major parasitic disease affecting a wide range of livestock and wild animals globally.", [["BackgroundCoccidiosis", "DISEASE", 0, 21], ["parasitic disease", "DISEASE", 33, 50], ["a major parasitic disease", "PROBLEM", 25, 50], ["major", "OBSERVATION_MODIFIER", 27, 32], ["parasitic disease", "OBSERVATION", 33, 50], ["wide", "OBSERVATION_MODIFIER", 63, 67], ["range", "OBSERVATION_MODIFIER", 68, 73], ["livestock", "OBSERVATION_MODIFIER", 77, 86]]], ["In pigs, Cystoisospora suis (syn.", [["pigs", "ORGANISM", 3, 7], ["Cystoisospora suis", "ORGANISM", 9, 27], ["pigs", "SPECIES", 3, 7], ["Cystoisospora suis", "SPECIES", 9, 27], ["pigs", "SPECIES", 3, 7], ["Cystoisospora suis", "SPECIES", 9, 27]]], ["Isospora suis) is the most pathogenic species of swine coccidian and most severely affects suckling piglets [1\u20134].", [["coccidian", "ANATOMY", 55, 64], ["Isospora suis", "DISEASE", 0, 13], ["swine coccidian", "DISEASE", 49, 64], ["Isospora suis", "ORGANISM", 0, 13], ["swine", "ORGANISM", 49, 54], ["piglets", "ORGANISM", 100, 107], ["Isospora suis", "SPECIES", 0, 13], ["swine", "SPECIES", 49, 54], ["piglets", "SPECIES", 100, 107], ["Isospora suis", "SPECIES", 0, 13], ["swine", "SPECIES", 49, 54], ["Isospora suis", "PROBLEM", 0, 13], ["most pathogenic", "OBSERVATION_MODIFIER", 22, 37], ["most severely", "OBSERVATION_MODIFIER", 69, 82]]], ["Clinical signs include pasty to watery non-hemorrhagic diarrhea, weight loss and ill thrift [5\u201310].", [["pasty", "DISEASE", 23, 28], ["diarrhea", "DISEASE", 55, 63], ["weight loss", "DISEASE", 65, 76], ["Clinical signs", "TEST", 0, 14], ["pasty", "PROBLEM", 23, 28], ["watery non-hemorrhagic diarrhea", "PROBLEM", 32, 63], ["weight loss", "PROBLEM", 65, 76], ["ill thrift", "PROBLEM", 81, 91], ["non-hemorrhagic", "OBSERVATION_MODIFIER", 39, 54], ["diarrhea", "OBSERVATION", 55, 63], ["weight loss", "OBSERVATION_MODIFIER", 65, 76]]], ["At present, cystoisosporosis is considered as one of the leading causes of diarrhea in neonatal piglets with high prevalences worldwide [3, 7, 11\u201314].", [["cystoisosporosis", "DISEASE", 12, 28], ["diarrhea", "DISEASE", 75, 83], ["piglets", "ORGANISM", 96, 103], ["piglets", "SPECIES", 96, 103], ["cystoisosporosis", "PROBLEM", 12, 28], ["diarrhea", "PROBLEM", 75, 83], ["neonatal piglets", "PROBLEM", 87, 103], ["cystoisosporosis", "OBSERVATION", 12, 28], ["diarrhea", "OBSERVATION", 75, 83]]], ["Oocysts are highly resistant to desiccation and antimicrobial compounds [14, 15] making elimination virtually impossible once they have been introduced into the farm.", [["Oocysts", "ANATOMY", 0, 7], ["Oocysts", "PROBLEM", 0, 7], ["antimicrobial compounds", "TREATMENT", 48, 71], ["resistant", "OBSERVATION_MODIFIER", 19, 28], ["antimicrobial compounds", "OBSERVATION_MODIFIER", 48, 71]]], ["The disease shows a very high morbidity with low mortality, and not all the piglets in a litter are equally affected, resulting in reduced, uneven weaning weights and thus, ultimately in often significant economic losses [5, 11, 16, 17].BackgroundIn the European Union (EU), control of cystoisosporosis is commonly achieved with a single oral administration of toltrazuril in the prepatent period (day 3\u20135 of life).", [["oral", "ANATOMY", 338, 342], ["cystoisosporosis", "DISEASE", 286, 302], ["toltrazuril", "CHEMICAL", 361, 372], ["toltrazuril", "CHEMICAL", 361, 372], ["piglets", "ORGANISM", 76, 83], ["oral", "ORGANISM_SUBDIVISION", 338, 342], ["toltrazuril", "SIMPLE_CHEMICAL", 361, 372], ["piglets", "SPECIES", 76, 83], ["The disease", "PROBLEM", 0, 11], ["a very high morbidity", "PROBLEM", 18, 39], ["low mortality", "PROBLEM", 45, 58], ["significant economic losses", "PROBLEM", 193, 220], ["cystoisosporosis", "PROBLEM", 286, 302], ["toltrazuril", "TREATMENT", 361, 372], ["disease", "OBSERVATION", 4, 11], ["very", "OBSERVATION_MODIFIER", 20, 24], ["high", "OBSERVATION_MODIFIER", 25, 29], ["morbidity", "OBSERVATION", 30, 39], ["low mortality", "OBSERVATION_MODIFIER", 45, 58], ["reduced", "OBSERVATION_MODIFIER", 131, 138], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["economic losses", "OBSERVATION", 205, 220]]], ["Baycox\u00ae is the trade name of a broad spectrum anticoccidial drug containing the triazine trione toltrazuril [18].", [["Baycox\u00ae", "CHEMICAL", 0, 7], ["triazine", "CHEMICAL", 80, 88], ["toltrazuril", "CHEMICAL", 96, 107], ["triazine trione", "CHEMICAL", 80, 95], ["toltrazuril", "CHEMICAL", 96, 107], ["Baycox\u00ae", "SIMPLE_CHEMICAL", 0, 7], ["triazine trione", "SIMPLE_CHEMICAL", 80, 95], ["a broad spectrum anticoccidial drug", "TREATMENT", 29, 64], ["the triazine trione toltrazuril", "TREATMENT", 76, 107]]], ["Use of Baycox\u00ae in piglet coccidiosis was first authorized in Australia in 1998 to be administered once in the first week of life at a dose of 20 mg/kg body weight (BW) [19].", [["body", "ANATOMY", 151, 155], ["Baycox\u00ae", "CHEMICAL", 7, 14], ["coccidiosis", "DISEASE", 25, 36], ["Baycox\u00ae", "SIMPLE_CHEMICAL", 7, 14], ["piglet", "ORGANISM", 18, 24], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["piglet", "SPECIES", 18, 24], ["piglet", "SPECIES", 18, 24], ["Baycox\u00ae", "TREATMENT", 7, 14], ["piglet coccidiosis", "PROBLEM", 18, 36], ["coccidiosis", "OBSERVATION", 25, 36]]], ["A single oral treatment with toltrazuril administered during the prepatent period provided effective and sustained suppression of oocyst shedding and diarrhea in piglets experimentally infected with C. suis [17, 20\u201322] and under field conditions [23\u201328].", [["oral", "ANATOMY", 9, 13], ["oocyst", "ANATOMY", 130, 136], ["toltrazuril", "CHEMICAL", 29, 40], ["diarrhea", "DISEASE", 150, 158], ["toltrazuril", "CHEMICAL", 29, 40], ["oral", "ORGANISM_SUBDIVISION", 9, 13], ["toltrazuril", "SIMPLE_CHEMICAL", 29, 40], ["piglets", "ORGANISM", 162, 169], ["C. suis", "ORGANISM", 199, 206], ["piglets", "SPECIES", 162, 169], ["C. suis", "SPECIES", 199, 206], ["piglets", "SPECIES", 162, 169], ["C. suis", "SPECIES", 199, 206], ["A single oral treatment", "TREATMENT", 0, 23], ["toltrazuril", "TREATMENT", 29, 40], ["the prepatent period", "TREATMENT", 61, 81], ["oocyst shedding", "PROBLEM", 130, 145], ["diarrhea", "PROBLEM", 150, 158], ["oocyst", "OBSERVATION", 130, 136]]], ["However, emerging resistance in poultry coccidia against anticoccidials including toltrazuril is of growing concern [29\u201331].", [["poultry coccidia", "DISEASE", 32, 48], ["toltrazuril", "CHEMICAL", 82, 93], ["toltrazuril", "CHEMICAL", 82, 93], ["poultry coccidia", "ORGANISM", 32, 48], ["toltrazuril", "SIMPLE_CHEMICAL", 82, 93], ["poultry", "SPECIES", 32, 39], ["emerging resistance in poultry coccidia", "PROBLEM", 9, 48], ["toltrazuril", "TREATMENT", 82, 93]]], ["Constant treatment regimens with toltrazuril have been applied for controlling porcine cystoisosporosis in the EU for almost two decades now, but the possibility of resistance development in C. suis isolates has not been addressed so far, despite limited availability of treatment alternatives.", [["toltrazuril", "CHEMICAL", 33, 44], ["cystoisosporosis", "DISEASE", 87, 103], ["toltrazuril", "CHEMICAL", 33, 44], ["toltrazuril", "SIMPLE_CHEMICAL", 33, 44], ["porcine", "ORGANISM", 79, 86], ["C. suis", "ORGANISM", 191, 198], ["isolates", "ORGANISM", 199, 207], ["C. suis", "SPECIES", 191, 198], ["C. suis", "SPECIES", 191, 198], ["Constant treatment regimens", "TREATMENT", 0, 27], ["toltrazuril", "TREATMENT", 33, 44], ["controlling porcine cystoisosporosis", "PROBLEM", 67, 103], ["resistance development in C. suis isolates", "PROBLEM", 165, 207], ["treatment alternatives", "TREATMENT", 271, 293], ["porcine cystoisosporosis", "OBSERVATION", 79, 103]]], ["In 2014, a pig farmer in The Netherlands, with a farrow-to-finish herd of 330 sows, complained about pasty feces in 60% of the piglets from 10 days of age until weaning despite treatment with the recommended dose of toltrazuril.", [["pasty feces", "ANATOMY", 101, 112], ["pasty feces", "DISEASE", 101, 112], ["toltrazuril", "CHEMICAL", 216, 227], ["toltrazuril", "CHEMICAL", 216, 227], ["pig", "ORGANISM", 11, 14], ["feces", "ORGANISM_SUBDIVISION", 107, 112], ["piglets", "ORGANISM", 127, 134], ["toltrazuril", "SIMPLE_CHEMICAL", 216, 227], ["pig", "SPECIES", 11, 14], ["piglets", "SPECIES", 127, 134], ["pig", "SPECIES", 11, 14], ["treatment", "TREATMENT", 177, 186], ["toltrazuril", "TREATMENT", 216, 227]]], ["The involvement of bacterial and viral pathogens was excluded as the possible pathogens associated with piglets\u2019 diarrhea could neither be re-isolated nor be detected by polymerase chain reaction (PCR).", [["diarrhea", "DISEASE", 113, 121], ["piglets", "ORGANISM", 104, 111], ["piglets", "SPECIES", 104, 111], ["piglets", "SPECIES", 104, 111], ["bacterial and viral pathogens", "PROBLEM", 19, 48], ["pathogens", "PROBLEM", 78, 87], ["piglets", "PROBLEM", 104, 111], ["diarrhea", "PROBLEM", 113, 121], ["polymerase chain reaction", "PROBLEM", 170, 195], ["PCR", "TEST", 197, 200], ["bacterial", "OBSERVATION_MODIFIER", 19, 28], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["pathogens", "OBSERVATION", 39, 48]]], ["Presence of villous atrophy and fusion in the histological sections of jejunum indicated cystoisosporosis [32, 33], which was later confirmed by the detection and isolation of C. suis oocysts in the fecal samples.", [["villous", "ANATOMY", 12, 19], ["sections", "ANATOMY", 59, 67], ["jejunum", "ANATOMY", 71, 78], ["fecal samples", "ANATOMY", 199, 212], ["villous atrophy", "DISEASE", 12, 27], ["cystoisosporosis", "DISEASE", 89, 105], ["villous", "TISSUE", 12, 19], ["jejunum", "ORGAN", 71, 78], ["C. suis oocysts", "ORGANISM", 176, 191], ["fecal samples", "ORGANISM_SUBSTANCE", 199, 212], ["C. suis", "SPECIES", 176, 183], ["C. suis", "SPECIES", 176, 183], ["villous atrophy", "PROBLEM", 12, 27], ["fusion", "TREATMENT", 32, 38], ["cystoisosporosis", "PROBLEM", 89, 105], ["the detection", "TEST", 145, 158], ["C. suis oocysts", "PROBLEM", 176, 191], ["the fecal samples", "TEST", 195, 212], ["villous atrophy", "OBSERVATION", 12, 27], ["fusion", "OBSERVATION", 32, 38], ["jejunum", "ANATOMY", 71, 78], ["cystoisosporosis", "OBSERVATION", 89, 105], ["suis oocysts", "OBSERVATION", 179, 191], ["fecal", "ANATOMY", 199, 204]]], ["Evaluation of the administered amount of toltrazuril on the farm level revealed no under-dosing.", [["toltrazuril", "CHEMICAL", 41, 52], ["toltrazuril", "CHEMICAL", 41, 52], ["toltrazuril", "SIMPLE_CHEMICAL", 41, 52], ["Evaluation", "TEST", 0, 10], ["toltrazuril", "TREATMENT", 41, 52], ["the farm level", "TEST", 56, 70], ["no", "UNCERTAINTY", 80, 82]]], ["Moreover, application of twice the recommended dose (40 mg/kg) of toltrazuril also did not have any effect on the clinical picture and thus loss of efficacy was suspected.", [["toltrazuril", "CHEMICAL", 66, 77], ["toltrazuril", "CHEMICAL", 66, 77], ["toltrazuril", "SIMPLE_CHEMICAL", 66, 77], ["toltrazuril", "TREATMENT", 66, 77], ["loss of efficacy", "PROBLEM", 140, 156]]], ["In the present study, the efficacy of toltrazuril against C. suis infections in suckling piglets was evaluated in experimental infections with the mentioned field isolate, Holland-I, and a toltrazuril-sensitive strain, Wien-I.", [["toltrazuril", "CHEMICAL", 38, 49], ["C. suis infections", "DISEASE", 58, 76], ["infections", "DISEASE", 127, 137], ["toltrazuril", "CHEMICAL", 189, 200], ["toltrazuril", "CHEMICAL", 38, 49], ["toltrazuril", "CHEMICAL", 189, 200], ["toltrazuril", "SIMPLE_CHEMICAL", 38, 49], ["C. suis", "ORGANISM", 58, 65], ["piglets", "ORGANISM", 89, 96], ["toltrazuril", "SIMPLE_CHEMICAL", 189, 200], ["C. suis", "SPECIES", 58, 65], ["piglets", "SPECIES", 89, 96], ["C. suis", "SPECIES", 58, 65], ["Holland-I", "SPECIES", 172, 181], ["Wien-I.", "SPECIES", 219, 226], ["the present study", "TEST", 3, 20], ["toltrazuril", "TREATMENT", 38, 49], ["C. suis infections", "PROBLEM", 58, 76], ["suckling piglets", "PROBLEM", 80, 96], ["experimental infections", "PROBLEM", 114, 137], ["a toltrazuril", "TREATMENT", 187, 200], ["infections", "OBSERVATION", 127, 137]]], ["In the past, experimental studies have indicated development of resistance under field conditions in Eimeria of poultry [34\u201336].", [["Eimeria", "ORGANISM", 101, 108], ["experimental studies", "TEST", 13, 33], ["resistance under field conditions", "PROBLEM", 64, 97], ["resistance", "OBSERVATION", 64, 74]]], ["To our knowledge, this is the first report of experimentally confirmed toltrazuril resistance in a field isolate of C. suis.Study animals ::: MethodsA total of 34 conventionally raised healthy piglets from three crossbred sows (Landrace \u00d7 Large White) were allotted to five treatment groups (Table 1).", [["toltrazuril", "CHEMICAL", 71, 82], ["toltrazuril", "CHEMICAL", 71, 82], ["toltrazuril", "SIMPLE_CHEMICAL", 71, 82], ["C. suis", "ORGANISM", 116, 123], ["piglets", "ORGANISM", 193, 200], ["sows", "ORGANISM", 222, 226], ["C. suis", "SPECIES", 116, 123], ["piglets", "SPECIES", 193, 200], ["sows", "SPECIES", 222, 226], ["C. suis", "SPECIES", 116, 123], ["toltrazuril resistance", "PROBLEM", 71, 93], ["MethodsA", "TEST", 142, 150], ["Landrace \u00d7 Large White)", "TREATMENT", 228, 251], ["toltrazuril resistance", "OBSERVATION", 71, 93]]], ["Sows were housed on straw in individual farrowing crates in the animal husbandry facility of the Institute of Parasitology, University of Veterinary Medicine Vienna, Austria.", [["straw", "TREATMENT", 20, 25]]], ["All rooms were equipped with daylight and ventilation, and room temperature of 18\u201320 \u00b0C was maintained throughout the trial.", [["ventilation", "TREATMENT", 42, 53]]], ["Fresh drinking water was provided ad libitum to the sows and piglets.", [["sows", "ORGANISM_SUBDIVISION", 52, 56], ["piglets", "ORGANISM", 61, 68], ["piglets", "SPECIES", 61, 68]]], ["The sows were fed once daily with a commercial feed without coccidiostat according to the manufacturer\u2019s recommendation and the piglets received milk from the sow followed by starter feed from the second week of life.", [["milk", "ANATOMY", 145, 149], ["coccidiostat", "CHEMICAL", 60, 72], ["coccidiostat", "CHEMICAL", 60, 72], ["sows", "ORGANISM", 4, 8], ["coccidiostat", "SIMPLE_CHEMICAL", 60, 72], ["piglets", "ORGANISM", 128, 135], ["milk", "ORGANISM_SUBSTANCE", 145, 149], ["sow", "ORGANISM_SUBDIVISION", 159, 162], ["piglets", "SPECIES", 128, 135], ["a commercial feed", "TREATMENT", 34, 51], ["coccidiostat", "TREATMENT", 60, 72]]], ["The day of birth of piglets was considered as study day 1 (SD 1).", [["piglets", "ORGANISM", 20, 27], ["piglets", "SPECIES", 20, 27]]], ["All piglets were ear-marked and received 100 mg iron dextran on SD 2 to prevent iron deficiency.", [["iron dextran", "CHEMICAL", 48, 60], ["iron", "CHEMICAL", 80, 84], ["iron", "CHEMICAL", 48, 52], ["iron", "CHEMICAL", 80, 84], ["piglets", "ORGANISM", 4, 11], ["iron dextran", "SIMPLE_CHEMICAL", 48, 60], ["iron", "SIMPLE_CHEMICAL", 80, 84], ["piglets", "SPECIES", 4, 11], ["100 mg iron dextran", "TREATMENT", 41, 60], ["iron deficiency", "PROBLEM", 80, 95], ["iron deficiency", "OBSERVATION", 80, 95]]], ["The sows arrived two weeks prior to the expected parturition date for adaptation to the new environment.", [["sows", "ORGANISM", 4, 8]]]], "PMC7274339": [["Even if we restrict attention to t-norm based logics, where a left continuous t-norm", [["left", "ANATOMY_MODIFIER", 62, 66]]]], "90cc93e5eac1e836f5cbce50fe92ded531045abf": [["I n most eukaryotes, polymerase II (Pol II) dependent transcripts are modified co-transcriptionally at their 5'end by the addition of a 7-methyl guanosine (m 7 G) cap to the first nucleoside of the nascent transcript.", [["7-methyl guanosine", "CHEMICAL", 136, 154], ["nucleoside", "CHEMICAL", 180, 190], ["7-methyl guanosine", "CHEMICAL", 136, 154], ["nucleoside", "CHEMICAL", 180, 190], ["polymerase II", "GENE_OR_GENE_PRODUCT", 21, 34], ["Pol II", "GENE_OR_GENE_PRODUCT", 36, 42], ["7-methyl guanosine", "SIMPLE_CHEMICAL", 136, 154], ["polymerase II", "PROTEIN", 21, 34], ["Pol II) dependent transcripts", "PROTEIN", 36, 65], ["nascent transcript", "RNA", 198, 216], ["polymerase II (Pol II) dependent transcripts", "TREATMENT", 21, 65], ["a 7-methyl guanosine (m", "TREATMENT", 134, 157], ["nascent transcript", "OBSERVATION", 198, 216]]], ["If no additional modifications are made to the cap-adjacent nucleotides, the structure is referred to as a cap0.", [["nucleotides", "CHEMICAL", 60, 71], ["cap0", "GENE_OR_GENE_PRODUCT", 107, 111], ["cap-adjacent nucleotides", "DNA", 47, 71], ["cap0", "DNA", 107, 111]]], ["In yeast and plants, only cap0 structures are found, however, in animals, modifications of the two nucleotides adjacent to the m 7 G are possible The methylation of the first nucleotide on the ribose residue ( Fig. 1a) will form a cap1 structure 1 .", [["nucleotide", "CHEMICAL", 175, 185], ["ribose", "CHEMICAL", 193, 199], ["nucleotides", "CHEMICAL", 99, 110], ["nucleotide", "CHEMICAL", 175, 185], ["ribose", "CHEMICAL", 193, 199], ["cap0", "GENE_OR_GENE_PRODUCT", 26, 30], ["m 7 G", "GENE_OR_GENE_PRODUCT", 127, 132], ["m 7 G", "DNA", 127, 132], ["cap1 structure 1", "PROTEIN", 231, 247], ["yeast", "SPECIES", 3, 8], ["yeast", "SPECIES", 3, 8], ["the two nucleotides", "TREATMENT", 91, 110], ["the ribose residue", "TREATMENT", 189, 207], ["a cap1 structure", "TREATMENT", 229, 245], ["cap1 structure", "OBSERVATION", 231, 245]]], ["Cap1 messages can be converted to cap2 structures if a further 2'ribose methylation takes place on the next nucleotide following the cap1 (Fig. 1b) .", [["ribose", "CHEMICAL", 65, 71], ["2'ribose", "CHEMICAL", 63, 71], ["nucleotide", "CHEMICAL", 108, 118], ["Cap1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cap2", "GENE_OR_GENE_PRODUCT", 34, 38], ["ribose", "SIMPLE_CHEMICAL", 65, 71], ["Cap1", "PROTEIN", 0, 4], ["cap1", "DNA", 133, 137], ["Cap1 messages", "TREATMENT", 0, 13], ["cap2 structures", "TREATMENT", 34, 49], ["a further 2'ribose methylation", "TREATMENT", 53, 83], ["the cap1", "TREATMENT", 129, 137]]], ["These methylation steps are sequential and carried out by nuclear located methylases [1] [2] [3] .", [["nuclear", "ANATOMY", 58, 65], ["These methylation steps", "TREATMENT", 0, 23]]], ["In a transcript where the first nucleotide is an adenosine in a cap1 structure, a further methylation of the 2'-O-dimethyladenosine (Am) at the N 6 position of the adenine can take place to give N 6 ,2'-O-dimethyladenosine (m 6 Am) (Fig. 1c) 4 .", [["nucleotide", "CHEMICAL", 32, 42], ["adenosine", "CHEMICAL", 49, 58], ["2'-O-dimethyladenosine", "CHEMICAL", 109, 131], ["adenine", "CHEMICAL", 164, 171], ["N 6 ,2'-O-dimethyladenosine", "CHEMICAL", 195, 222], ["nucleotide", "CHEMICAL", 32, 42], ["adenosine", "CHEMICAL", 49, 58], ["2'-O-dimethyladenosine", "CHEMICAL", 109, 131], ["N", "CHEMICAL", 144, 145], ["adenine", "CHEMICAL", 164, 171], ["N 6 ,2'-O-dimethyladenosine", "CHEMICAL", 195, 222], ["adenosine", "SIMPLE_CHEMICAL", 49, 58], ["2'-O-dimethyladenosine", "SIMPLE_CHEMICAL", 109, 131], ["adenine", "SIMPLE_CHEMICAL", 164, 171], ["N 6 ,2'-O-dimethyladenosine", "SIMPLE_CHEMICAL", 195, 222], ["m 6 Am", "SIMPLE_CHEMICAL", 224, 230], ["Fig. 1c) 4", "SIMPLE_CHEMICAL", 233, 243], ["cap1 structure", "PROTEIN", 64, 78], ["N 6 position", "DNA", 144, 156], ["an adenosine in a cap1 structure", "TREATMENT", 46, 78], ["the adenine", "TREATMENT", 160, 171]]], ["The methyltransferase that carries out this modification has been partially characterized and appears to be predominantly located in the cytoplasm 5 .", [["cytoplasm", "ANATOMY", 137, 146], ["cytoplasm", "ORGANISM_SUBSTANCE", 137, 146], ["methyltransferase", "PROTEIN", 4, 21], ["The methyltransferase", "TREATMENT", 0, 21], ["methyltransferase", "OBSERVATION", 4, 21], ["appears to be", "UNCERTAINTY", 94, 107], ["predominantly", "OBSERVATION_MODIFIER", 108, 121], ["cytoplasm", "OBSERVATION", 137, 146]]], ["Transcription start sites of focused promoters are usually contained within an initiator motif (Inr) of general sequence YYANWYY (Y5pyrimidine, N-any nucleotide, W5A or T) where the A is the principal start site and neighbouring nucleotides may be used to varying degrees 6 .", [["Y5pyrimidine", "CHEMICAL", 130, 142], ["Y5pyrimidine", "CHEMICAL", 130, 142], ["N", "CHEMICAL", 144, 145], ["nucleotide", "CHEMICAL", 150, 160], ["nucleotides", "CHEMICAL", 229, 240], ["Y5pyrimidine", "SIMPLE_CHEMICAL", 130, 142], ["Transcription start sites", "DNA", 0, 25], ["focused promoters", "DNA", 29, 46], ["initiator motif", "DNA", 79, 94], ["Inr", "DNA", 96, 99], ["Y5pyrimidine, N-any nucleotide", "DNA", 130, 160], ["A", "DNA", 182, 183], ["principal start site", "DNA", 191, 211], ["Transcription", "TREATMENT", 0, 13], ["an initiator motif", "TREATMENT", 76, 94], ["Inr", "TEST", 96, 99], ["general sequence YYANWYY", "TREATMENT", 104, 128], ["Y5pyrimidine", "TREATMENT", 130, 142], ["any nucleotide", "TREATMENT", 146, 160], ["neighbouring nucleotides", "TREATMENT", 216, 240]]], ["Since, A is often the first nucleotide after the m 7 G cap, its modification may have a functional role.", [["nucleotide", "CHEMICAL", 28, 38], ["nucleotide", "CHEMICAL", 28, 38], ["A", "GENE_OR_GENE_PRODUCT", 7, 8], ["m 7 G cap", "DNA", 49, 58], ["the m 7 G cap", "TREATMENT", 45, 58]]], ["In order to study the effect of m 6 Am present in cap1 messages, the chemical synthesis of RNA oligonucleotide sequences that contain m 6 Am in well-defined positions, is necessary.", [["RNA oligonucleotide sequences", "TREATMENT", 91, 120]]], ["A number of methods exist in the literature for the preparation of N 6 -methylated adenosine derivatives, with the Dimroth rearrangement being perhaps the most well known [7] [8] [9] .", [["adenosine", "CHEMICAL", 83, 92], ["N 6 -methylated adenosine", "CHEMICAL", 67, 92], ["N 6 -methylated adenosine derivatives", "SIMPLE_CHEMICAL", 67, 104], ["Dimroth", "SIMPLE_CHEMICAL", 115, 122], ["[7] [8] [9]", "SIMPLE_CHEMICAL", 171, 182], ["methods", "TREATMENT", 12, 19], ["the preparation of N 6 -methylated adenosine derivatives", "TREATMENT", 48, 104], ["the Dimroth rearrangement", "TREATMENT", 111, 136]]], ["This transformation relies upon an initial N1-methylation of the adenine ring followed by an alkali-mediated rearrangement to give the N6-methylated adenine product.", [["adenine", "CHEMICAL", 65, 72], ["adenine", "CHEMICAL", 149, 156], ["adenine", "CHEMICAL", 65, 72], ["N6-methylated adenine", "CHEMICAL", 135, 156], ["adenine ring", "SIMPLE_CHEMICAL", 65, 77], ["N6-methylated adenine product", "SIMPLE_CHEMICAL", 135, 164], ["the adenine ring", "TREATMENT", 61, 77], ["the N6-methylated adenine product", "TREATMENT", 131, 164]]], ["An alternative method for accessing N6-alkylated adenines has been developed, which involves the nucleophilic aromatic substitution of adenine derivitives, that are activated at the 6-position, with amine nucleophiles (i.e. MeNH 2 ) [10] [11] [12] [13] .", [["N6-alkylated adenines", "CHEMICAL", 36, 57], ["adenine", "CHEMICAL", 135, 142], ["amine nucleophiles", "CHEMICAL", 199, 217], ["MeNH", "CHEMICAL", 224, 228], ["N6-alkylated adenines", "CHEMICAL", 36, 57], ["adenine", "CHEMICAL", 135, 142], ["amine", "CHEMICAL", 199, 204], ["MeNH", "CHEMICAL", 224, 228], ["N6-alkylated adenines", "SIMPLE_CHEMICAL", 36, 57], ["adenine derivitives", "SIMPLE_CHEMICAL", 135, 154], ["amine nucleophiles", "SIMPLE_CHEMICAL", 199, 217], ["MeNH 2 ) [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 224, 252], ["An alternative method", "TREATMENT", 0, 21], ["accessing N6-alkylated adenines", "TREATMENT", 26, 57], ["adenine derivitives", "TREATMENT", 135, 154], ["amine nucleophiles", "TREATMENT", 199, 217], ["alkylated adenines", "OBSERVATION", 39, 57], ["adenine derivitives", "OBSERVATION", 135, 154]]], ["In order to obtain the N6-methylated phosphoramidite reagents from these adenine derivatives, a number of additional synthetic steps are required, which results in a 6 to 8 step synthesis being needed to produce each phosphoramidite reagent [10] [11] [12] [13] .", [["phosphoramidite", "CHEMICAL", 37, 52], ["adenine", "CHEMICAL", 73, 80], ["phosphoramidite", "CHEMICAL", 217, 232], ["N6-methylated phosphoramidite", "CHEMICAL", 23, 52], ["adenine", "CHEMICAL", 73, 80], ["phosphoramidite", "CHEMICAL", 217, 232], ["adenine derivatives", "SIMPLE_CHEMICAL", 73, 92], ["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 241, 260], ["the N6-methylated phosphoramidite reagents", "TREATMENT", 19, 61], ["these adenine derivatives", "TREATMENT", 67, 92], ["additional synthetic steps", "TREATMENT", 106, 132], ["a 6 to 8 step synthesis", "TREATMENT", 164, 187], ["each phosphoramidite reagent", "TREATMENT", 212, 240]]], ["Such approaches are not realistic other than in synthetic chemistry laboratories.", [["synthetic chemistry laboratories", "TEST", 48, 80]]]], "5d724fd6b5bd4ce9a79bbd3d7a07d0f5c204ce80": [["IntroductionEdwardsiella tarda is a gram-negative, facultative anaerobe that is a member of the family Enterobacteriaceae and was first described by Ewing et al. in 1965 [1] .", [["Edwardsiella tarda", "DISEASE", 12, 30], ["Edwardsiella tarda", "ORGANISM", 12, 30], ["Edwardsiella tarda", "SPECIES", 12, 30], ["Edwardsiella tarda", "SPECIES", 12, 30], ["a gram", "TEST", 34, 40]]], ["Since then, a growing body of literature has reported E. tarda isolates particularly related to brackish water and marine ecosystems, including reptiles, amphibians, and fish [2] .", [["E. tarda", "ORGANISM", 54, 62], ["E. tarda", "SPECIES", 54, 62], ["E. tarda", "SPECIES", 54, 62], ["E. tarda isolates", "PROBLEM", 54, 71]]], ["E. tarda human infections are rare and mainly present as gastroenteritis; however, extraintestinal and systemic infections have been reported that, when present, are a potentially life-threatening condition carrying up to 50% risk of mortality [3] .", [["human infections", "DISEASE", 9, 25], ["gastroenteritis", "DISEASE", 57, 72], ["extraintestinal and systemic infections", "DISEASE", 83, 122], ["E. tarda", "ORGANISM", 0, 8], ["human", "ORGANISM", 9, 14], ["E. tarda", "SPECIES", 0, 8], ["human", "SPECIES", 9, 14], ["E. tarda human", "SPECIES", 0, 14], ["E. tarda human infections", "PROBLEM", 0, 25], ["gastroenteritis", "PROBLEM", 57, 72], ["extraintestinal and systemic infections", "PROBLEM", 83, 122], ["tarda human", "OBSERVATION_MODIFIER", 3, 14], ["infections", "OBSERVATION", 15, 25], ["gastroenteritis", "OBSERVATION", 57, 72], ["systemic", "OBSERVATION_MODIFIER", 103, 111], ["infections", "OBSERVATION", 112, 122]]], ["Such infections include bacteremia; infections of skin, soft tissue, and biliary tract; liver and tubo-ovarian abscesses; and peritonitis, particularly in immunocompromised hosts [4, 5] .", [["skin", "ANATOMY", 50, 54], ["soft tissue", "ANATOMY", 56, 67], ["biliary tract", "ANATOMY", 73, 86], ["liver", "ANATOMY", 88, 93], ["tubo", "ANATOMY", 98, 102], ["ovarian abscesses", "ANATOMY", 103, 120], ["infections", "DISEASE", 5, 15], ["bacteremia", "DISEASE", 24, 34], ["infections", "DISEASE", 36, 46], ["liver and tubo-ovarian abscesses", "DISEASE", 88, 120], ["peritonitis", "DISEASE", 126, 137], ["skin", "ORGAN", 50, 54], ["soft tissue", "TISSUE", 56, 67], ["biliary tract", "ORGAN", 73, 86], ["liver", "ORGAN", 88, 93], ["ovarian", "ORGAN", 103, 110], ["Such infections", "PROBLEM", 0, 15], ["bacteremia", "PROBLEM", 24, 34], ["infections of skin, soft tissue, and biliary tract", "PROBLEM", 36, 86], ["liver and tubo-ovarian abscesses", "PROBLEM", 88, 120], ["peritonitis", "PROBLEM", 126, 137], ["infections", "OBSERVATION", 5, 15], ["bacteremia", "OBSERVATION", 24, 34], ["infections", "OBSERVATION", 36, 46], ["skin", "ANATOMY", 50, 54], ["soft tissue", "ANATOMY", 56, 67], ["biliary tract", "ANATOMY", 73, 86], ["liver", "ANATOMY", 88, 93], ["ovarian", "ANATOMY", 103, 110], ["abscesses", "OBSERVATION", 111, 120], ["peritonitis", "OBSERVATION", 126, 137]]], ["We report a case of E. tarda infection that presented as multiple liver abscesses leading to fulminant septic shock in a previously healthy 37-year-old woman.Case presentationA 37-year-old Southeast Asian woman presented to the emergency department of our hospital with a 5-day history of abdominal pain, fever, and vomiting.", [["liver abscesses", "ANATOMY", 66, 81], ["abdominal", "ANATOMY", 289, 298], ["E. tarda infection", "DISEASE", 20, 38], ["liver abscesses", "DISEASE", 66, 81], ["septic shock", "DISEASE", 103, 115], ["abdominal pain", "DISEASE", 289, 303], ["fever", "DISEASE", 305, 310], ["vomiting", "DISEASE", 316, 324], ["E. tarda", "ORGANISM", 20, 28], ["liver", "ORGAN", 66, 71], ["woman", "ORGANISM", 152, 157], ["woman", "ORGANISM", 205, 210], ["abdominal", "ORGANISM_SUBDIVISION", 289, 298], ["E. tarda", "SPECIES", 20, 28], ["woman", "SPECIES", 152, 157], ["woman", "SPECIES", 205, 210], ["E. tarda", "SPECIES", 20, 28], ["E. tarda infection", "PROBLEM", 20, 38], ["multiple liver abscesses", "PROBLEM", 57, 81], ["fulminant septic shock", "PROBLEM", 93, 115], ["abdominal pain", "PROBLEM", 289, 303], ["fever", "PROBLEM", 305, 310], ["vomiting", "PROBLEM", 316, 324], ["E. tarda", "OBSERVATION_MODIFIER", 20, 28], ["infection", "OBSERVATION", 29, 38], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["liver", "ANATOMY", 66, 71], ["abscesses", "OBSERVATION", 72, 81], ["fulminant", "OBSERVATION_MODIFIER", 93, 102], ["septic shock", "OBSERVATION", 103, 115], ["abdominal", "ANATOMY", 289, 298], ["pain", "OBSERVATION", 299, 303], ["fever", "OBSERVATION", 305, 310]]], ["Her past medical history was unremarkable apart from a laparoscopic cholecystectomy 10 months earlier.", [["a laparoscopic cholecystectomy", "TREATMENT", 53, 83], ["unremarkable", "OBSERVATION", 29, 41], ["laparoscopic", "OBSERVATION_MODIFIER", 55, 67], ["cholecystectomy", "OBSERVATION", 68, 83]]], ["Upon presentation, the patient had high-grade fever, tachycardia, and hypotension suggestive of worsening sepsis, which eventually progressed rapidly to septic shock requiring high doses of noradrenaline and vasopressin.", [["fever", "DISEASE", 46, 51], ["tachycardia", "DISEASE", 53, 64], ["hypotension", "DISEASE", 70, 81], ["sepsis", "DISEASE", 106, 112], ["shock", "DISEASE", 160, 165], ["noradrenaline", "CHEMICAL", 190, 203], ["vasopressin", "CHEMICAL", 208, 219], ["noradrenaline", "CHEMICAL", 190, 203], ["vasopressin", "CHEMICAL", 208, 219], ["patient", "ORGANISM", 23, 30], ["noradrenaline", "SIMPLE_CHEMICAL", 190, 203], ["vasopressin", "SIMPLE_CHEMICAL", 208, 219], ["patient", "SPECIES", 23, 30], ["high-grade fever", "PROBLEM", 35, 51], ["tachycardia", "PROBLEM", 53, 64], ["hypotension", "PROBLEM", 70, 81], ["worsening sepsis", "PROBLEM", 96, 112], ["septic shock", "PROBLEM", 153, 165], ["noradrenaline", "TREATMENT", 190, 203], ["vasopressin", "TREATMENT", 208, 219], ["fever", "OBSERVATION", 46, 51], ["tachycardia", "OBSERVATION", 53, 64], ["hypotension", "OBSERVATION", 70, 81], ["suggestive of", "UNCERTAINTY", 82, 95], ["worsening", "OBSERVATION_MODIFIER", 96, 105], ["sepsis", "OBSERVATION", 106, 112], ["septic shock", "OBSERVATION", 153, 165]]], ["She was intubated, mechanically ventilated, and admitted to the intensive care unit (ICU) accordingly.", [["intubated", "TREATMENT", 8, 17]]], ["Upon ICU admission, an abdominal computed tomographic (CT) scan with contrast ( Fig. 1 ) revealed hypodense lesions occupying the right and left liver lobes with calcification foci suspicious of abscesses as well as mild intraabdominal free fluid collection.", [["hypodense lesions", "ANATOMY", 98, 115], ["right", "ANATOMY", 130, 135], ["left liver lobes", "ANATOMY", 140, 156], ["abscesses", "ANATOMY", 195, 204], ["intraabdominal", "ANATOMY", 221, 235], ["calcification", "DISEASE", 162, 175], ["abscesses", "DISEASE", 195, 204], ["hypodense lesions", "CANCER", 98, 115], ["liver", "ORGAN", 145, 150], ["abscesses", "PATHOLOGICAL_FORMATION", 195, 204], ["an abdominal computed tomographic (CT) scan with contrast ( Fig. 1 )", "TEST", 20, 88], ["hypodense lesions", "PROBLEM", 98, 115], ["calcification foci", "PROBLEM", 162, 180], ["abscesses", "PROBLEM", 195, 204], ["mild intraabdominal free fluid collection", "PROBLEM", 216, 257], ["abdominal", "ANATOMY", 23, 32], ["hypodense", "OBSERVATION_MODIFIER", 98, 107], ["lesions", "OBSERVATION", 108, 115], ["right", "ANATOMY_MODIFIER", 130, 135], ["left", "ANATOMY_MODIFIER", 140, 144], ["liver", "ANATOMY", 145, 150], ["lobes", "ANATOMY_MODIFIER", 151, 156], ["calcification", "OBSERVATION", 162, 175], ["abscesses", "OBSERVATION", 195, 204], ["mild", "OBSERVATION_MODIFIER", 216, 220], ["intraabdominal", "ANATOMY", 221, 235], ["free", "OBSERVATION_MODIFIER", 236, 240], ["fluid", "OBSERVATION", 241, 246]]], ["Initial investigations revealed a hemoglobin level of 10.4 g/dl and a white blood cell count of 18.9 \u00d7 10 9 /L with 89% neutrophils.", [["white blood cell", "ANATOMY", 70, 86], ["neutrophils", "ANATOMY", 120, 131], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 34, 44], ["blood cell", "CELL", 76, 86], ["neutrophils", "CELL", 120, 131], ["hemoglobin", "PROTEIN", 34, 44], ["neutrophils", "CELL_TYPE", 120, 131], ["Initial investigations", "TEST", 0, 22], ["a hemoglobin level", "TEST", 32, 50], ["a white blood cell count", "TEST", 68, 92], ["neutrophils", "TEST", 120, 131]]], ["Her platelet count was normal.", [["platelet", "ANATOMY", 4, 12], ["platelet", "CELL", 4, 12], ["Her platelet count", "TEST", 0, 18], ["platelet count", "OBSERVATION", 4, 18], ["normal", "OBSERVATION", 23, 29]]], ["Her blood urea nitrogen was raised at 12.1 mmol/L (normal range 2.5-6.4 mmol/L), but her serum creatinine was within normal limits at 115 IU/L (normal range 71-115 IU/L).", [["blood", "ANATOMY", 4, 9], ["serum", "ANATOMY", 89, 94], ["blood urea nitrogen", "CHEMICAL", 4, 23], ["creatinine", "CHEMICAL", 95, 105], ["urea", "CHEMICAL", 10, 14], ["nitrogen", "CHEMICAL", 15, 23], ["creatinine", "CHEMICAL", 95, 105], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["urea", "SIMPLE_CHEMICAL", 10, 14], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["creatinine", "SIMPLE_CHEMICAL", 95, 105], ["Her blood urea nitrogen", "TEST", 0, 23], ["her serum creatinine", "TEST", 85, 105]]], ["Her renal function was completely normalized following administration of intravenous fluids a few hours after ICU admission.", [["renal", "ANATOMY", 4, 9], ["intravenous", "ANATOMY", 73, 84], ["renal", "ORGAN", 4, 9], ["intravenous fluids", "TREATMENT", 73, 91], ["renal", "ANATOMY", 4, 9]]], ["The findings of blood film obtained for malarial parasites were negative.", [["blood", "ANATOMY", 16, 21], ["malarial parasites", "DISEASE", 40, 58], ["blood film", "MULTI-TISSUE_STRUCTURE", 16, 26], ["blood film", "TEST", 16, 26], ["malarial parasites", "PROBLEM", 40, 58]]], ["Notwithstanding this, liver function tests were remarkable with a total bilirubin of 25.3 \u03bcmol/L (direct 13.6 \u03bcmol/L, indirect 11.7 \u03bcmol/L), albumin 19.5 g/L, globulin 44.9 g/L, alkaline phosphatase 416 U/L, alanine aminotransferase 549 IU/L, aspartate aminotransferase 765 IU/L, prothrombin time 16.5 with international normalized ratio 1.41, activated partial thromboplastin time 39.9 seconds, and glucose 5.5 mmol/L. The patient's physical examination and chest xray were unremarkable.", [["liver", "ANATOMY", 22, 27], ["chest", "ANATOMY", 459, 464], ["bilirubin", "CHEMICAL", 72, 81], ["alanine", "CHEMICAL", 208, 215], ["aspartate", "CHEMICAL", 243, 252], ["glucose", "CHEMICAL", 400, 407], ["bilirubin", "CHEMICAL", 72, 81], ["alanine", "CHEMICAL", 208, 215], ["aspartate", "CHEMICAL", 243, 252], ["glucose", "CHEMICAL", 400, 407], ["liver", "ORGAN", 22, 27], ["bilirubin", "SIMPLE_CHEMICAL", 72, 81], ["albumin", "GENE_OR_GENE_PRODUCT", 141, 148], ["globulin", "GENE_OR_GENE_PRODUCT", 159, 167], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 178, 198], ["alanine", "AMINO_ACID", 208, 215], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 216, 232], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 243, 269], ["prothrombin", "GENE_OR_GENE_PRODUCT", 280, 291], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 362, 376], ["glucose", "SIMPLE_CHEMICAL", 400, 407], ["patient", "ORGANISM", 424, 431], ["albumin", "PROTEIN", 141, 148], ["globulin", "PROTEIN", 159, 167], ["alkaline phosphatase", "PROTEIN", 178, 198], ["alanine aminotransferase", "PROTEIN", 208, 232], ["aspartate aminotransferase", "PROTEIN", 243, 269], ["prothrombin", "PROTEIN", 280, 291], ["patient", "SPECIES", 424, 431], ["liver function tests", "TEST", 22, 42], ["a total bilirubin", "TEST", 64, 81], ["direct", "TEST", 98, 104], ["\u03bcmol", "TEST", 110, 114], ["L", "TEST", 115, 116], ["indirect", "TEST", 118, 126], ["\u03bcmol", "TEST", 132, 136], ["albumin", "TEST", 141, 148], ["g", "TEST", 154, 155], ["globulin", "TEST", 159, 167], ["g", "TEST", 173, 174], ["alkaline phosphatase", "TEST", 178, 198], ["U/L", "TEST", 203, 206], ["alanine aminotransferase", "TEST", 208, 232], ["IU", "TEST", 237, 239], ["aspartate aminotransferase", "TEST", 243, 269], ["IU/L", "TEST", 274, 278], ["prothrombin time", "TEST", 280, 296], ["international normalized ratio", "TEST", 307, 337], ["activated partial thromboplastin time", "TEST", 344, 381], ["glucose", "TEST", 400, 407], ["The patient's physical examination", "TEST", 420, 454], ["chest xray", "TEST", 459, 469], ["liver", "ANATOMY", 22, 27], ["chest", "ANATOMY", 459, 464], ["unremarkable", "OBSERVATION", 475, 487]]], ["CT-guided percutaneous drainage of the liver abscesses with supplementary cultures was performed while blood cultures were derived accordingly.", [["percutaneous", "ANATOMY", 10, 22], ["liver abscesses", "ANATOMY", 39, 54], ["blood", "ANATOMY", 103, 108], ["liver abscesses", "DISEASE", 39, 54], ["liver", "ORGAN", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["CT", "TEST", 0, 2], ["guided percutaneous drainage", "TREATMENT", 3, 31], ["the liver abscesses", "PROBLEM", 35, 54], ["supplementary cultures", "TEST", 60, 82], ["blood cultures", "TEST", 103, 117], ["drainage", "OBSERVATION", 23, 31], ["liver", "ANATOMY", 39, 44], ["abscesses", "OBSERVATION", 45, 54]]], ["The analysis of the fluid drained from the liver abscess showed a high white blood cell count (11.8 \u00d7 10 3 /\u03bcl) with polymorphic predominance (77%) and high bilirubin and lactate dehydrogenase levels.", [["fluid", "ANATOMY", 20, 25], ["liver abscess", "ANATOMY", 43, 56], ["white blood cell", "ANATOMY", 71, 87], ["liver abscess", "DISEASE", 43, 56], ["bilirubin", "CHEMICAL", 157, 166], ["lactate", "CHEMICAL", 171, 178], ["bilirubin", "CHEMICAL", 157, 166], ["lactate", "CHEMICAL", 171, 178], ["liver", "ORGAN", 43, 48], ["blood cell", "CELL", 77, 87], ["bilirubin", "SIMPLE_CHEMICAL", 157, 166], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 171, 192], ["bilirubin", "PROTEIN", 157, 166], ["lactate dehydrogenase", "PROTEIN", 171, 192], ["The analysis", "TEST", 0, 12], ["the fluid", "TEST", 16, 25], ["the liver abscess", "PROBLEM", 39, 56], ["a high white blood cell count", "PROBLEM", 64, 93], ["polymorphic predominance", "PROBLEM", 117, 141], ["high bilirubin and lactate dehydrogenase levels", "PROBLEM", 152, 199], ["fluid", "OBSERVATION", 20, 25], ["liver", "ANATOMY", 43, 48], ["abscess", "OBSERVATION", 49, 56], ["high", "OBSERVATION_MODIFIER", 66, 70], ["polymorphic", "OBSERVATION_MODIFIER", 117, 128], ["predominance", "OBSERVATION_MODIFIER", 129, 141], ["high bilirubin", "OBSERVATION", 152, 166]]], ["Moreover, a gram-stained smear of the pus aspirated from the liver abscess showed few gram-negative bacilli and necrotic debris.", [["pus", "ANATOMY", 38, 41], ["liver abscess", "ANATOMY", 61, 74], ["necrotic debris", "ANATOMY", 112, 127], ["liver abscess", "DISEASE", 61, 74], ["necrotic", "DISEASE", 112, 120], ["pus", "PATHOLOGICAL_FORMATION", 38, 41], ["liver", "ORGAN", 61, 66], ["a gram-stained smear", "TEST", 10, 30], ["the pus", "PROBLEM", 34, 41], ["the liver abscess", "PROBLEM", 57, 74], ["few gram-negative bacilli", "PROBLEM", 82, 107], ["necrotic debris", "PROBLEM", 112, 127], ["pus", "OBSERVATION", 38, 41], ["liver", "ANATOMY", 61, 66], ["abscess", "OBSERVATION", 67, 74], ["few", "OBSERVATION_MODIFIER", 82, 85], ["negative bacilli", "OBSERVATION", 91, 107], ["necrotic", "OBSERVATION_MODIFIER", 112, 120], ["debris", "OBSERVATION", 121, 127]]], ["All blood cultures as well as stool samples that were collected for 3 consecutive days grew E. tarda [6] .", [["blood cultures", "ANATOMY", 4, 18], ["stool samples", "ANATOMY", 30, 43], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["stool samples", "ORGANISM_SUBSTANCE", 30, 43], ["E. tarda", "SPECIES", 92, 100], ["E. tarda", "SPECIES", 92, 100], ["All blood cultures", "TEST", 0, 18], ["stool samples", "TEST", 30, 43]]], ["Specifically, blood cultures were obtained under sterile conditions and were processed using BacT/ ALERT 3D (bioM\u00e9rieux, Marcy l'Etoile, France).", [["blood cultures", "ANATOMY", 14, 28], ["blood cultures", "ORGANISM_SUBSTANCE", 14, 28], ["blood cultures", "TEST", 14, 28]]], ["Strains of E. tarda were identified using the MicroScan Walk-Away 96si system (Siemens, Erlangen, Germany).", [["E. tarda", "ORGANISM", 11, 19], ["E. tarda", "SPECIES", 11, 19], ["E. tarda", "SPECIES", 11, 19]]], ["We evaluated the drug susceptibility of the pathogen based on clinical breakpoints set by the Clinical and Laboratory Standards Institute using E-test (bioM\u00e9rieux) [7] .Case presentationNotably, the results of all other infectious and systemic disease workup were negative.", [["the pathogen", "PROBLEM", 40, 52], ["all other infectious", "PROBLEM", 210, 230], ["systemic disease workup", "TEST", 235, 258], ["infectious", "OBSERVATION", 220, 230]]], ["Upon ICU admission, piperacillin-tazobactam was initiated empirically (at a dose of 4.5 g intravenously every 6 hours) because the results of the aforementioned cultures were not available at that time.", [["piperacillin-tazobactam", "CHEMICAL", 20, 43], ["piperacillin-tazobactam", "CHEMICAL", 20, 43], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 20, 43], ["piperacillin-tazobactam", "TREATMENT", 20, 43], ["the aforementioned cultures", "TEST", 142, 169]]], ["Forty-eight hours later, due to lack of clinical improvement and worsening shock despite fluid resuscitation, antibiotics were empirically once more upgraded to meropenem (1 g every 8 hours by intravenous infusion over 3 hours) and linezolid (600 mg intravenously every 12 hours).", [["intravenous", "ANATOMY", 193, 204], ["shock", "DISEASE", 75, 80], ["meropenem", "CHEMICAL", 161, 170], ["linezolid", "CHEMICAL", 232, 241], ["meropenem", "CHEMICAL", 161, 170], ["linezolid", "CHEMICAL", 232, 241], ["meropenem", "SIMPLE_CHEMICAL", 161, 170], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 193, 204], ["linezolid", "SIMPLE_CHEMICAL", 232, 241], ["worsening shock", "PROBLEM", 65, 80], ["fluid resuscitation", "TREATMENT", 89, 108], ["antibiotics", "TREATMENT", 110, 121], ["meropenem", "TREATMENT", 161, 170], ["linezolid", "TREATMENT", 232, 241], ["worsening", "OBSERVATION_MODIFIER", 65, 74], ["shock", "OBSERVATION", 75, 80], ["fluid resuscitation", "OBSERVATION", 89, 108]]], ["As mentioned in the paragraphs above, all cultures grew E. tarda.", [["E. tarda", "ORGANISM", 56, 64], ["E. tarda", "SPECIES", 56, 64], ["E. tarda", "SPECIES", 56, 64], ["all cultures", "TEST", 38, 50], ["E. tarda", "OBSERVATION_MODIFIER", 56, 64]]], ["The antibiogram (available when the patient had already received the upgraded antibiotics for 48 hours) showed, interestingly, that the pathogen was resistant to piperacillintazobactam and carbapenems while being sensitive to gentamicin and ciprofloxacin.", [["piperacillintazobactam", "CHEMICAL", 162, 184], ["carbapenems", "CHEMICAL", 189, 200], ["gentamicin", "CHEMICAL", 226, 236], ["ciprofloxacin", "CHEMICAL", 241, 254], ["piperacillintazobactam", "CHEMICAL", 162, 184], ["carbapenems", "CHEMICAL", 189, 200], ["gentamicin", "CHEMICAL", 226, 236], ["ciprofloxacin", "CHEMICAL", 241, 254], ["patient", "ORGANISM", 36, 43], ["piperacillintazobactam", "SIMPLE_CHEMICAL", 162, 184], ["carbapenems", "SIMPLE_CHEMICAL", 189, 200], ["gentamicin", "SIMPLE_CHEMICAL", 226, 236], ["ciprofloxacin", "SIMPLE_CHEMICAL", 241, 254], ["patient", "SPECIES", 36, 43], ["The antibiogram", "TEST", 0, 15], ["the upgraded antibiotics", "TREATMENT", 65, 89], ["the pathogen", "PROBLEM", 132, 144], ["piperacillintazobactam", "TREATMENT", 162, 184], ["carbapenems", "TREATMENT", 189, 200], ["gentamicin", "TREATMENT", 226, 236], ["ciprofloxacin", "TREATMENT", 241, 254]]], ["Hence, the antibiotic regimen was updated to ciprofloxacin (400 mg intravenously every 12 hours for 14 days) and gentamicin (400 mg intravenously once daily for 14 days) on the basis of the pertinent antibiogram.", [["intravenously", "ANATOMY", 132, 145], ["ciprofloxacin", "CHEMICAL", 45, 58], ["gentamicin", "CHEMICAL", 113, 123], ["ciprofloxacin", "CHEMICAL", 45, 58], ["gentamicin", "CHEMICAL", 113, 123], ["ciprofloxacin", "SIMPLE_CHEMICAL", 45, 58], ["gentamicin", "SIMPLE_CHEMICAL", 113, 123], ["the antibiotic regimen", "TREATMENT", 7, 29], ["ciprofloxacin", "TREATMENT", 45, 58], ["gentamicin", "TREATMENT", 113, 123], ["the pertinent antibiogram", "TEST", 186, 211]]], ["The clinical status of the patient gradually improved, and she was successfully weaned off vasopressors and the mechanical ventilator.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["vasopressors", "TREATMENT", 91, 103], ["the mechanical ventilator", "TREATMENT", 108, 133], ["mechanical ventilator", "OBSERVATION", 112, 133]]], ["Thereafter, she was transferred to the gastroenterology ward, where follow-up endoscopic studies revealed mild nonspecific enteritis that eventually resolved completely, and she was discharged from the hospital free of symptoms and in good health.DiscussionE. tarda, a member of the Enterobacteriaceae family, belongs to the genus Edwardsiella along with E. hoshinae and E. ictaluri, and is a facultative anaerobic gramnegative bacillus.", [["enteritis", "DISEASE", 123, 132], ["tarda", "DISEASE", 260, 265], ["tarda", "ORGANISM", 260, 265], ["E. hoshinae", "ORGANISM", 355, 366], ["E. ictaluri", "ORGANISM", 371, 382], ["E. hoshinae", "SPECIES", 355, 366], ["E. ictaluri", "SPECIES", 371, 382], ["tarda", "SPECIES", 260, 265], ["E. hoshinae", "SPECIES", 355, 366], ["E. ictaluri", "SPECIES", 371, 382], ["follow-up endoscopic studies", "TEST", 68, 96], ["mild nonspecific enteritis", "PROBLEM", 106, 132], ["symptoms", "PROBLEM", 219, 227], ["a facultative anaerobic gramnegative bacillus", "PROBLEM", 391, 436], ["mild", "OBSERVATION_MODIFIER", 106, 110], ["nonspecific", "OBSERVATION_MODIFIER", 111, 122], ["enteritis", "OBSERVATION", 123, 132], ["genus Edwardsiella", "ANATOMY", 325, 343], ["gramnegative bacillus", "OBSERVATION", 415, 436]]], ["It has a worldwide distribution especially in water environments, whereas its role as a fish Fig. 1 Abdominal computed tomographic scan with contrast revealing liver abscesses (black arrows) due to Edwardsiella tarda infection pathogen has long been recognized [8] .", [["liver abscesses", "ANATOMY", 160, 175], ["liver abscesses", "DISEASE", 160, 175], ["Edwardsiella tarda infection", "DISEASE", 198, 226], ["liver", "ORGAN", 160, 165], ["Edwardsiella tarda", "ORGANISM", 198, 216], ["Edwardsiella tarda", "SPECIES", 198, 216], ["Edwardsiella tarda", "SPECIES", 198, 216], ["1 Abdominal computed tomographic scan with contrast", "TEST", 98, 149], ["liver abscesses", "PROBLEM", 160, 175], ["black arrows", "PROBLEM", 177, 189], ["Edwardsiella tarda infection pathogen", "PROBLEM", 198, 235], ["worldwide", "OBSERVATION_MODIFIER", 9, 18], ["distribution", "OBSERVATION_MODIFIER", 19, 31], ["water environments", "OBSERVATION_MODIFIER", 46, 64], ["Abdominal", "ANATOMY", 100, 109], ["liver", "ANATOMY", 160, 165], ["abscesses", "OBSERVATION", 166, 175], ["Edwardsiella tarda", "OBSERVATION_MODIFIER", 198, 216], ["infection", "OBSERVATION", 217, 226]]], ["Exposure to water environments as well as aquatic animals (reptiles, snakes, turtles, and amphibians), iron overload disorders, and ingestion of contaminated raw fish were previously reported as risk factors for infection [3] .", [["iron", "CHEMICAL", 103, 107], ["overload disorders", "DISEASE", 108, 126], ["infection", "DISEASE", 212, 221], ["iron", "CHEMICAL", 103, 107], ["snakes", "ORGANISM_SUBDIVISION", 69, 75], ["iron", "SIMPLE_CHEMICAL", 103, 107], ["iron overload disorders", "PROBLEM", 103, 126], ["contaminated raw fish", "PROBLEM", 145, 166], ["infection", "PROBLEM", 212, 221], ["water environments", "OBSERVATION_MODIFIER", 12, 30], ["overload disorders", "OBSERVATION", 108, 126]]], ["Aeromonas species, Vibrio vulnificus, and Mycobacterium marinum share the same environment and therefore a similar exposure risk to E. tarda; moreover, the clinical presentation of the former infections could be similar to E. tarda infections. although M. marinum infections tend to be generally idle and not associated with systemic manifestations [9] .", [["Vibrio vulnificus", "DISEASE", 19, 36], ["E. tarda", "DISEASE", 132, 140], ["infections", "DISEASE", 192, 202], ["E. tarda infections", "DISEASE", 223, 242], ["M. marinum infections", "DISEASE", 253, 274], ["Aeromonas species", "ORGANISM", 0, 17], ["Vibrio vulnificus", "ORGANISM", 19, 36], ["Mycobacterium marinum", "ORGANISM", 42, 63], ["E. tarda", "ORGANISM", 132, 140], ["E. tarda", "ORGANISM", 223, 231], ["M. marinum", "ORGANISM", 253, 263], ["Vibrio vulnificus", "SPECIES", 19, 36], ["Mycobacterium marinum", "SPECIES", 42, 63], ["E. tarda", "SPECIES", 132, 140], ["E. tarda", "SPECIES", 223, 231], ["M. marinum", "SPECIES", 253, 263], ["Vibrio vulnificus", "SPECIES", 19, 36], ["Mycobacterium marinum", "SPECIES", 42, 63], ["E. tarda", "SPECIES", 132, 140], ["E. tarda", "SPECIES", 223, 231], ["M. marinum", "SPECIES", 253, 263], ["Aeromonas species", "TEST", 0, 17], ["Vibrio vulnificus", "PROBLEM", 19, 36], ["Mycobacterium marinum", "PROBLEM", 42, 63], ["the former infections", "PROBLEM", 181, 202], ["E. tarda infections", "PROBLEM", 223, 242], ["M. marinum infections", "PROBLEM", 253, 274], ["systemic manifestations", "PROBLEM", 325, 348], ["Vibrio vulnificus", "OBSERVATION_MODIFIER", 19, 36], ["Mycobacterium marinum", "OBSERVATION", 42, 63], ["E. tarda", "OBSERVATION_MODIFIER", 132, 140], ["infections", "OBSERVATION", 192, 202], ["E. tarda", "OBSERVATION_MODIFIER", 223, 231], ["infections", "OBSERVATION", 232, 242], ["marinum", "ANATOMY", 256, 263], ["infections", "OBSERVATION", 264, 274]]], ["Humans appear to become uncommonly infected with E. tarda.", [["E. tarda", "DISEASE", 49, 57], ["Humans", "ORGANISM", 0, 6], ["E. tarda", "ORGANISM", 49, 57], ["E. tarda", "SPECIES", 49, 57], ["E. tarda", "SPECIES", 49, 57], ["infected", "OBSERVATION", 35, 43], ["E. tarda", "OBSERVATION_MODIFIER", 49, 57]]], ["Mild gastroenteritis is the most common manifestation associated with this pathogen, but invasive enterocolitis and serious extraintestinal infections, such as necrotizing fasciitis, sepsis, wound abscess, gynecological infections, peritonitis, and osteomyelitis, have been reported in individuals with underlying systemic diseases such as malignancy, impaired immune status, diabetes mellitus, and hepatobiliary diseases [8] [9] [10] .", [["wound abscess", "ANATOMY", 191, 204], ["gynecological", "ANATOMY", 206, 219], ["hepatobiliary", "ANATOMY", 399, 412], ["gastroenteritis", "DISEASE", 5, 20], ["invasive enterocolitis", "DISEASE", 89, 111], ["extraintestinal infections", "DISEASE", 124, 150], ["necrotizing fasciitis", "DISEASE", 160, 181], ["sepsis", "DISEASE", 183, 189], ["wound abscess", "DISEASE", 191, 204], ["gynecological infections", "DISEASE", 206, 230], ["peritonitis", "DISEASE", 232, 243], ["osteomyelitis", "DISEASE", 249, 262], ["systemic diseases", "DISEASE", 314, 331], ["malignancy", "DISEASE", 340, 350], ["impaired immune status", "DISEASE", 352, 374], ["diabetes mellitus", "DISEASE", 376, 393], ["hepatobiliary diseases", "DISEASE", 399, 421], ["wound", "PATHOLOGICAL_FORMATION", 191, 196], ["Mild gastroenteritis", "PROBLEM", 0, 20], ["this pathogen", "PROBLEM", 70, 83], ["invasive enterocolitis", "PROBLEM", 89, 111], ["serious extraintestinal infections", "PROBLEM", 116, 150], ["necrotizing fasciitis", "PROBLEM", 160, 181], ["sepsis", "PROBLEM", 183, 189], ["wound abscess", "PROBLEM", 191, 204], ["gynecological infections", "PROBLEM", 206, 230], ["peritonitis", "PROBLEM", 232, 243], ["osteomyelitis", "PROBLEM", 249, 262], ["underlying systemic diseases", "PROBLEM", 303, 331], ["malignancy", "PROBLEM", 340, 350], ["impaired immune status", "PROBLEM", 352, 374], ["diabetes mellitus", "PROBLEM", 376, 393], ["hepatobiliary diseases", "PROBLEM", 399, 421], ["gastroenteritis", "OBSERVATION", 5, 20], ["most common", "OBSERVATION_MODIFIER", 28, 39], ["invasive", "OBSERVATION_MODIFIER", 89, 97], ["enterocolitis", "OBSERVATION", 98, 111], ["serious", "OBSERVATION_MODIFIER", 116, 123], ["extraintestinal", "OBSERVATION_MODIFIER", 124, 139], ["infections", "OBSERVATION", 140, 150], ["necrotizing", "OBSERVATION_MODIFIER", 160, 171], ["fasciitis", "OBSERVATION", 172, 181], ["sepsis", "OBSERVATION", 183, 189], ["wound", "OBSERVATION_MODIFIER", 191, 196], ["abscess", "OBSERVATION", 197, 204], ["gynecological", "ANATOMY", 206, 219], ["infections", "OBSERVATION", 220, 230], ["peritonitis", "OBSERVATION", 232, 243], ["osteomyelitis", "OBSERVATION", 249, 262], ["systemic", "OBSERVATION_MODIFIER", 314, 322], ["diseases", "OBSERVATION", 323, 331], ["malignancy", "OBSERVATION", 340, 350], ["hepatobiliary", "ANATOMY", 399, 412]]], ["Although gastrointestinal infections are generally self-limited [10] , E. tarda-related septicemia mortality ranges from 38% to 50%, and it should be considered a life-threatening condition [3, 11] .", [["gastrointestinal", "ANATOMY", 9, 25], ["gastrointestinal infections", "DISEASE", 9, 36], ["tarda", "DISEASE", 74, 79], ["septicemia", "DISEASE", 88, 98], ["gastrointestinal", "ORGAN", 9, 25], ["E. tarda", "ORGANISM", 71, 79], ["E. tarda", "SPECIES", 71, 79], ["gastrointestinal infections", "PROBLEM", 9, 36], ["E. tarda", "TEST", 71, 79], ["septicemia mortality", "PROBLEM", 88, 108], ["gastrointestinal", "ANATOMY", 9, 25], ["infections", "OBSERVATION", 26, 36], ["septicemia", "OBSERVATION", 88, 98]]], ["This suggests that a dysfunctional intestinal barrier and/or immune system impairment related to underlying conditions might play a key role in the bacterial translocation across intestinal epithelium, which could in turn facilitate systemic dissemination [11] .DiscussionWe report a case of a previously healthy woman who developed liver abscesses and septic shock due to E. tarda infection.", [["intestinal", "ANATOMY", 35, 45], ["immune system", "ANATOMY", 61, 74], ["intestinal epithelium", "ANATOMY", 179, 200], ["liver abscesses", "ANATOMY", 333, 348], ["liver abscesses", "DISEASE", 333, 348], ["septic shock", "DISEASE", 353, 365], ["E. tarda infection", "DISEASE", 373, 391], ["intestinal barrier", "MULTI-TISSUE_STRUCTURE", 35, 53], ["intestinal epithelium", "TISSUE", 179, 200], ["woman", "ORGANISM", 313, 318], ["liver", "ORGAN", 333, 338], ["E. tarda", "ORGANISM", 373, 381], ["woman", "SPECIES", 313, 318], ["E. tarda", "SPECIES", 373, 381], ["E. tarda", "SPECIES", 373, 381], ["a dysfunctional intestinal barrier", "PROBLEM", 19, 53], ["immune system impairment", "PROBLEM", 61, 85], ["underlying conditions", "PROBLEM", 97, 118], ["the bacterial translocation across intestinal epithelium", "PROBLEM", 144, 200], ["liver abscesses", "PROBLEM", 333, 348], ["septic shock", "PROBLEM", 353, 365], ["E. tarda infection", "PROBLEM", 373, 391], ["dysfunctional", "OBSERVATION_MODIFIER", 21, 34], ["intestinal", "ANATOMY", 35, 45], ["intestinal epithelium", "ANATOMY", 179, 200], ["liver", "ANATOMY", 333, 338], ["abscesses", "OBSERVATION", 339, 348], ["septic shock", "OBSERVATION", 353, 365], ["E. tarda", "OBSERVATION_MODIFIER", 373, 381], ["infection", "OBSERVATION", 382, 391]]], ["Although our patient had a history of cholecystectomy 10 months earlier, she did not have any history of chronic illnesses and denied any exposure to aquatic environments.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["cholecystectomy", "TREATMENT", 38, 53], ["chronic illnesses", "PROBLEM", 105, 122], ["cholecystectomy", "OBSERVATION", 38, 53], ["chronic", "OBSERVATION_MODIFIER", 105, 112], ["illnesses", "OBSERVATION", 113, 122]]], ["All cultures that were derived prior to the empirical administration of antibiotics grew E. tarda.", [["cultures", "ANATOMY", 4, 12], ["E. tarda", "ORGANISM", 89, 97], ["E. tarda", "SPECIES", 89, 97], ["E. tarda", "SPECIES", 89, 97], ["All cultures", "TEST", 0, 12], ["the empirical administration of antibiotics", "TREATMENT", 40, 83]]], ["We are unaware whether previous cholecystectomy per se might be considered as a risk factor for developing E. tarda infection.", [["E. tarda infection", "DISEASE", 107, 125], ["E. tarda", "ORGANISM", 107, 115], ["E. tarda", "SPECIES", 107, 115], ["E. tarda", "SPECIES", 107, 115], ["previous cholecystectomy", "TREATMENT", 23, 47], ["developing E. tarda infection", "PROBLEM", 96, 125], ["cholecystectomy", "OBSERVATION", 32, 47], ["tarda", "OBSERVATION_MODIFIER", 110, 115], ["infection", "OBSERVATION", 116, 125]]], ["A few case reports have outlined patients with a history of cholecystectomy and E. tarda infection, but those were also characterized by major underlying disorders [4, 11] .", [["E. tarda infection", "DISEASE", 80, 98], ["patients", "ORGANISM", 33, 41], ["E. tarda", "ORGANISM", 80, 88], ["patients", "SPECIES", 33, 41], ["E. tarda", "SPECIES", 80, 88], ["E. tarda", "SPECIES", 80, 88], ["cholecystectomy", "TREATMENT", 60, 75], ["E. tarda infection", "PROBLEM", 80, 98], ["major underlying disorders", "PROBLEM", 137, 163], ["cholecystectomy", "OBSERVATION", 60, 75], ["E. tarda", "OBSERVATION_MODIFIER", 80, 88], ["infection", "OBSERVATION", 89, 98]]], ["Moreover, previously published articles reported E. tarda infections that presented as liver abscesses and/or bacteremia with variable modalities of management and patient outcomes [3, 5, [11] [12] [13] [14] [15] .DiscussionIn vitro studies revealed that almost all E. tarda isolates are susceptible to a wide range of antibacterial agents (ampicillin, most \u03b2-lactam antibiotics, quinolones, chloramphenicol, tetracycline, and aminoglycosides) that are commonly used against gram-negative bacteria [16] .", [["liver abscesses", "ANATOMY", 87, 102], ["E. tarda infections", "DISEASE", 49, 68], ["liver abscesses", "DISEASE", 87, 102], ["bacteremia", "DISEASE", 110, 120], ["ampicillin", "CHEMICAL", 341, 351], ["\u03b2-lactam", "CHEMICAL", 358, 366], ["quinolones", "CHEMICAL", 380, 390], ["chloramphenicol", "CHEMICAL", 392, 407], ["tetracycline", "CHEMICAL", 409, 421], ["aminoglycosides", "CHEMICAL", 427, 442], ["ampicillin", "CHEMICAL", 341, 351], ["\u03b2-lactam", "CHEMICAL", 358, 366], ["quinolones", "CHEMICAL", 380, 390], ["chloramphenicol", "CHEMICAL", 392, 407], ["tetracycline", "CHEMICAL", 409, 421], ["aminoglycosides", "CHEMICAL", 427, 442], ["E. tarda", "ORGANISM", 49, 57], ["liver", "ORGAN", 87, 92], ["patient", "ORGANISM", 164, 171], ["[11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 188, 212], ["E. tarda", "ORGANISM", 266, 274], ["ampicillin", "SIMPLE_CHEMICAL", 341, 351], ["\u03b2-lactam antibiotics", "SIMPLE_CHEMICAL", 358, 378], ["quinolones", "SIMPLE_CHEMICAL", 380, 390], ["chloramphenicol", "SIMPLE_CHEMICAL", 392, 407], ["tetracycline", "SIMPLE_CHEMICAL", 409, 421], ["aminoglycosides", "SIMPLE_CHEMICAL", 427, 442], ["E. tarda", "SPECIES", 49, 57], ["patient", "SPECIES", 164, 171], ["E. tarda", "SPECIES", 266, 274], ["E. tarda", "SPECIES", 49, 57], ["E. tarda", "SPECIES", 266, 274], ["tarda infections", "PROBLEM", 52, 68], ["liver abscesses", "PROBLEM", 87, 102], ["bacteremia", "PROBLEM", 110, 120], ["management", "TREATMENT", 149, 159], ["vitro studies", "TEST", 227, 240], ["almost all E. tarda isolates", "PROBLEM", 255, 283], ["antibacterial agents", "TREATMENT", 319, 339], ["ampicillin", "TREATMENT", 341, 351], ["most \u03b2-lactam antibiotics", "TREATMENT", 353, 378], ["quinolones", "TREATMENT", 380, 390], ["chloramphenicol", "TREATMENT", 392, 407], ["tetracycline", "TREATMENT", 409, 421], ["aminoglycosides", "TREATMENT", 427, 442], ["gram-negative bacteria", "PROBLEM", 475, 497], ["tarda", "OBSERVATION_MODIFIER", 52, 57], ["infections", "OBSERVATION", 58, 68], ["liver", "ANATOMY", 87, 92], ["abscesses", "OBSERVATION", 93, 102], ["bacteremia", "OBSERVATION", 110, 120]]], ["In our patient's case, for the first time, to the best of our knowledge, resistance to broad-spectrum antibiotics such as carbapenems and piperacillin-tazobactam was clearly documented, whereas the E. tarda strain was susceptible to ciprofloxacin and aminoglycosides.DiscussionOur patient improved gradually during her ICU hospitalization.", [["carbapenems", "CHEMICAL", 122, 133], ["piperacillin-tazobactam", "CHEMICAL", 138, 161], ["ciprofloxacin", "CHEMICAL", 233, 246], ["aminoglycosides", "CHEMICAL", 251, 266], ["carbapenems", "CHEMICAL", 122, 133], ["piperacillin-tazobactam", "CHEMICAL", 138, 161], ["ciprofloxacin", "CHEMICAL", 233, 246], ["aminoglycosides", "CHEMICAL", 251, 266], ["patient", "ORGANISM", 7, 14], ["carbapenems", "SIMPLE_CHEMICAL", 122, 133], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 138, 161], ["E. tarda", "ORGANISM", 198, 206], ["strain", "ORGANISM", 207, 213], ["ciprofloxacin", "SIMPLE_CHEMICAL", 233, 246], ["aminoglycosides", "SIMPLE_CHEMICAL", 251, 266], ["patient", "ORGANISM", 281, 288], ["patient", "SPECIES", 7, 14], ["E. tarda", "SPECIES", 198, 206], ["patient", "SPECIES", 281, 288], ["E. tarda", "SPECIES", 198, 206], ["broad-spectrum antibiotics", "TREATMENT", 87, 113], ["carbapenems", "TREATMENT", 122, 133], ["piperacillin", "TREATMENT", 138, 150], ["tazobactam", "TREATMENT", 151, 161], ["the E. tarda strain", "PROBLEM", 194, 213], ["ciprofloxacin", "TREATMENT", 233, 246], ["aminoglycosides", "TREATMENT", 251, 266], ["her ICU hospitalization", "TREATMENT", 315, 338]]], ["She finally survived despite the grave clinical presentation of the infection.", [["infection", "DISEASE", 68, 77], ["the infection", "PROBLEM", 64, 77], ["infection", "OBSERVATION", 68, 77]]], ["Surely, our patient was immunocompetent and had no definitive risk factors for E. tarda infection, as previously discussed.", [["E. tarda infection", "DISEASE", 79, 97], ["patient", "ORGANISM", 12, 19], ["E. tarda", "ORGANISM", 79, 87], ["patient", "SPECIES", 12, 19], ["E. tarda", "SPECIES", 79, 87], ["E. tarda", "SPECIES", 79, 87], ["immunocompetent", "PROBLEM", 24, 39], ["definitive risk factors", "PROBLEM", 51, 74], ["E. tarda infection", "PROBLEM", 79, 97], ["tarda", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97]]], ["Moreover, the patient was discharged from the hospital in good health.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21]]], ["She shared her appreciation and approval regarding the received treatment and care.", [["treatment", "TREATMENT", 64, 73], ["care", "TREATMENT", 78, 82]]], ["We speculate that her survival may be at least partially attributed to both the effective drainage of the liver abscess and the administration of culture-based specific antibiotic therapy apart from the prompt initiation of supportive ICU care.", [["liver abscess", "ANATOMY", 106, 119], ["liver abscess", "DISEASE", 106, 119], ["liver", "ORGAN", 106, 111], ["the effective drainage", "TREATMENT", 76, 98], ["the liver abscess", "PROBLEM", 102, 119], ["culture", "TEST", 146, 153], ["specific antibiotic therapy", "TREATMENT", 160, 187], ["supportive ICU care", "TREATMENT", 224, 243], ["effective", "OBSERVATION_MODIFIER", 80, 89], ["drainage", "OBSERVATION", 90, 98], ["liver", "ANATOMY", 106, 111], ["abscess", "OBSERVATION", 112, 119]]], ["A currently growing body of literature has established E. tarda as an unusual cause of serious infections associated with septic shock, even in immunocompetent hosts; hence, intensivists should be aware of this potentially lethal pathogen.ConclusionE. tarda human infections could present as liver abscesses and fulminant septic shock even in immunocompetent patients.", [["liver abscesses", "ANATOMY", 292, 307], ["E. tarda", "DISEASE", 55, 63], ["infections", "DISEASE", 95, 105], ["septic shock", "DISEASE", 122, 134], ["infections", "DISEASE", 264, 274], ["liver abscesses", "DISEASE", 292, 307], ["septic shock", "DISEASE", 322, 334], ["E. tarda", "ORGANISM", 55, 63], ["human", "ORGANISM", 258, 263], ["liver", "ORGAN", 292, 297], ["patients", "ORGANISM", 359, 367], ["E. tarda", "SPECIES", 55, 63], ["human", "SPECIES", 258, 263], ["patients", "SPECIES", 359, 367], ["E. tarda", "SPECIES", 55, 63], ["human", "SPECIES", 258, 263], ["serious infections", "PROBLEM", 87, 105], ["septic shock", "PROBLEM", 122, 134], ["this potentially lethal pathogen", "PROBLEM", 206, 238], ["tarda human infections", "PROBLEM", 252, 274], ["liver abscesses", "PROBLEM", 292, 307], ["fulminant septic shock", "PROBLEM", 312, 334], ["E. tarda", "OBSERVATION_MODIFIER", 55, 63], ["serious", "OBSERVATION_MODIFIER", 87, 94], ["infections", "OBSERVATION", 95, 105], ["septic shock", "OBSERVATION", 122, 134], ["infections", "OBSERVATION", 264, 274], ["liver", "ANATOMY", 292, 297], ["abscesses", "OBSERVATION", 298, 307], ["fulminant", "OBSERVATION_MODIFIER", 312, 321], ["septic shock", "OBSERVATION", 322, 334]]], ["E. tarda strains could be resistant to broad-spectrum antibiotics; hence, culture-based antibiotics should be used accordingly.", [["E. tarda", "ORGANISM", 0, 8], ["E. tarda", "SPECIES", 0, 8], ["E. tarda", "SPECIES", 0, 8], ["E. tarda strains", "PROBLEM", 0, 16], ["broad-spectrum antibiotics", "TREATMENT", 39, 65], ["culture", "TEST", 74, 81], ["antibiotics", "TREATMENT", 88, 99], ["tarda strains", "OBSERVATION", 3, 16]]], ["Clinicians should be aware of this rare and potentially lethal infection.", [["infection", "DISEASE", 63, 72], ["lethal infection", "PROBLEM", 56, 72], ["infection", "OBSERVATION", 63, 72]]], ["Ethics approval and consent to participate Written informed consent was obtained from the patient's next-of-kin for the publication of this case report and any accompanying images.", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["any accompanying images", "TEST", 156, 179]]]], "dcecb3ef49f22680bf9e96142f00142f3b1d0873": [["IntroductionInfectious diseases, such as the MERS (Middle East Respiratory Syndrome), smallpox and human immunodeficiency virus, continue to significantly impact morbidity, mortality, and economic outcomes in many population [1] [2] [3] [4] [5] .", [["IntroductionInfectious diseases", "DISEASE", 0, 31], ["Middle East Respiratory Syndrome", "DISEASE", 51, 83], ["smallpox", "DISEASE", 86, 94], ["human immunodeficiency virus", "DISEASE", 99, 127], ["[1] [2] [3] [4] [5]", "CHEMICAL", 225, 244], ["human immunodeficiency virus", "ORGANISM", 99, 127], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 225, 244], ["human", "SPECIES", 99, 104], ["immunodeficiency virus", "SPECIES", 105, 127], ["human immunodeficiency virus", "SPECIES", 99, 127], ["IntroductionInfectious diseases", "PROBLEM", 0, 31], ["the MERS (Middle East Respiratory Syndrome)", "PROBLEM", 41, 84], ["smallpox", "PROBLEM", 86, 94], ["human immunodeficiency virus", "PROBLEM", 99, 127]]], ["The primary intervention method for preventing transmission of infectious diseases is vaccination.", [["infectious diseases", "DISEASE", 63, 82], ["The primary intervention method", "TREATMENT", 0, 31], ["infectious diseases", "PROBLEM", 63, 82], ["infectious", "OBSERVATION", 63, 73]]], ["That is because in deciding whether to vaccinate themselves, people consider the risk of morbidity from vaccination, the probability that they will become infected, and the risk of morbidity from such an infection [7] [8] [9] .", [["infection", "DISEASE", 204, 213], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["morbidity", "PROBLEM", 89, 98], ["vaccination", "TREATMENT", 104, 115], ["infected", "PROBLEM", 155, 163], ["morbidity", "PROBLEM", 181, 190], ["an infection", "PROBLEM", 201, 213]]], ["However, the game theoretical approach could be suitable to describe the decision-making processes [10] [11] [12] [13] [14] [15] .IntroductionGame theory attempts to predict individual behavior in such a setting, where the payoff to strategies chosen by individuals depends on the strategies adopted by others in the population [16] [17] [18] [19] .", [["[10] [11] [12] [13] [14] [15]", "CHEMICAL", 99, 128], ["[10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 99, 128]]], ["Zhang [20] et al. investigated Braess's Paradox in epidemic game, the results indicated that improving the successful rate of self-protection does not necessarily suppress the epidemic or increase the whole society payoff.", [["self-protection", "TREATMENT", 126, 141]]], ["Based on the probabilistic cellular automaton, Schimita [22] et al. proposed a vaccination game according to public health actions and personal decisions in which the players are the government and the susceptible newborns.", [["cellular", "ANATOMY", 27, 35], ["cellular", "CELL", 27, 35], ["newborns", "ORGANISM", 214, 222], ["a vaccination game", "TREATMENT", 77, 95]]], ["The results supported showed the disease is not fully eliminated and the government implements quasi-periodic vaccination campaigns.", [["the disease", "PROBLEM", 29, 40], ["quasi-periodic vaccination campaigns", "TREATMENT", 95, 131], ["disease", "OBSERVATION", 33, 40]]], ["Alessio [23] et al. analyzed the evolution of voluntary vaccination in scale-free networks and random networks.", [["voluntary vaccination in scale", "TREATMENT", 46, 76]]], ["The results showed that if the vaccine is perfect, scale-free networks enhance the vaccination behavior, however, imperfection may lead to a cross-over effect.", [["the vaccine", "TREATMENT", 27, 38]]], ["Eunha Shim [24] et al. investigated the game dynamic model of the vaccine skeptics and vaccine believers.", [["the vaccine skeptics", "TREATMENT", 62, 82], ["vaccine", "TREATMENT", 87, 94]]], ["They demonstrated that the pursuit of vaccine skeptics-interest among vaccine skeptics often leads to vaccination levels that are suboptimal for a population, even if complete coverage is achieved among vaccine believers.", [["vaccine skeptics", "TREATMENT", 38, 54], ["among vaccine skeptics", "TREATMENT", 64, 86], ["vaccination levels", "TEST", 102, 120]]], ["In recent years, there have been extensive research activities on time-varying networks, or called temporal networks, which evolve on a time scale comparable to the timescale of the propagation process [28, 29] .", [["temporal networks", "MULTI-TISSUE_STRUCTURE", 99, 116], ["extensive", "OBSERVATION_MODIFIER", 33, 42]]], ["The time-varying structure of link activations affects the network dynamics, from disease contagion to information diffusion [30, 31] .", [["information diffusion", "TEST", 103, 124], ["link activations", "OBSERVATION", 30, 46]]], ["The role of individual behavior in the spreading of epidemic diseases is becoming increasingly important due to increased travel activity on both short (commuting) and long (leisure or business trips) space and time scales [32, 33] .", [["epidemic diseases", "PROBLEM", 52, 69], ["increased travel activity", "PROBLEM", 112, 137]]], ["Their results showed the interaction patterns of the infected population play a major role in sustaining the epidemic.", [["infected", "OBSERVATION", 53, 61], ["epidemic", "OBSERVATION", 109, 117]]], ["Michele [35] et al. explored the immunization strategies for epidemic processes in time-varying contact networks.", [["contact networks", "MULTI-TISSUE_STRUCTURE", 96, 112], ["the immunization strategies", "TREATMENT", 29, 56]]], ["Their results suggested that the strong variation of temporal networks, however, limits the efficiency of immunization strategy.", [["temporal networks", "MULTI-TISSUE_STRUCTURE", 53, 70], ["immunization strategy", "TREATMENT", 106, 127], ["temporal networks", "OBSERVATION", 53, 70]]], ["However, the characterization and modeling of time-varying networks are still open and active areas of research [37, 38] .", [["the characterization", "TEST", 9, 29], ["active", "OBSERVATION_MODIFIER", 87, 93], ["areas", "OBSERVATION_MODIFIER", 94, 99]]], ["On the other hand, the researchers often make an assumption on the activity driven network: each activated vertex connects with the other nodes randomly.", [["nodes", "OBSERVATION", 138, 143]]], ["For example, a Chinese person will connect the other Chinese more often than American people.", [["people", "ORGANISM", 86, 92], ["person", "SPECIES", 23, 29], ["people", "SPECIES", 86, 92]]], ["We first investigate the case that vaccination is not allowed.", [["vaccination", "TREATMENT", 35, 46]]], ["The results show that under different closeness p the final density of recovered increases with the value of \u03bb/\u00b5.", [["density", "OBSERVATION_MODIFIER", 60, 67], ["recovered", "OBSERVATION_MODIFIER", 71, 80], ["increases", "OBSERVATION_MODIFIER", 81, 90]]], ["However, when vaccination is allowed, under different closeness p the final density of recovered individual first increases and then decreases with the value of \u03bb/\u00b5.", [["vaccination", "TREATMENT", 14, 25]]], ["Besides, the results point out that the closeness p may have an active role in weakening both the spreading of epidemic and the vaccination.", [["active", "OBSERVATION_MODIFIER", 64, 70]]], ["The results indicate the recovered frequency increases with the increases of the individuals' activities.", [["recovered", "OBSERVATION_MODIFIER", 25, 34], ["frequency", "OBSERVATION_MODIFIER", 35, 44], ["increases", "OBSERVATION_MODIFIER", 45, 54], ["increases", "OBSERVATION_MODIFIER", 64, 73]]], ["Meanwhile, the immune fee has less impact on individuals' vaccination than the closeness p.", [["the immune fee", "TREATMENT", 11, 25], ["individuals' vaccination", "TREATMENT", 45, 69]]], ["With the increase of the value of \u03bb/\u00b5, the recovered frequency of the whole crowds reduces.", [["\u03bb", "PROTEIN", 34, 35], ["increase", "OBSERVATION_MODIFIER", 9, 17]]], ["From the perspective of human behaviors, our findings reveal that the best of intentions may lead to backfire.IntroductionThe rest of the paper is organized into three sections.", [["sections", "ANATOMY", 168, 176], ["human", "ORGANISM", 24, 29], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29]]], ["The evolution of vaccination game is detailed and illustrated in Section 3.", [["vaccination game", "TEST", 17, 33]]], ["Section 5 presents the conclusions and the relevant discussions.The epidemic spreading in the modified activity driven networkIn most social and information systems the activity of agents generates rapidly evolving time-varying networks.", [["The epidemic spreading", "PROBLEM", 64, 86], ["epidemic", "OBSERVATION_MODIFIER", 68, 76], ["spreading", "OBSERVATION_MODIFIER", 77, 86]]], ["Activity driven models consider heterogeneous populations where each node i is characterized by a specific activity rate \u03b1 i .", [["node", "ANATOMY", 69, 73], ["heterogeneous populations", "PROBLEM", 32, 57], ["heterogeneous", "OBSERVATION_MODIFIER", 32, 45], ["populations", "OBSERVATION", 46, 57], ["node", "OBSERVATION", 69, 73]]], ["Variables \u03b1 i do not change in time and are independent and identically distributed realizations of a random variable \u03b1 i , with a probability density function F (\u03b1).", [["F (\u03b1)", "PROTEIN", 160, 165]]], ["In general, the density function is considered as a heavy-tailed form F (\u03b1) \u221d \u03b1 \u2212\u03b3 .", [["\u03b1 \u2212\u03b3", "GENE_OR_GENE_PRODUCT", 78, 82], ["\u03b1", "PROTEIN", 73, 74], ["\u03b1 \u2212\u03b3", "PROTEIN", 78, 82], ["density", "OBSERVATION", 16, 23]]], ["Realizations \u03b1 i of the random variable \u03b1 are constrained as \u03be < \u03b1 \u2264 1, where \u03be is a cutoff value that is suitably chosen to avoid the possible divergences of F (\u03b1) close to the origin.", [["F (\u03b1)", "GENE_OR_GENE_PRODUCT", 159, 164], ["F (\u03b1)", "PROTEIN", 159, 164], ["a cutoff value", "TEST", 83, 97], ["origin", "ANATOMY_MODIFIER", 178, 184]]], ["Some researchers usually make an assumption when they investigate the activity driven network: each individual which becomes active will connect with the other nodes randomly.", [["nodes", "OBSERVATION", 160, 165]]], ["For example, a Chinese person may connect the other Chinese people more often than American people.", [["people", "ORGANISM", 60, 66], ["people", "ORGANISM", 92, 98], ["person", "SPECIES", 23, 29], ["people", "SPECIES", 60, 66], ["people", "SPECIES", 92, 98]]], ["In this paper, we research a modified activity driven network.", [["a modified activity driven network", "TREATMENT", 27, 61]]], ["Considering a network with N nodes, the epidemic processes in an epidemic cycle (the epidemic cycle is defined in the following) can be described as follows.The epidemic spreading in the modified activity driven network(1) At each discrete time step t, a network G t with N nodes and zero edges is generated.The epidemic spreading in the modified activity driven network(2) Each vertex i becomes active with probability \u03b1 i and generates n links.", [["N nodes", "MULTI-TISSUE_STRUCTURE", 27, 34], ["N nodes", "PROBLEM", 27, 34], ["the epidemic processes", "PROBLEM", 36, 58], ["The epidemic spreading", "PROBLEM", 157, 179], ["N nodes and zero edges", "TREATMENT", 272, 294], ["The epidemic spreading", "PROBLEM", 308, 330], ["nodes", "OBSERVATION", 29, 34], ["epidemic", "OBSERVATION_MODIFIER", 161, 169], ["spreading", "OBSERVATION_MODIFIER", 170, 179], ["nodes", "OBSERVATION", 274, 279], ["epidemic", "OBSERVATION_MODIFIER", 312, 320], ["spreading", "OBSERVATION_MODIFIER", 321, 330], ["active", "OBSERVATION_MODIFIER", 396, 402]]], ["Taking into account the two ways of connection in activity driven network: Each link is connected to the node which has been connected with probability p (we assume if an activated individual has not connected with others, this node will select other nodes randomly).", [["node", "ANATOMY", 105, 109], ["node", "ANATOMY", 228, 232], ["node", "MULTI-TISSUE_STRUCTURE", 105, 109], ["node", "OBSERVATION", 105, 109], ["node", "OBSERVATION", 228, 232]]], ["Otherwise, it will connect with an arbitrary node with probability 1 \u2212 p.", [["node", "ANATOMY", 45, 49], ["node", "MULTI-TISSUE_STRUCTURE", 45, 49], ["an arbitrary node", "TREATMENT", 32, 49], ["node", "OBSERVATION", 45, 49]]], ["Note that when the closeness p = 1, all the individuals only connect with the individuals who have been connected, otherwise the individual select others randomly when the closeness p = 0.The epidemic spreading in the modified activity driven network(4) At time t + 1, all the links in the network G t are removed, and the process starts again from step (1).The evolution of vaccination gameThe primary intervention method for preventing transmission of infectious diseases is vaccination.", [["infectious diseases", "DISEASE", 454, 473], ["G t", "DNA", 298, 301], ["The epidemic spreading", "PROBLEM", 188, 210], ["The primary intervention method", "TREATMENT", 391, 422], ["infectious diseases", "PROBLEM", 454, 473], ["epidemic", "OBSERVATION_MODIFIER", 192, 200], ["spreading", "OBSERVATION_MODIFIER", 201, 210], ["infectious", "OBSERVATION", 454, 464]]], ["However, under the complexity of human mobility and interaction, the individuals decide whether or not to vaccinate mainly results from a tradeoff between their cost and the potential risk.", [["human", "ORGANISM", 33, 38], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38]]], ["Therefore, the game theoretical approach could be suitable to describe the decisionmaking processes.The evolution of vaccination gameWith respect to the epidemic model, our model is based on the evolution of the SIR epidemic dynamics.", [["the game theoretical approach", "TREATMENT", 11, 40], ["vaccination", "TREATMENT", 117, 128]]], ["Some assumes and instructions for the vaccination game are given as follows:The evolution of vaccination game(1) An epidemic cycle T is defined as lasting from the time the infection is first introduced to the time the last infection disappears from the population.", [["infection", "DISEASE", 173, 182], ["infection", "DISEASE", 224, 233], ["the vaccination game", "TREATMENT", 34, 54], ["the infection", "PROBLEM", 169, 182], ["the last infection", "PROBLEM", 215, 233], ["infection", "OBSERVATION", 173, 182], ["infection", "OBSERVATION", 224, 233]]], ["In general, for a large \u03ba, individuals are less responsive to payoff difference, and the strategy of the individual with a high payoff becomes less likely to be adopted.", [["a large \u03ba, individuals", "PROBLEM", 16, 38]]], ["In this paper, we let \u03ba = 0.1.The evolution of vaccination gameAn unvaccinated individual faces two different results: he will pay b if he is infected, otherwise, he will pay none if he escapes from infection.", [["infection", "DISEASE", 199, 208], ["infected", "PROBLEM", 142, 150], ["infection", "PROBLEM", 199, 208], ["infected", "OBSERVATION", 142, 150], ["infection", "OBSERVATION", 199, 208]]], ["Without loss of generality, we set the cost of infection b = 1.", [["infection", "DISEASE", 47, 56], ["loss of generality", "PROBLEM", 8, 26], ["infection b", "PROBLEM", 47, 58], ["infection", "OBSERVATION", 47, 56]]], ["Meanwhile, once one takes vaccination, he needs to pay the cost of vaccination c (in general c < 1), and the individuals can escape from contagion.", [["individuals", "ORGANISM", 109, 120], ["vaccination", "TREATMENT", 26, 37], ["vaccination c", "TREATMENT", 67, 80]]], ["The cost c includes the immediate monetary cost for vaccine and the potential risk of vaccine side-effects.", [["vaccine", "TREATMENT", 52, 59], ["vaccine side", "TREATMENT", 86, 98]]], ["After the epidemic, people have the highest payoffs are the ones who neither take vaccination nor being infected, and they pay nothing, we usually call the lucky individuals as free-riders, as they payoff from others vaccination efforts.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26]]], ["The proposed vaccination game in modified activity driven network is illustrated in Fig. 1.", [["The proposed vaccination game", "TREATMENT", 0, 29]]], ["In a cycle, the activated node connects the others according to the closeness p.", [["node", "ANATOMY", 26, 30], ["node", "MULTI-TISSUE_STRUCTURE", 26, 30], ["the activated node", "PROBLEM", 12, 30], ["node", "OBSERVATION", 26, 30]]], ["After each epidemic cycle, the individuals decide whether or not to take vaccination in the following epidemic cycle mainly results from a tradeoff between their cost and the potential risk.", [["individuals", "ORGANISM", 31, 42], ["vaccination", "TREATMENT", 73, 84]]], ["The persons who are infected pay b, otherwise pay 0.", [["persons", "ORGANISM", 4, 11], ["persons", "SPECIES", 4, 11], ["infected", "OBSERVATION", 20, 28]]], ["Once one takes vaccination, he needs to pay c.ResultsWe begin by presenting vaccination game on a network with the total population N = 2000.", [["vaccination", "TREATMENT", 15, 26]]], ["Initially, 1 percentage of vaccination and 1 percentage of infected are randomly distributed among the whole population.", [["vaccination", "TREATMENT", 27, 38], ["infected", "PROBLEM", 59, 67], ["infected", "OBSERVATION", 59, 67]]], ["Let \u03c1 V , \u03c1 R , \u03c1 S be the final density of vaccination, recovered and free-rides in the end of each cycle.", [["Let \u03c1 V", "GENE_OR_GENE_PRODUCT", 0, 7], ["\u03c1 R", "GENE_OR_GENE_PRODUCT", 10, 13], ["\u03c1 S", "GENE_OR_GENE_PRODUCT", 16, 19], ["density", "OBSERVATION", 33, 40], ["free", "OBSERVATION_MODIFIER", 71, 75]]], ["Note that the final density of recovered \u03c1 R is equal to the density of those have been infected.", [["\u03c1 R", "GENE_OR_GENE_PRODUCT", 41, 44], ["\u03c1 R", "PROTEIN", 41, 44], ["infected", "PROBLEM", 88, 96], ["final", "OBSERVATION_MODIFIER", 14, 19], ["density", "OBSERVATION", 20, 27], ["equal", "OBSERVATION_MODIFIER", 48, 53], ["density", "OBSERVATION", 61, 68], ["infected", "OBSERVATION", 88, 96]]], ["[36] , the exponents are taken \u03b3 \u2208 [2, 3], however, in this paper we used a deterministic power law distribution F (\u03b1) \u221d \u03b1 \u2212\u03b3 with \u03b3 = 1.63 and the lower cutoff \u03be = 0.01.", [["\u2212\u03b3", "TEST", 123, 125], ["\u03b3", "TEST", 131, 132], ["the lower cutoff \u03be", "TEST", 144, 162]]], ["We start our discussion by briefly reporting the behavior of the epidemic model when no vaccination is implemented.", [["vaccination", "TREATMENT", 88, 99]]], ["Fig. 2 shows the epidemic diagram \u03c1 R for the modified activity driven network when vaccination is not allowed.", [["\u03c1 R", "GENE_OR_GENE_PRODUCT", 34, 37], ["vaccination", "TREATMENT", 84, 95]]], ["As illustrated in Fig. 2 , the final density of the recovered increases with the value of \u03bb/\u00b5.", [["Fig", "OBSERVATION_MODIFIER", 18, 21], ["final", "OBSERVATION_MODIFIER", 31, 36], ["density", "OBSERVATION", 37, 44], ["recovered", "OBSERVATION_MODIFIER", 52, 61], ["increases", "OBSERVATION_MODIFIER", 62, 71]]], ["Moreover, a larger value of the closeness p could help suppress the epidemic spreading.", [["the epidemic spreading", "PROBLEM", 64, 86], ["larger", "OBSERVATION_MODIFIER", 12, 18], ["epidemic", "OBSERVATION_MODIFIER", 68, 76], ["spreading", "OBSERVATION_MODIFIER", 77, 86]]], ["That is because a larger closeness p means the individuals would like to connect with their old friends, which may effectively constrain the epidemic diffusion within localized groups of individuals.", [["the epidemic diffusion", "PROBLEM", 137, 159], ["larger", "OBSERVATION_MODIFIER", 18, 24]]], ["However, when the closeness p is relative small, the individuals could connect more other people in a cycle.ResultsThe next, we are interested in studying on how the individuals' decisions affect the final contagion densities in the modified activity driven network.", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["small", "OBSERVATION_MODIFIER", 42, 47]]], ["Obviously, one can see the vaccination density increases rapidly in the beginning, and then tends to be stable in the last.", [["the vaccination density", "PROBLEM", 23, 46], ["density", "OBSERVATION", 39, 46], ["increases", "OBSERVATION_MODIFIER", 47, 56], ["rapidly", "OBSERVATION_MODIFIER", 57, 64], ["stable", "OBSERVATION_MODIFIER", 104, 110]]], ["However, the recovered density greatly declines.", [["recovered", "OBSERVATION_MODIFIER", 13, 22], ["density", "OBSERVATION", 23, 30], ["greatly", "OBSERVATION_MODIFIER", 31, 38], ["declines", "OBSERVATION_MODIFIER", 39, 47]]], ["If people would like to vaccinate, the final size of an epidemic would significantly reduce.", [["people", "ORGANISM", 3, 9], ["people", "SPECIES", 3, 9], ["an epidemic", "PROBLEM", 53, 64], ["size", "OBSERVATION_MODIFIER", 45, 49], ["epidemic", "OBSERVATION", 56, 64]]], ["However, vaccinated individuals are tempted not to take the vaccine due to the benefits.", [["individuals", "ORGANISM", 20, 31], ["the vaccine", "TREATMENT", 56, 67]]], ["Once people get know that their immune neighbor have more payoff than them, they will take vaccination soon, and then it will form a large-scale emergence of immunity so that the immune density fast rise.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["the immune density fast rise", "PROBLEM", 175, 203]]], ["On the other hand, as time goes, people make the decision whether or not to take vaccination mainly according to comparing the payoff with their friends.", [["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["vaccination", "TREATMENT", 81, 92]]], ["With the immune number increasing, people who do not taking vaccination are more likely to connect to the vaccinated, so they will not be infected and their payoff will maintain a high level.", [["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41], ["vaccination", "TREATMENT", 60, 71]]], ["However, the free-rides will have a higher risk of infection when they contact the infected neighbors.", [["infection", "DISEASE", 51, 60], ["infection", "PROBLEM", 51, 60], ["infection", "OBSERVATION", 51, 60]]], ["In this case, the freerides will take vaccination again.", [["vaccination", "TREATMENT", 38, 49]]], ["Eventually the recovered density and free-rider density would stabilize.ResultsThe evolutions of the average fraction of recovered and vaccinated on the first 100 cycles for different closeness p are shown in Fig. 4 (we do lots of simulations by choosing different parameters, the stable-state could be obtained in the first 100 cycles.", [["the average fraction", "TEST", 97, 117], ["recovered", "OBSERVATION_MODIFIER", 15, 24], ["density", "OBSERVATION", 25, 32], ["free", "OBSERVATION_MODIFIER", 37, 41], ["rider density", "OBSERVATION", 42, 55]]], ["Interestingly, we find that a large closeness p is responsible for not only constraining the epidemic diffusion within localized groups but preventing people to vaccinate.", [["people", "ORGANISM", 151, 157], ["people", "SPECIES", 151, 157], ["the epidemic diffusion", "PROBLEM", 89, 111], ["large", "OBSERVATION_MODIFIER", 30, 35]]], ["At the same time, the average final vaccination density minimum coincides with peaks in the average final recovered density.", [["the average final vaccination density minimum", "TREATMENT", 18, 63], ["peaks", "OBSERVATION_MODIFIER", 79, 84], ["recovered", "OBSERVATION_MODIFIER", 106, 115], ["density", "OBSERVATION", 116, 123]]], ["Although the individuals may feel crisis according to the outside information (such as TV, broadcast, Internet, newspaper, and so on), however, such crisis awareness is far less than that when they get know their friends are infected.", [["crisis", "PROBLEM", 34, 40], ["infected", "OBSERVATION", 225, 233]]], ["Therefore, if the individuals only connect with limited people, that would weaken their crisis awareness.", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62]]], ["As a result, people would not take immune even if the disease exists in the network.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["the disease", "PROBLEM", 50, 61], ["disease", "OBSERVATION", 54, 61]]], ["That would sharply increase the probability of individuals to be infected.", [["individuals", "PROBLEM", 47, 58], ["infected", "PROBLEM", 65, 73], ["infected", "OBSERVATION", 65, 73]]], ["However, if the effective number of ''acquaintance'' becomes smaller and the closeness p is bigger enough (in this paper the p is close to 0.7), the total recovered individuals will reduce with the increase of the closeness p.", [["smaller", "OBSERVATION_MODIFIER", 61, 68]]], ["Above all, the results point out that the closeness p may have an active role in weakening both the spreading of epidemic and the vaccination.ResultsIn order to investigate the vaccination game processes in more detail, Fig. 5 shows the mean final density of recovered and vaccinated individuals as a function of the p and \u03bb/\u00b5 in the modified activity driven network.", [["active", "OBSERVATION_MODIFIER", 66, 72]]], ["As shown in Fig. 5 (a1)-(a3), we may observe some counterintuitive phenomena: under some certain closeness p, the final density of recovered individual first increases and then decreases with the value of \u03bb/\u00b5.", [["some counterintuitive phenomena", "PROBLEM", 45, 76], ["counterintuitive phenomena", "OBSERVATION", 50, 76]]], ["On the one hand, there are few higher activity individuals throughout the crowds which result in a few connections between individuals.", [["few higher activity individuals", "PROBLEM", 27, 58], ["few", "OBSERVATION_MODIFIER", 27, 30], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["activity", "OBSERVATION_MODIFIER", 38, 46], ["few", "OBSERVATION_MODIFIER", 99, 102]]], ["On the other hand, the recovery rate is relatively larger when the value of \u03bb/\u00b5 is smaller.", [["\u03bb", "PROTEIN", 76, 77], ["the recovery rate", "TEST", 19, 36], ["the value", "TEST", 63, 72], ["relatively", "OBSERVATION_MODIFIER", 40, 50], ["larger", "OBSERVATION", 51, 57], ["smaller", "OBSERVATION_MODIFIER", 83, 90]]], ["Therefore, although some individuals are infected, the epidemic could not spread widely.", [["individuals", "ORGANISM", 25, 36], ["infected", "PROBLEM", 41, 49], ["infected", "OBSERVATION", 41, 49]]], ["However, once the value of \u03bb/\u00b5 is larger enough, the probability that the susceptible to be infected increases.", [["\u03bb", "PROTEIN", 27, 28], ["the value", "TEST", 14, 23], ["\u03bb/\u00b5", "PROBLEM", 27, 30], ["larger", "OBSERVATION_MODIFIER", 34, 40], ["infected", "OBSERVATION", 92, 100]]], ["Due to the crisis awareness has been escalated, more individuals would like to take immune avoiding to be infected.", [["the crisis awareness", "PROBLEM", 7, 27], ["infected", "PROBLEM", 106, 114], ["infected", "OBSERVATION", 106, 114]]], ["Therefore, according to Fig. 5 (b1)-(b3), we could observe that the density of vaccination increases with the \u03bb/\u00b5.", [["vaccination", "PROBLEM", 79, 90], ["density", "OBSERVATION", 68, 75]]], ["In order to investigate the relation between individuals' activities and their states, we set two variables named F R (\u03b1) and F V (\u03b1) that denote the frequency of the individual with activity \u03b1 of becoming recovered or taking vaccination during some given cycles, respectively.", [["F R", "GENE_OR_GENE_PRODUCT", 114, 117], ["F V", "GENE_OR_GENE_PRODUCT", 126, 129], ["F R", "PROTEIN", 114, 117], ["vaccination", "TREATMENT", 226, 237]]], ["We express them by using the following equations: where T denotes the total cycles of the epidemic process, C R (\u03b1) and C V (\u03b1) are the times of an individual with activity \u03b1 of becoming recovered or taking vaccination during T cycles, respectively.", [["C R", "GENE_OR_GENE_PRODUCT", 108, 111], ["C V (\u03b1)", "GENE_OR_GENE_PRODUCT", 120, 127]]], ["As shown in Fig. 6(a) , as expected, the frequency of recovered becomes larger with the increase of the individuals' activity.ResultsFor the case of p = 0, which means the activated individuals connect with others randomly, the gap of recovered frequency for the individuals with maximum and the minimum activity approaches to F R (\u03b1 max ) \u2212 F R (\u03b1 min ) \u2243 0.1.", [["larger", "OBSERVATION_MODIFIER", 72, 78], ["increase", "OBSERVATION_MODIFIER", 88, 96]]], ["However, for the case of p = 1, which means the activated individuals only connect with the one who have been known, the gap of recovered frequency for the individuals with maximum and the minimum activity approaches toResultsThe results indicate the difference of recovered frequency becomes smaller with the decreases of the closeness p.", [["smaller", "OBSERVATION_MODIFIER", 293, 300], ["decreases", "OBSERVATION_MODIFIER", 310, 319]]], ["According to Fig. 6(b) , the frequency of vaccination becomes larger when p is larger.", [["vaccination", "TREATMENT", 42, 53], ["larger", "OBSERVATION_MODIFIER", 62, 68], ["larger", "OBSERVATION_MODIFIER", 79, 85]]], ["However, the disparity of vaccination between the maximum and the minimum activity individuals is not obvious.", [["vaccination", "TREATMENT", 26, 37], ["disparity", "OBSERVATION_MODIFIER", 13, 22], ["maximum", "OBSERVATION_MODIFIER", 50, 57], ["not obvious", "UNCERTAINTY", 98, 109]]], ["As one can see from Fig. 7(a) , the recovered frequency for the same individual increases with the immune cost.", [["the immune cost", "TREATMENT", 95, 110]]], ["Fig. 7(b) shows that the vaccinated frequency increases with the individuals' activity.", [["the vaccinated frequency", "PROBLEM", 21, 45]]], ["The results indicate the immune cost has less effect on the vaccination than the closeness p.ResultsAs illustrated in Fig. 8(a) , the recovered frequency, counterintuitive, declines with the increase of the value of \u03bb/\u00b5.", [["the immune cost", "PROBLEM", 21, 36], ["the vaccination", "TREATMENT", 56, 71]]], ["Meanwhile, as shown in Fig. 8(b) , more people would like to take immune while the value of \u03bb/\u00b5 becomes larger.", [["people", "ORGANISM", 40, 46], ["\u03bb", "PROTEIN", 92, 93], ["people", "SPECIES", 40, 46], ["\u03bb/\u00b5", "PROBLEM", 92, 95], ["larger", "OBSERVATION_MODIFIER", 104, 110]]], ["[20] .Conclusion and discussionWe explore an evolutionary vaccination game in a modified activity driven network by considering the closeness.", [["an evolutionary vaccination", "TREATMENT", 42, 69]]], ["Firstly, when vaccination is not allowed, under different closeness p the final density of recovered increases with the value of \u03bb/\u00b5.", [["vaccination", "TREATMENT", 14, 25], ["increases", "OBSERVATION_MODIFIER", 101, 110]]], ["However, when vaccination is allowed, under different closeness p the final density of recovered individual first increases and then decreases with the value of \u03bb/\u00b5.", [["vaccination", "TREATMENT", 14, 25]]], ["Moreover, our results point out that the closeness p may have an active role in weakening both the spreading of epidemic and the vaccination.", [["active", "OBSERVATION_MODIFIER", 65, 71]]], ["The results indicate recovered frequency increases with the increase of the individuals' activity.", [["recovered", "OBSERVATION_MODIFIER", 21, 30], ["frequency", "OBSERVATION_MODIFIER", 31, 40], ["increases", "OBSERVATION_MODIFIER", 41, 50]]], ["Meanwhile, the immune fee has less impact on individual than the closeness p.", [["the immune fee", "TREATMENT", 11, 25], ["less impact", "OBSERVATION_MODIFIER", 30, 41]]], ["With the increase of the value of \u03bb/\u00b5, the recovered frequency of the whole crowds reduces.Conclusion and discussionAlthough the epidemic may be suppressed within localized groups if an individual only connect with their old friends, the available information become less.", [["\u03bb", "PROTEIN", 34, 35], ["increase", "OBSERVATION_MODIFIER", 9, 17]]], ["Because the crisis awareness can influence the individuals' attitude towards epidemic, some better hope (such as reducing the connection) may lead to backfire.", [["the crisis awareness", "PROBLEM", 8, 28], ["epidemic", "PROBLEM", 77, 85], ["crisis", "OBSERVATION", 12, 18]]]], "670fba401fbf5bd8e647e4cc2a4fb61d64929f81": [["The importance of public sector operationsThe importance of the public sector in providing crucial services to citizens regardless of income or status is clearly evidenced through the provision of healthcare, education, housing, the military, law enforcement and infrastructure.", [["public sector operations", "TREATMENT", 18, 42]]], ["In the UK alone there are over 5.39 million people employed in the public sector as of March 2019 (Office for National Statistics, 2020), which is equivalent to 39.5% of GDP in the 2018e19 fiscal year.", [["GDP", "CHEMICAL", 170, 173], ["people", "ORGANISM", 44, 50], ["GDP", "SIMPLE_CHEMICAL", 170, 173], ["people", "SPECIES", 44, 50]]], ["The size and scale of public sector operations have raised questions from policymakers about its efficiency, productivity and service levels.", [["public sector operations", "TREATMENT", 22, 46], ["size", "OBSERVATION_MODIFIER", 4, 8], ["scale", "OBSERVATION_MODIFIER", 13, 18]]], ["Following the 2008 global financial crisis, the public sector has been subject to governmental reforms and transformations with the objective of enhancing management capacities and capabilities.", [["the 2008 global financial crisis", "PROBLEM", 10, 42], ["financial crisis", "OBSERVATION", 26, 42]]], ["This efficiency focus has led to calls from researchers, management consultants, policymakers and think tanks to increase the application of operations management practices within the public sector.", [["operations management practices", "TREATMENT", 141, 172]]], ["It is important to note that the public sector context of efficiency goes beyond saving money and requires effort to improve the quality of service delivery.", [["delivery", "TREATMENT", 148, 156]]], ["Co-producing public services with citizens and beneficiaries, and innovative applications of continuous improvement methodologies are perceived as mechanisms for driving structural public sector transformational change (Meijer, 2016) .Operations management driving public sector improvementAgainst a backdrop of competition in both public and private services, the need to improve remains constant.", [["beneficiaries", "TREATMENT", 47, 60], ["innovative applications", "TREATMENT", 66, 89], ["continuous improvement methodologies", "TREATMENT", 93, 129], ["Operations management", "TREATMENT", 235, 256]]], ["There are numerous approaches to service improvement and organisations will have used many of these in their pursuit of improved service and product quality.", [["numerous", "OBSERVATION_MODIFIER", 10, 18]]], ["There are disparate views about adopting 'off-the-shelf' service improvement packages (possibly leading to blind Lean implementation) as opposed to those which are customised to meet the needs of individual organisations (Carter et al., 2011; Holmemo, Ingvaldsen, & Benders, 2017; Osborne, Radnor, Kinder, & Vidal, 2015) .", [["blind Lean implementation", "TREATMENT", 107, 132]]], ["However, Antony, Rodgers, and Gijo (2016) argue that applications of Lean Six Sigma might be more widespread than one may appreciate.", [["Lean Six Sigma", "TREATMENT", 69, 83]]], ["They report on Lean Six Sigma practices in criminal justice, healthcare, education and local government, demonstrating cost reduction and financial gain, quality improvement and increase in throughput times.", [["cost reduction", "TREATMENT", 119, 133], ["increase", "OBSERVATION_MODIFIER", 178, 186]]], ["Radnor and Johnston (2013) draw on two extensive case studies of large UK Government departments to demonstrate that while Lean leads to improvement, it is not consistently linked with the concept of value or customer service, which will be critical for sustained improvements in the future.", [["large", "OBSERVATION_MODIFIER", 65, 70]]], ["Moreover, Lindsay et al. (2014) , in their discussion on Lean in the UK NHS, report that compared to other European countries the UK has more tendency towards applying Lean methods.", [["UK", "GENE_OR_GENE_PRODUCT", 130, 132], ["Lean methods", "TREATMENT", 168, 180]]], ["This predominant application in the UK is reported in more detail at a country and global level in recent research by Lukrafka, Souza Silva & Echeveste (2020) .", [["UK", "GENE_OR_GENE_PRODUCT", 36, 38], ["predominant", "OBSERVATION_MODIFIER", 5, 16], ["application", "OBSERVATION", 17, 28]]], ["In their study, the sectors represented in the literature in the context of Europe are health, education, central government and local government.", [["their study", "TEST", 3, 14]]], ["Having said that, it has been suggested that for public service improvement to be fully embedded, when compared with the private sector, a greater level of employee integration, empowerment and engagement is necessary, and this should be driven by governments and other public institutions (Antony et al., 2016) .The need to plan for the future and innovateThe purpose of adopting Lean, Six Sigma, Process Reengineering, and all other quality improvement philosophies, tools and techniques, is to improve business results, service delivery, product manufacturing, and operational and people performance.", [["people", "ORGANISM", 584, 590], ["people", "SPECIES", 584, 590]]], ["Moreover, this strategy has to be embedded in a culture that seeks to change and adapt to being agile and resilient.", [["a culture", "TEST", 46, 55]]], ["This approach can be a challenge for traditional public sector services but is not insurmountable.", [["traditional public sector services", "TREATMENT", 37, 71]]], ["Some improvement can be incremental (Kaizen) and some rapid, responsive and innovative (Breakthrough).", [["some rapid, responsive and innovative (Breakthrough)", "PROBLEM", 49, 101], ["improvement", "OBSERVATION_MODIFIER", 5, 16], ["rapid", "OBSERVATION_MODIFIER", 54, 59]]], ["The latter poses significant opportunities and risks to organisations choosing to adopt this strategy.", [["this strategy", "TREATMENT", 88, 101]]], ["Yet, with risks come gains and thus this is a worthwhile endeavour for some organisations.The need to plan for the future and innovateThe concept of Public Service Innovation has also been increasing in relevance and a typology of focus (strategy, capacity and operation) and locus (internal or external) is proposed (Chen, Walker, & Sawhney, 2019) .", [["operation", "TREATMENT", 261, 270]]], ["In this vein, the leadership role in the public sector is brought to the fore by Leslie and Canwell (2010) who argue that public sector organisations need leaders who can promote change within complex systems, deal with challenging environments, motivate people and promote leadership development at all levels of the organisation.", [["vein", "ANATOMY", 8, 12], ["vein", "MULTI-TISSUE_STRUCTURE", 8, 12], ["people", "ORGANISM", 255, 261], ["people", "SPECIES", 255, 261], ["vein", "ANATOMY", 8, 12]]], ["Healthcare is an excellent example of a Complex Adaptive System (Fylan, Tranmer, Armitage, & Blenkinsopp, 2019) and so its management requires a blend of incremental and innovation improvement agendas.The need to plan for the future and innovateIn order for public sector organisations to achieve efficiencies and improved service provision, the modus operandi has shifted towards cross-sectoral provision, where public sector organisations are the clients of private sector providers (e.g. Jost, Dawson, & Shaw, 2005) and there is increased outsourcing of back-office functions, such as finance and accounting and facilities management, e.g. McIvor, McCracken, and McHugh (2011) .", [["public sector organisations", "TREATMENT", 258, 285], ["increased", "OBSERVATION_MODIFIER", 532, 541]]], ["This paves the way for service model development focussing on all aspects of the operation including the adoption of new technologies and connection with customers, patients and users.", [["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["the operation", "TREATMENT", 77, 90]]], ["Technology, project management and performance measurement are also often identified as key catalysts and drivers enabling the public sector to morph, modernise and mimic the private sector in order to be more effective and efficient in delivering 'value for money' (Armitage, 2019; Beynon-Davies & Martin, 2004; Fryer, Antony, & Ogden, 2009 ).", [["performance measurement", "TEST", 35, 58]]], ["Strategically combining improvement agendas such as resource efficiency, service delivery, effective use of technology and meeting the needs of patients is a challenge but can be done within the public sector.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152]]], ["This is demonstrated by Xie, Breen, Cherrett, Zheng, and Allen (2016) in their examination of reverse exchange systems for medical devices in the NHS and, similarly, by Cole, Lindsay, and Barker (2018) in relation to hearing aid equipment.", [["their examination", "TEST", 73, 90], ["reverse exchange systems", "TREATMENT", 94, 118], ["medical devices", "TREATMENT", 123, 138], ["hearing aid equipment", "TREATMENT", 217, 238]]], ["This issue is further addressed in this Management Focus with the example of workforce skills development in the pharmacy profession (Breen, Acosta Gomez, Tomlinson, Medlinskiene & Elies-Gomez, 2020) .About this Management Focus sectionThis Management Focus section was inspired by the constant challenges that public sector organisations in Europe face, not to mention all the current issues, such as forced migration, Covid-19 and Brexit, to name just a few.", [["this Management", "TREATMENT", 35, 50], ["this Management", "TREATMENT", 207, 222], ["Covid", "TEST", 420, 425]]], ["It seems that public sector organisations in European countries need to be prepared to serve the increasing demands of their population within the context of austerity measures and delivering value for money.", [["austerity measures", "TREATMENT", 158, 176]]], ["We set out to go beyond country-specific studies and promoted comparative crosscountry analyses in the call for papers for this Management Focus section.", [["specific studies", "TEST", 32, 48], ["this Management", "TREATMENT", 123, 138]]], ["The reason for this was to facilitate the sharing of good practice and to subsequently avoid the pitfalls identified in tried and tested studies.", [["tested studies", "TEST", 130, 144]]], ["We believe they will contribute to the current debates and discussions around the modernisation of European public services as well as provide practical solutions to improve performance and 'value for money'.", [["practical solutions", "TREATMENT", 143, 162]]], ["We also anticipate that public sector organisations will be encouraged to innovate and adopt best practices based on this collection of articles.About this Management Focus sectionFirst, Liz Breen, Jaime Acosta-G omez, Justine Tomlinson, Kristina Medlinskiene and Jacobo Elies-Gomez (A preliminary insight into the role and importance of management skills in the prevention of occupational derailment: An exploratory analysis of UK and Spanish pharmacists) compare the role of management skills for pharmacists in both UK and Spain.", [["this Management", "TREATMENT", 151, 166], ["Justine Tomlinson", "TREATMENT", 219, 236], ["Kristina Medlinskiene", "TREATMENT", 238, 259], ["management skills", "TREATMENT", 338, 355]]], ["They used semi-structured online surveys to collect data, which offer preliminary insights into the importance of management (non-technical) skills in role deployment and practice resilience.", [["practice resilience", "TREATMENT", 171, 190]]], ["The authors also pause to consider the negative consequences on future healthcare provision if these skills are not acquired and further developed.About this Management Focus sectionSecond, Tatiany Lukrafka, Diego Souza Silva and Marcia Echeveste (A geographic picture of Lean adoption in the public sector: Cases, approaches, and a refreshed agenda) present the results of a qualitative systematic review of Lean application in the public sector around the globe, which provides a strategic overview of the spread of the Lean concept in different countries.", [["this Management", "TREATMENT", 153, 168], ["Lean application", "TREATMENT", 409, 425], ["globe", "ANATOMY", 458, 463]]], ["Relevant insights and future research agendas are derived from their study.About this Management Focus sectionThird, Heather Skipworth, Emanuela Delbufalo and Carlos Mena (Logistics and procurement outsourcing in the healthcare sector: a comparative analysis) compare the logistics and procurement outsourcing practices of healthcare providers in the UK and Italy.", [["their study", "TEST", 63, 74], ["this Management", "TREATMENT", 81, 96], ["a comparative analysis", "TEST", 236, 258]]], ["They provide some insights on the processes and dimensions that are relevant and irrelevant in relation to other contexts.About this Management Focus sectionFinally, Graham Manville and Richard Greatbanks (Performance management in hybrid organisations: A study in social housing) present the hybridization issues of social housing in the UK, mainly through the provision of services via third sector organisations.", [["this Management", "TREATMENT", 128, 143], ["A study", "TEST", 254, 261]]], ["Within this work, there is a concerted focus on a comparative exploration of social housing in Europe that provides the grounding for a more detailed analysis of the UK social housing sector.", [["a comparative exploration", "TEST", 48, 73]]], ["The authors advocate the alignment with strategic performance measurement, when assessing such hybrid issues.About this Management Focus sectionThe future research agenda points towards the following: developing key aspects of the strategic management of public sector organisations, such as workforce development, knowledge management systems and performance measurement practices that are fit for purpose for public sector organisations.", [["strategic performance measurement", "TEST", 40, 73], ["such hybrid issues", "PROBLEM", 90, 108], ["this Management", "TREATMENT", 115, 130], ["performance measurement practices", "TEST", 348, 381], ["public sector organisations", "TREATMENT", 411, 438]]], ["An emphasis on learning from different public sector contexts is also essential, as demonstrated by the European comparative focus of this Management Focus section.", [["this Management", "TREATMENT", 134, 149]]], ["Finally, in delivering to this Management Focus, the papers present research grounded in a range of qualitative methods, including online surveys, interviews, case study analysis and systematic literature review.", [["this Management", "TREATMENT", 26, 41], ["case study analysis", "TEST", 159, 178], ["systematic literature review", "TEST", 183, 211]]], ["Each of which was instrumental in producing the resultant analysis and insights into public sector improvement activities in the UK and Europe.", [["the resultant analysis", "TEST", 44, 66]]], ["These are important in directing further research to support public sector organisations and social communities in responding to the impact of this threat.About this Management Focus sectionWe would like to thank all authors, reviewers and the Editor-in-Chief of the European Management Journal who made this Management Focus section possible.", [["this Management", "TREATMENT", 161, 176], ["this Management", "TREATMENT", 304, 319]]], ["There were 13 submissions, with 9 rejected articles for the following reasons: not within the scope of this call and inadequate provision of comparative analysis.", [["comparative analysis", "TEST", 141, 161]]]], "17845fc831495c6ed20d436bbab6a7a0c77a48ec": [["Abstract The \"wait and see\" approach in acute otitis media (AOM), consisting of postponing the antibiotic administration for a few days, has been advocated mainly to counteract the increased bacterial resistance in respiratory infections.", [["respiratory", "ANATOMY", 215, 226], ["otitis", "DISEASE", 46, 52], ["AOM", "DISEASE", 60, 63], ["respiratory infections", "DISEASE", 215, 237], ["acute otitis media", "PROBLEM", 40, 58], ["the antibiotic administration", "TREATMENT", 91, 120], ["the increased bacterial resistance in respiratory infections", "PROBLEM", 177, 237], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["otitis", "OBSERVATION", 46, 52], ["increased", "OBSERVATION_MODIFIER", 181, 190], ["bacterial resistance", "OBSERVATION", 191, 211], ["respiratory infections", "OBSERVATION", 215, 237]]], ["This approach is not justified in children less than 2 years of age and this for several reasons.", [["children", "ORGANISM", 34, 42], ["children", "SPECIES", 34, 42], ["not justified", "UNCERTAINTY", 17, 30]]], ["First, AOM is an acute inflammation of the middle ear caused in about 70% of cases by bacteria.", [["middle ear", "ANATOMY", 43, 53], ["AOM", "DISEASE", 7, 10], ["inflammation of the middle ear", "DISEASE", 23, 53], ["ear", "ORGAN", 50, 53], ["AOM", "PROBLEM", 7, 10], ["an acute inflammation of the middle ear", "PROBLEM", 14, 53], ["bacteria", "PROBLEM", 86, 94], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["inflammation", "OBSERVATION", 23, 35], ["middle ear", "ANATOMY", 43, 53], ["bacteria", "OBSERVATION", 86, 94]]], ["Redness and bulging of the tympanic membrane are characteristic findings in bacterial AOM.", [["tympanic membrane", "ANATOMY", 27, 44], ["AOM", "DISEASE", 86, 89], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 27, 44], ["Redness", "PROBLEM", 0, 7], ["bulging of the tympanic membrane", "PROBLEM", 12, 44], ["bacterial AOM", "PROBLEM", 76, 89], ["bulging", "OBSERVATION", 12, 19], ["tympanic membrane", "ANATOMY", 27, 44], ["bacterial AOM", "OBSERVATION", 76, 89]]], ["Second, AOM is associated with long-term dysfunction of the inflamed eustachian tube (ET), particularly in children less than 2 years of age.", [["eustachian tube", "ANATOMY", 69, 84], ["AOM", "DISEASE", 8, 11], ["eustachian tube", "MULTI-TISSUE_STRUCTURE", 69, 84], ["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["AOM", "PROBLEM", 8, 11], ["long-term dysfunction of the inflamed eustachian tube", "PROBLEM", 31, 84], ["AOM", "OBSERVATION", 8, 11], ["long-term", "OBSERVATION_MODIFIER", 31, 40], ["dysfunction", "OBSERVATION", 41, 52], ["inflamed", "OBSERVATION_MODIFIER", 60, 68], ["eustachian tube", "OBSERVATION", 69, 84]]], ["In this age group, the small calibre of the ET together with its horizontal direction result in impaired clearance, ventilation and protection of the middle ear.", [["middle ear", "ANATOMY", 150, 160], ["ear", "ORGAN", 157, 160], ["impaired clearance", "PROBLEM", 96, 114], ["ventilation", "TREATMENT", 116, 127], ["protection of the middle ear", "TREATMENT", 132, 160], ["small", "OBSERVATION_MODIFIER", 23, 28], ["calibre", "OBSERVATION_MODIFIER", 29, 36], ["horizontal", "OBSERVATION_MODIFIER", 65, 75], ["impaired", "OBSERVATION_MODIFIER", 96, 104], ["clearance", "OBSERVATION", 105, 114], ["middle ear", "ANATOMY", 150, 160]]], ["Third, recent prospective studies have shown poor long-term prognosis of AOM in children below 2 years with at least 50% of recurrences and persisting otitis media with effusion (OME) in about 35% 6 months after AOM.", [["AOM", "DISEASE", 73, 76], ["otitis media", "DISEASE", 151, 163], ["effusion", "DISEASE", 169, 177], ["OME", "DISEASE", 179, 182], ["AOM", "DISEASE", 212, 215], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["recent prospective studies", "TEST", 7, 33], ["AOM", "PROBLEM", 73, 76], ["recurrences", "PROBLEM", 124, 135], ["persisting otitis media", "PROBLEM", 140, 163], ["effusion", "PROBLEM", 169, 177], ["OME", "PROBLEM", 179, 182], ["AOM", "PROBLEM", 212, 215], ["poor long-term", "OBSERVATION_MODIFIER", 45, 59], ["AOM", "OBSERVATION", 73, 76], ["recurrences", "OBSERVATION", 124, 135], ["persisting", "OBSERVATION_MODIFIER", 140, 150], ["otitis", "OBSERVATION", 151, 157], ["effusion", "OBSERVATION", 169, 177]]], ["Viruses elicit AOM in about 30% of children.", [["AOM", "DISEASE", 15, 18], ["AOM", "CANCER", 15, 18], ["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43], ["AOM", "OBSERVATION", 15, 18]]], ["A prolonged course of AOM has been observed when bacterial and viral infections are combined because viral infection is also associated with ET dysfunction in young children.", [["AOM", "DISEASE", 22, 25], ["bacterial and viral infections", "DISEASE", 49, 79], ["viral infection", "DISEASE", 101, 116], ["ET dysfunction", "DISEASE", 141, 155], ["children", "ORGANISM", 165, 173], ["children", "SPECIES", 165, 173], ["AOM", "PROBLEM", 22, 25], ["bacterial", "PROBLEM", 49, 58], ["viral infections", "PROBLEM", 63, 79], ["viral infection", "PROBLEM", 101, 116], ["ET dysfunction", "PROBLEM", 141, 155], ["viral", "OBSERVATION_MODIFIER", 63, 68], ["infections", "OBSERVATION", 69, 79], ["infection", "OBSERVATION", 107, 116]]], ["Bacterial and viral testing of the nasopharyngeal aspirate is an excellent tool both for initial treatment and recurrence of AOM.", [["nasopharyngeal aspirate", "ANATOMY", 35, 58], ["AOM", "DISEASE", 125, 128], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 35, 58], ["AOM", "PATHOLOGICAL_FORMATION", 125, 128], ["Bacterial", "PROBLEM", 0, 9], ["viral testing", "TEST", 14, 27], ["the nasopharyngeal aspirate", "TEST", 31, 58], ["initial treatment", "TREATMENT", 89, 106], ["AOM", "PROBLEM", 125, 128], ["viral", "OBSERVATION", 14, 19], ["nasopharyngeal", "ANATOMY", 35, 49], ["aspirate", "OBSERVATION", 50, 58], ["AOM", "OBSERVATION", 125, 128]]], ["Antibiotic treatment of AOM is mandatory in children less than 2 years of age to decrease inflammation in the middle ear but also of the ET particularly during the first episode.", [["middle ear", "ANATOMY", 110, 120], ["AOM", "DISEASE", 24, 27], ["inflammation", "DISEASE", 90, 102], ["children", "ORGANISM", 44, 52], ["ear", "ORGAN", 117, 120], ["children", "SPECIES", 44, 52], ["Antibiotic treatment", "TREATMENT", 0, 20], ["AOM", "PROBLEM", 24, 27], ["inflammation in the middle ear", "PROBLEM", 90, 120], ["AOM", "OBSERVATION", 24, 27], ["decrease", "OBSERVATION_MODIFIER", 81, 89], ["inflammation", "OBSERVATION", 90, 102], ["middle ear", "ANATOMY", 110, 120]]], ["The best choice is amoxicillin because of its superior penetration in the middle ear.", [["middle ear", "ANATOMY", 74, 84], ["amoxicillin", "CHEMICAL", 19, 30], ["amoxicillin", "CHEMICAL", 19, 30], ["amoxicillin", "SIMPLE_CHEMICAL", 19, 30], ["ear", "ORGAN", 81, 84], ["amoxicillin", "TREATMENT", 19, 30], ["its superior penetration in the middle ear", "PROBLEM", 42, 84], ["superior", "OBSERVATION_MODIFIER", 46, 54], ["penetration", "OBSERVATION", 55, 66], ["middle ear", "ANATOMY", 74, 84]]], ["Streptococci pneumoniae with intermediary bacterial resistance to penicillin are particularly associated with recurrent AOM.", [["penicillin", "CHEMICAL", 66, 76], ["AOM", "DISEASE", 120, 123], ["penicillin", "CHEMICAL", 66, 76], ["Streptococci pneumoniae", "ORGANISM", 0, 23], ["penicillin", "SIMPLE_CHEMICAL", 66, 76], ["AOM", "PATHOLOGICAL_FORMATION", 120, 123], ["Streptococci pneumoniae", "SPECIES", 0, 23], ["Streptococci pneumoniae", "SPECIES", 0, 23], ["Streptococci pneumoniae", "PROBLEM", 0, 23], ["intermediary bacterial resistance", "PROBLEM", 29, 62], ["penicillin", "TREATMENT", 66, 76], ["recurrent AOM", "PROBLEM", 110, 123], ["pneumoniae", "OBSERVATION", 13, 23], ["intermediary bacterial resistance", "OBSERVATION", 29, 62], ["recurrent", "OBSERVATION_MODIFIER", 110, 119], ["AOM", "OBSERVATION", 120, 123]]], ["Therefore the dosage of amoxicillin should be 90 mg/kg per day in three doses.", [["amoxicillin", "CHEMICAL", 24, 35], ["amoxicillin", "CHEMICAL", 24, 35], ["amoxicillin", "SIMPLE_CHEMICAL", 24, 35], ["amoxicillin", "TREATMENT", 24, 35]]], ["In recurrent AOM with \u03b2-lactamase-producing bacilli, amoxicillin should be associated with clavulanic acid at a dose of 6.4 mg/kg per day.", [["AOM", "DISEASE", 13, 16], ["amoxicillin", "CHEMICAL", 53, 64], ["clavulanic acid", "CHEMICAL", 91, 106], ["amoxicillin", "CHEMICAL", 53, 64], ["clavulanic acid", "CHEMICAL", 91, 106], ["\u03b2-lactamase-producing bacilli", "SIMPLE_CHEMICAL", 22, 51], ["amoxicillin", "SIMPLE_CHEMICAL", 53, 64], ["clavulanic acid", "SIMPLE_CHEMICAL", 91, 106], ["recurrent AOM", "PROBLEM", 3, 16], ["\u03b2-lactamase", "TEST", 22, 33], ["bacilli", "PROBLEM", 44, 51], ["amoxicillin", "TREATMENT", 53, 64], ["clavulanic acid", "TREATMENT", 91, 106], ["recurrent", "OBSERVATION_MODIFIER", 3, 12], ["AOM", "OBSERVATION", 13, 16]]], ["The duration of the treatment is not established yet but 10 days is reasonable for a first episode of AOM.", [["AOM", "DISEASE", 102, 105], ["AOM", "PATHOLOGICAL_FORMATION", 102, 105], ["the treatment", "TREATMENT", 16, 29], ["AOM", "PROBLEM", 102, 105], ["AOM", "OBSERVATION", 102, 105]]], ["OME may be a precursor initiating AOM but also a complication thereof.", [["OME", "DISEASE", 0, 3], ["AOM", "DISEASE", 34, 37], ["AOM", "CANCER", 34, 37], ["OME", "PROBLEM", 0, 3], ["a precursor initiating AOM", "PROBLEM", 11, 37], ["a complication thereof", "PROBLEM", 47, 69]]], ["OME needs a watchful waiting approach.", [["OME", "DISEASE", 0, 3], ["a watchful waiting approach", "TREATMENT", 10, 37]]], ["When associated with deafness for 2-3 months in children over 2 years of age, an antibiotic should be given according to the results of the bacterial resistance in the nasopharyngeal aspirate.", [["nasopharyngeal aspirate", "ANATOMY", 168, 191], ["deafness", "DISEASE", 21, 29], ["children", "ORGANISM", 48, 56], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 168, 191], ["children", "SPECIES", 48, 56], ["deafness", "PROBLEM", 21, 29], ["an antibiotic", "TREATMENT", 78, 91], ["the bacterial resistance in the nasopharyngeal aspirate", "PROBLEM", 136, 191], ["bacterial resistance", "OBSERVATION", 140, 160], ["nasopharyngeal", "ANATOMY", 168, 182], ["aspirate", "OBSERVATION", 183, 191]]], ["The high rate of complications of tympanostomy tube insertion outweighs the beneficial effect on hearing loss.", [["hearing loss", "DISEASE", 97, 109], ["tube", "TISSUE", 47, 51], ["tympanostomy tube insertion", "TREATMENT", 34, 61], ["hearing loss", "PROBLEM", 97, 109], ["high", "OBSERVATION_MODIFIER", 4, 8], ["complications", "OBSERVATION", 17, 30], ["tympanostomy tube", "OBSERVATION", 34, 51], ["insertion", "OBSERVATION", 52, 61], ["hearing loss", "OBSERVATION", 97, 109]]], ["The poor results of this procedure are due to the absence of effects on ET dysfunction.", [["this procedure", "TREATMENT", 20, 34], ["ET dysfunction", "PROBLEM", 72, 86]]], ["Pneumococcal vaccination has little beneficial effects on recurrent AOM and its use in infants needs further studies.", [["AOM", "DISEASE", 68, 71], ["infants", "ORGANISM", 87, 94], ["infants", "SPECIES", 87, 94], ["Pneumococcal vaccination", "TREATMENT", 0, 24], ["recurrent AOM", "PROBLEM", 58, 71], ["further studies", "TEST", 101, 116], ["AOM", "OBSERVATION", 68, 71]]], ["Treatment with amoxicillin is indicated in all children younger than 2 years with a first episode of AOM presenting with redness and bulging of the tympanic membrane.", [["tympanic membrane", "ANATOMY", 148, 165], ["amoxicillin", "CHEMICAL", 15, 26], ["AOM", "DISEASE", 101, 104], ["redness", "DISEASE", 121, 128], ["amoxicillin", "CHEMICAL", 15, 26], ["amoxicillin", "SIMPLE_CHEMICAL", 15, 26], ["children", "ORGANISM", 47, 55], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 148, 165], ["children", "SPECIES", 47, 55], ["amoxicillin", "TREATMENT", 15, 26], ["AOM", "PROBLEM", 101, 104], ["redness", "PROBLEM", 121, 128], ["bulging of the tympanic membrane", "PROBLEM", 133, 165], ["AOM", "OBSERVATION", 101, 104], ["redness", "OBSERVATION", 121, 128], ["bulging", "OBSERVATION", 133, 140], ["tympanic membrane", "ANATOMY", 148, 165]]], ["Combined amoxicillin and clavulanic acid should be given in patients with \u03b2lactamase-producing bacteria.", [["amoxicillin and clavulanic acid", "CHEMICAL", 9, 40], ["amoxicillin", "CHEMICAL", 9, 20], ["clavulanic acid", "CHEMICAL", 25, 40], ["amoxicillin", "SIMPLE_CHEMICAL", 9, 20], ["clavulanic acid", "SIMPLE_CHEMICAL", 25, 40], ["patients", "ORGANISM", 60, 68], ["\u03b2lactamase", "GENE_OR_GENE_PRODUCT", 74, 84], ["patients", "SPECIES", 60, 68], ["Combined amoxicillin", "TREATMENT", 0, 20], ["clavulanic acid", "TREATMENT", 25, 40], ["\u03b2lactamase", "TEST", 74, 84], ["bacteria", "PROBLEM", 95, 103]]], ["The duration of treatment is estimated to be at least 10 days depending on the findings by pneumo-otoscopy and tympanometry.", [["treatment", "TREATMENT", 16, 25], ["pneumo-otoscopy", "TEST", 91, 106], ["tympanometry", "TEST", 111, 123]]], ["Bacterial and viral testing of the nasopharyngeal aspirate is highly recommended particularly in children in day care centres as well as for regular follow-up.", [["nasopharyngeal aspirate", "ANATOMY", 35, 58], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 35, 58], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["Bacterial", "PROBLEM", 0, 9], ["viral testing", "TEST", 14, 27], ["the nasopharyngeal aspirate", "TEST", 31, 58], ["viral", "OBSERVATION", 14, 19], ["nasopharyngeal", "ANATOMY", 35, 49], ["aspirate", "OBSERVATION", 50, 58]]], ["The high recurrence rate is due to the long-lasting dysfunction of the eustachian tube and the immune immaturity of children less than 2 years of age.IntroductionThe number of publications relating to acute otitis media (AOM) and otitis media with effusion (OME) has been increasing markedly within the last 2 years [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] .", [["eustachian tube", "ANATOMY", 71, 86], ["acute otitis media", "DISEASE", 201, 219], ["AOM", "DISEASE", 221, 224], ["otitis media", "DISEASE", 230, 242], ["effusion", "DISEASE", 248, 256], ["OME", "DISEASE", 258, 261], ["[40] [41] [42] [43] [44] [45] [46] [47]", "CHEMICAL", 316, 355], ["eustachian tube", "TISSUE", 71, 86], ["children", "ORGANISM", 116, 124], ["[41] [42] [43] [44] [45] [46] [47] [48] [49]", "SIMPLE_CHEMICAL", 321, 365], ["children", "SPECIES", 116, 124], ["The high recurrence rate", "PROBLEM", 0, 24], ["the long-lasting dysfunction of the eustachian tube", "PROBLEM", 35, 86], ["acute otitis media", "PROBLEM", 201, 219], ["AOM", "PROBLEM", 221, 224], ["otitis media", "PROBLEM", 230, 242], ["effusion", "PROBLEM", 248, 256], ["high", "OBSERVATION_MODIFIER", 4, 8], ["recurrence", "OBSERVATION", 9, 19], ["eustachian tube", "OBSERVATION", 71, 86], ["acute", "OBSERVATION_MODIFIER", 201, 206], ["otitis", "OBSERVATION", 207, 213], ["effusion", "OBSERVATION", 248, 256], ["increasing", "OBSERVATION_MODIFIER", 272, 282], ["markedly", "OBSERVATION_MODIFIER", 283, 291]]], ["It points to the difficulties in giving generally accepted guidelines for treatment.", [["treatment", "TREATMENT", 74, 83]]], ["The confusion can be partially explained by the absence of uniform definitions and inhomogeneous groups of patients being included in clinical studies.IntroductionAOM is an acute inflammation of the middle ear, frequently elicited by viral infections and characterized by redness and bulging of the tympanum.", [["middle ear", "ANATOMY", 199, 209], ["tympanum", "ANATOMY", 299, 307], ["confusion", "DISEASE", 4, 13], ["IntroductionAOM", "DISEASE", 151, 166], ["inflammation of the middle ear", "DISEASE", 179, 209], ["viral infections", "DISEASE", 234, 250], ["patients", "ORGANISM", 107, 115], ["ear", "ORGAN", 206, 209], ["tympanum", "ORGAN", 299, 307], ["patients", "SPECIES", 107, 115], ["The confusion", "PROBLEM", 0, 13], ["clinical studies", "TEST", 134, 150], ["an acute inflammation of the middle ear", "PROBLEM", 170, 209], ["viral infections", "PROBLEM", 234, 250], ["redness", "PROBLEM", 272, 279], ["bulging of the tympanum", "PROBLEM", 284, 307], ["confusion", "OBSERVATION", 4, 13], ["uniform", "OBSERVATION_MODIFIER", 59, 66], ["definitions", "OBSERVATION", 67, 78], ["inhomogeneous", "OBSERVATION_MODIFIER", 83, 96], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["inflammation", "OBSERVATION", 179, 191], ["middle ear", "ANATOMY", 199, 209], ["viral", "OBSERVATION_MODIFIER", 234, 239], ["infections", "OBSERVATION", 240, 250], ["redness", "OBSERVATION", 272, 279], ["bulging", "OBSERVATION", 284, 291], ["tympanum", "ANATOMY", 299, 307]]], ["Infections with bacteria can be identified in at least 70% of the cases by culture of the middle ear purulent fluid containing mainly polymorphonuclear cells [35] .", [["ear purulent fluid", "ANATOMY", 97, 115], ["polymorphonuclear cells", "ANATOMY", 134, 157], ["Infections", "DISEASE", 0, 10], ["ear", "ORGAN", 97, 100], ["purulent fluid", "ORGANISM_SUBSTANCE", 101, 115], ["polymorphonuclear cells", "CELL", 134, 157], ["polymorphonuclear cells", "CELL_TYPE", 134, 157], ["Infections", "PROBLEM", 0, 10], ["bacteria", "PROBLEM", 16, 24], ["culture", "TEST", 75, 82], ["the middle ear purulent fluid", "PROBLEM", 86, 115], ["mainly polymorphonuclear cells", "PROBLEM", 127, 157], ["bacteria", "OBSERVATION", 16, 24], ["middle ear", "ANATOMY", 90, 100], ["purulent fluid", "OBSERVATION", 101, 115], ["polymorphonuclear cells", "OBSERVATION", 134, 157]]], ["OME is an effusion of the middle ear without symptoms of acute inflammations such as pain and fever, with frequently an amber or opaque aspect of the tympanum, the effusion containing mainly macrophages.", [["middle ear", "ANATOMY", 26, 36], ["tympanum", "ANATOMY", 150, 158], ["macrophages", "ANATOMY", 191, 202], ["OME", "DISEASE", 0, 3], ["effusion of the middle ear", "DISEASE", 10, 36], ["inflammations", "DISEASE", 63, 76], ["pain", "DISEASE", 85, 89], ["fever", "DISEASE", 94, 99], ["effusion", "DISEASE", 164, 172], ["ear", "ORGAN", 33, 36], ["tympanum", "ORGAN", 150, 158], ["macrophages", "CELL", 191, 202], ["macrophages", "CELL_TYPE", 191, 202], ["OME", "PROBLEM", 0, 3], ["an effusion of the middle ear", "PROBLEM", 7, 36], ["symptoms", "PROBLEM", 45, 53], ["acute inflammations", "PROBLEM", 57, 76], ["pain", "PROBLEM", 85, 89], ["fever", "PROBLEM", 94, 99], ["frequently an amber or opaque aspect of the tympanum", "PROBLEM", 106, 158], ["the effusion", "PROBLEM", 160, 172], ["effusion", "OBSERVATION", 10, 18], ["middle ear", "ANATOMY", 26, 36], ["without", "UNCERTAINTY", 37, 44], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["inflammations", "OBSERVATION", 63, 76], ["pain", "OBSERVATION", 85, 89], ["fever", "OBSERVATION", 94, 99], ["amber", "OBSERVATION", 120, 125], ["opaque", "OBSERVATION_MODIFIER", 129, 135], ["tympanum", "ANATOMY", 150, 158], ["effusion", "OBSERVATION", 164, 172], ["mainly", "OBSERVATION_MODIFIER", 184, 190], ["macrophages", "OBSERVATION", 191, 202]]], ["Retraction of the tympanum with the light reflex still present may render the diagnosis difficult.", [["tympanum", "ANATOMY", 18, 26], ["tympanum", "ORGAN", 18, 26], ["the light reflex", "TEST", 32, 48], ["tympanum", "ANATOMY", 18, 26]]], ["Cultures for bacteria are positive in about 50% of cases whereas viruses have been identified in about 30% [35] .", [["Cultures", "TEST", 0, 8], ["bacteria", "PROBLEM", 13, 21], ["positive", "PROBLEM", 26, 34], ["viruses", "PROBLEM", 65, 72]]], ["OME may be a precursor event initiating suppurate AOM but it can be the continuum of AOM as well.", [["OME", "DISEASE", 0, 3], ["AOM", "DISEASE", 50, 53], ["AOM", "DISEASE", 85, 88], ["AOM", "CANCER", 85, 88], ["OME", "PROBLEM", 0, 3], ["a precursor event", "PROBLEM", 11, 28], ["suppurate AOM", "PROBLEM", 40, 53], ["AOM", "PROBLEM", 85, 88], ["AOM", "OBSERVATION", 85, 88]]], ["OME is the direct consequence of impaired middle ear ventilation.", [["ear", "ANATOMY", 49, 52], ["OME", "DISEASE", 0, 3], ["ear", "ORGAN", 49, 52], ["OME", "PROBLEM", 0, 3], ["impaired middle ear ventilation", "PROBLEM", 33, 64], ["impaired", "OBSERVATION", 33, 41], ["middle", "ANATOMY_MODIFIER", 42, 48], ["ear", "ANATOMY", 49, 52], ["ventilation", "OBSERVATION", 53, 64]]], ["Tympanometry (Fig. 1 ) shows a flat curve type b in both AOM and OME.", [["AOM", "DISEASE", 57, 60], ["OME", "DISEASE", 65, 68], ["Tympanometry", "TEST", 0, 12], ["OME", "PROBLEM", 65, 68], ["OME", "OBSERVATION", 65, 68]]], ["In contrast, in OME associated with incomplete obstruction of the eustachian tube (ET) a curve c with a peak in the negative pressure zone is observed.", [["eustachian tube", "ANATOMY", 66, 81], ["OME", "DISEASE", 16, 19], ["eustachian tube", "MULTI-TISSUE_STRUCTURE", 66, 81], ["OME", "PROBLEM", 16, 19], ["incomplete obstruction of the eustachian tube", "PROBLEM", 36, 81], ["incomplete", "OBSERVATION_MODIFIER", 36, 46], ["obstruction", "OBSERVATION", 47, 58], ["eustachian tube", "OBSERVATION", 66, 81], ["peak", "OBSERVATION_MODIFIER", 104, 108], ["negative pressure", "OBSERVATION", 116, 133], ["zone", "OBSERVATION_MODIFIER", 134, 138]]], ["Moreover, lower peak height and greater width in the negative pressure zone are frequent findings in OME [54] .IntroductionThis overview summarizes the main new findings about AOM and OME which are in accordance with some basic well-known but sometimes forgotten data and facts, with particular emphasis on the vulnerability of young children below the age of 2 years.", [["OME", "DISEASE", 101, 104], ["AOM", "DISEASE", 176, 179], ["OME", "DISEASE", 184, 187], ["children", "ORGANISM", 334, 342], ["children", "SPECIES", 334, 342], ["lower peak height", "TEST", 10, 27], ["AOM", "PROBLEM", 176, 179], ["OME", "PROBLEM", 184, 187], ["lower", "OBSERVATION_MODIFIER", 10, 15], ["peak", "OBSERVATION_MODIFIER", 16, 20], ["height", "OBSERVATION_MODIFIER", 21, 27], ["greater", "OBSERVATION_MODIFIER", 32, 39], ["width", "OBSERVATION_MODIFIER", 40, 45], ["negative", "OBSERVATION", 53, 61], ["pressure", "OBSERVATION_MODIFIER", 62, 70], ["zone", "OBSERVATION_MODIFIER", 71, 75]]], ["Fig. 1 The three main types of tympanograms showing: a a peak near atmospheric pressure expressed in daPa with stapedius reflex for different Hz frequencies, b a flat curve without stapedius reflex for 500, 2000, 4000 Hz pointing to presence of middle ear exudate: AOM or OME, c a lower peak in the negative pressure zone (\u2212235 daPa) with an enlarged width pointing to OME with partial permeability of ET to air entrance and still a stapedius reflexRole of the eustachian tubeThe great importance of the first attack of AOM in young children lies in the subsequent long-lasting dysfunction of the ET.", [["ear exudate", "ANATOMY", 252, 263], ["eustachian tube", "ANATOMY", 461, 476], ["AOM", "DISEASE", 265, 268], ["OME", "DISEASE", 272, 275], ["OME", "DISEASE", 369, 372], ["AOM", "DISEASE", 520, 523], ["ear", "ORGAN", 252, 255], ["eustachian tube", "TISSUE", 461, 476], ["AOM", "CANCER", 520, 523], ["children", "ORGANISM", 533, 541], ["daPa", "PROTEIN", 101, 105], ["children", "SPECIES", 533, 541], ["tympanograms", "TEST", 31, 43], ["a a peak near atmospheric pressure", "PROBLEM", 53, 87], ["stapedius reflex", "TEST", 111, 127], ["b a flat curve", "TEST", 158, 172], ["middle ear exudate", "PROBLEM", 245, 263], ["AOM", "PROBLEM", 265, 268], ["OME", "PROBLEM", 272, 275], ["a lower peak", "PROBLEM", 279, 291], ["an enlarged width", "PROBLEM", 339, 356], ["OME", "PROBLEM", 369, 372], ["partial permeability of ET to air entrance", "PROBLEM", 378, 420], ["a stapedius reflexRole of the eustachian tube", "TREATMENT", 431, 476], ["AOM", "PROBLEM", 520, 523], ["atmospheric pressure", "OBSERVATION", 67, 87], ["stapedius reflex", "OBSERVATION", 111, 127], ["middle ear", "ANATOMY", 245, 255], ["exudate", "OBSERVATION", 256, 263], ["AOM", "OBSERVATION", 265, 268], ["enlarged", "OBSERVATION_MODIFIER", 342, 350], ["width", "OBSERVATION_MODIFIER", 351, 356], ["partial", "OBSERVATION_MODIFIER", 378, 385], ["permeability", "OBSERVATION_MODIFIER", 386, 398], ["air entrance", "OBSERVATION", 408, 420], ["stapedius reflexRole", "OBSERVATION", 433, 453], ["eustachian tube", "OBSERVATION", 461, 476], ["great", "OBSERVATION_MODIFIER", 480, 485]]], ["Indeed, the main functions of the ET are ventilation, protection and clearance of the middle ears ( Fig. 2) [5, 35] and play a determining role in the recurrence of AOM.", [["middle ears", "ANATOMY", 86, 97], ["AOM", "DISEASE", 165, 168], ["ears", "ORGAN", 93, 97], ["AOM", "PATHOLOGICAL_FORMATION", 165, 168], ["ventilation", "TREATMENT", 41, 52], ["protection", "TREATMENT", 54, 64], ["AOM", "PROBLEM", 165, 168], ["main", "OBSERVATION_MODIFIER", 12, 16], ["middle ears", "ANATOMY", 86, 97], ["AOM", "OBSERVATION", 165, 168]]], ["Ventilation of the middle ear occurs by each deglutition by action of the tensor velum palatinum muscle leading to air equilibration with the atmospheric pressure.", [["middle ear", "ANATOMY", 19, 29], ["velum palatinum muscle", "ANATOMY", 81, 103], ["middle", "ORGANISM_SUBDIVISION", 19, 25], ["ear", "ORGAN", 26, 29], ["velum palatinum muscle", "TISSUE", 81, 103], ["Ventilation of the middle ear", "TREATMENT", 0, 29], ["each deglutition", "PROBLEM", 40, 56], ["air equilibration", "PROBLEM", 115, 132], ["the atmospheric pressure", "TEST", 138, 162], ["middle ear", "ANATOMY", 19, 29], ["deglutition", "OBSERVATION", 45, 56], ["velum", "ANATOMY_MODIFIER", 81, 86], ["palatinum muscle", "ANATOMY", 87, 103], ["air equilibration", "OBSERVATION", 115, 132], ["atmospheric pressure", "OBSERVATION", 142, 162]]], ["By obstruction of the ET, a negative pressure develops inside the middle ear resulting in effusion and aspiration of nasopharyngeal secretions.", [["middle ear", "ANATOMY", 66, 76], ["nasopharyngeal secretions", "ANATOMY", 117, 142], ["effusion", "DISEASE", 90, 98], ["ear", "ORGAN", 73, 76], ["nasopharyngeal secretions", "ORGANISM_SUBSTANCE", 117, 142], ["obstruction of the ET", "PROBLEM", 3, 24], ["effusion", "PROBLEM", 90, 98], ["aspiration of nasopharyngeal secretions", "PROBLEM", 103, 142], ["obstruction", "OBSERVATION", 3, 14], ["negative", "OBSERVATION", 28, 36], ["pressure", "OBSERVATION_MODIFIER", 37, 45], ["middle ear", "ANATOMY", 66, 76], ["effusion", "OBSERVATION", 90, 98], ["aspiration", "OBSERVATION", 103, 113], ["nasopharyngeal", "ANATOMY", 117, 131], ["secretions", "OBSERVATION", 132, 142]]], ["Poor ventilation leads to decreased PO 2 which results in decreased bactericide power of polymorphonuclear cells.", [["polymorphonuclear cells", "ANATOMY", 89, 112], ["PO 2", "GENE_OR_GENE_PRODUCT", 36, 40], ["polymorphonuclear cells", "CELL", 89, 112], ["polymorphonuclear cells", "CELL_TYPE", 89, 112], ["Poor ventilation leads", "PROBLEM", 0, 22], ["decreased bactericide power of polymorphonuclear cells", "PROBLEM", 58, 112], ["ventilation", "OBSERVATION", 5, 16], ["decreased", "OBSERVATION_MODIFIER", 58, 67], ["bactericide", "OBSERVATION_MODIFIER", 68, 79], ["polymorphonuclear cells", "OBSERVATION", 89, 112]]], ["Impaired clearance results in proliferation not only of aerobic but also anaerobic bacteria in the middle ear.", [["middle ear", "ANATOMY", 99, 109], ["ear", "ORGAN", 106, 109], ["aerobic", "PROBLEM", 56, 63], ["anaerobic bacteria in the middle ear", "PROBLEM", 73, 109], ["bacteria", "OBSERVATION", 83, 91], ["middle ear", "ANATOMY", 99, 109]]], ["Conversely, reflux otitis occurs with decreased compliance of the ET due to abnormal flaccidity.Role of the eustachian tubeET dysfunction is a major problem in the young child: the small calibre of the ET as well as its horizontal direction [5] (Figs.", [["eustachian", "ANATOMY", 108, 118], ["reflux otitis", "DISEASE", 12, 25], ["abnormal flaccidity", "DISEASE", 76, 95], ["eustachian tubeET dysfunction", "DISEASE", 108, 137], ["reflux otitis", "PROBLEM", 12, 25], ["abnormal flaccidity", "PROBLEM", 76, 95], ["the eustachian tubeET dysfunction", "PROBLEM", 104, 137], ["reflux", "OBSERVATION_MODIFIER", 12, 18], ["otitis", "OBSERVATION", 19, 25], ["abnormal", "OBSERVATION_MODIFIER", 76, 84], ["flaccidity", "OBSERVATION", 85, 95], ["eustachian", "ANATOMY", 108, 118], ["small", "OBSERVATION_MODIFIER", 181, 186], ["calibre", "OBSERVATION_MODIFIER", 187, 194]]], ["3 and 4) are responsible for both the high incidence of AOM and the frequent relapses by each viral infection.", [["AOM", "DISEASE", 56, 59], ["viral infection", "DISEASE", 94, 109], ["AOM", "PROBLEM", 56, 59], ["the frequent relapses", "PROBLEM", 64, 85], ["each viral infection", "PROBLEM", 89, 109], ["high", "OBSERVATION_MODIFIER", 38, 42], ["AOM", "OBSERVATION", 56, 59], ["frequent", "OBSERVATION_MODIFIER", 68, 76], ["relapses", "OBSERVATION", 77, 85], ["viral", "OBSERVATION_MODIFIER", 94, 99], ["infection", "OBSERVATION", 100, 109]]], ["This explains the poor long-term prognosis evidenced in a prospective study comprising 210 AOM patients of less than 2 years of age by Damoiseaux et al. [16] .", [["AOM", "DISEASE", 91, 94], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["the poor long-term prognosis", "PROBLEM", 14, 42], ["a prospective study", "TEST", 56, 75], ["poor long-term", "OBSERVATION_MODIFIER", 18, 32]]], ["At least 50% of the patients had recurrences of AOM and persistence of OME was observed in 47% of them after 3 months and in 35% after 6 months.", [["AOM", "DISEASE", 48, 51], ["OME", "DISEASE", 71, 74], ["patients", "ORGANISM", 20, 28], ["AOM", "PATHOLOGICAL_FORMATION", 48, 51], ["patients", "SPECIES", 20, 28], ["AOM", "PROBLEM", 48, 51], ["OME", "PROBLEM", 71, 74], ["AOM", "OBSERVATION", 48, 51], ["OME", "OBSERVATION", 71, 74]]], ["Yet, only 50% of these patients were treated with amoxicillin.", [["amoxicillin", "CHEMICAL", 50, 61], ["amoxicillin", "CHEMICAL", 50, 61], ["patients", "ORGANISM", 23, 31], ["amoxicillin", "SIMPLE_CHEMICAL", 50, 61], ["patients", "SPECIES", 23, 31], ["amoxicillin", "TREATMENT", 50, 61]]], ["Unfortunately, the authors do not mention either the delay of treatment or the dosage of the antibiotic.Role of the eustachian tubeIn other words, the first episode of AOM determines the evolution and the recurrences because of the associated acute inflammation involving also the ET.VirusesMost children are infected with respiratory syncytial virus (RSV) in their first year of life.", [["eustachian tube", "ANATOMY", 116, 131], ["AOM", "DISEASE", 168, 171], ["inflammation", "DISEASE", 249, 261], ["respiratory syncytial virus", "DISEASE", 323, 350], ["RSV", "DISEASE", 352, 355], ["eustachian tube", "MULTI-TISSUE_STRUCTURE", 116, 131], ["Viruses", "ORGANISM", 284, 291], ["children", "ORGANISM", 296, 304], ["respiratory syncytial virus", "ORGANISM", 323, 350], ["RSV", "ORGANISM", 352, 355], ["children", "SPECIES", 296, 304], ["respiratory syncytial virus", "SPECIES", 323, 350], ["Viruses", "SPECIES", 284, 291], ["respiratory syncytial virus", "SPECIES", 323, 350], ["RSV", "SPECIES", 352, 355], ["treatment", "TREATMENT", 62, 71], ["the antibiotic", "TREATMENT", 89, 103], ["the eustachian tube", "TREATMENT", 112, 131], ["AOM", "PROBLEM", 168, 171], ["the recurrences", "PROBLEM", 201, 216], ["the associated acute inflammation", "PROBLEM", 228, 261], ["Viruses", "PROBLEM", 284, 291], ["respiratory syncytial virus", "PROBLEM", 323, 350], ["eustachian tube", "OBSERVATION", 116, 131], ["AOM", "OBSERVATION", 168, 171], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["inflammation", "OBSERVATION", 249, 261], ["infected", "OBSERVATION", 309, 317], ["respiratory syncytial virus", "OBSERVATION", 323, 350]]], ["A prospective study [2] in 42 children aged 2-24 months with bronchiolitis showed that 26 of them had AOM at entry or within 10 days and an additional 10 developed OME; only 6 patients remained free of both AOM and OME during a 3-week observation period.", [["bronchiolitis", "DISEASE", 61, 74], ["AOM", "DISEASE", 102, 105], ["OME", "DISEASE", 164, 167], ["AOM", "DISEASE", 207, 210], ["OME", "DISEASE", 215, 218], ["children", "ORGANISM", 30, 38], ["patients", "ORGANISM", 176, 184], ["children", "SPECIES", 30, 38], ["patients", "SPECIES", 176, 184], ["A prospective study", "TEST", 0, 19], ["bronchiolitis", "PROBLEM", 61, 74], ["AOM", "PROBLEM", 102, 105], ["OME", "PROBLEM", 164, 167], ["OME", "PROBLEM", 215, 218], ["bronchiolitis", "OBSERVATION", 61, 74]]], ["These findings were confirmed in a recent study showing that in patients with persistent RSV antigen in the middle ear effusion, 31% relapsed despite a favourable outcome of the first AOM episode [50] .VirusesThe association of AOM with several viral infections has been largely documented.", [["middle ear effusion", "ANATOMY", 108, 127], ["ear effusion", "DISEASE", 115, 127], ["AOM", "DISEASE", 184, 187], ["AOM", "DISEASE", 228, 231], ["viral infections", "DISEASE", 245, 261], ["patients", "ORGANISM", 64, 72], ["RSV", "ORGANISM", 89, 92], ["ear", "ORGAN", 115, 118], ["RSV antigen", "PROTEIN", 89, 100], ["patients", "SPECIES", 64, 72], ["RSV", "SPECIES", 89, 92], ["a recent study", "TEST", 33, 47], ["persistent RSV antigen in the middle ear effusion", "PROBLEM", 78, 127], ["Viruses", "PROBLEM", 202, 209], ["AOM", "PROBLEM", 228, 231], ["several viral infections", "PROBLEM", 237, 261], ["persistent", "OBSERVATION_MODIFIER", 78, 88], ["RSV", "OBSERVATION", 89, 92], ["middle", "ANATOMY_MODIFIER", 108, 114], ["ear", "ANATOMY", 115, 118], ["effusion", "OBSERVATION", 119, 127], ["AOM", "OBSERVATION", 228, 231], ["several", "OBSERVATION_MODIFIER", 237, 244], ["viral", "OBSERVATION_MODIFIER", 245, 250], ["infections", "OBSERVATION", 251, 261]]], ["The prevalence of respiratory viruses in the middle ear fluid of 456 children, aged 7 months to 7 years, with AOM was 41% [21] .", [["middle ear fluid", "ANATOMY", 45, 61], ["respiratory viruses", "DISEASE", 18, 37], ["AOM", "DISEASE", 110, 113], ["ear fluid", "MULTI-TISSUE_STRUCTURE", 52, 61], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["respiratory viruses", "PROBLEM", 18, 37], ["AOM", "PROBLEM", 110, 113], ["respiratory viruses", "OBSERVATION", 18, 37], ["middle", "ANATOMY_MODIFIER", 45, 51], ["ear", "ANATOMY", 52, 55], ["fluid", "OBSERVATION", 56, 61]]], ["RSV was the most frequent virus isolated followed by parainfluenza, influenza, enteroviruses and adenoviruses.", [["parainfluenza, influenza, enteroviruses", "DISEASE", 53, 92], ["RSV", "ORGANISM", 0, 3], ["parainfluenza", "ORGANISM", 53, 66], ["enteroviruses", "ORGANISM", 79, 92], ["adenoviruses", "ORGANISM", 97, 109], ["parainfluenza", "SPECIES", 53, 66], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["the most frequent virus", "PROBLEM", 8, 31], ["parainfluenza", "PROBLEM", 53, 66], ["influenza", "PROBLEM", 68, 77], ["enteroviruses", "PROBLEM", 79, 92], ["adenoviruses", "PROBLEM", 97, 109]]], ["These findings have been confirmed by others [18, 32, 33, 41, 50] and rhinovirus, coronavirus and metapneumovirus should be added to the above-mentioned list [53] .", [["rhinovirus, coronavirus and metapneumovirus", "DISEASE", 70, 113], ["rhinovirus", "ORGANISM", 70, 80], ["coronavirus", "ORGANISM", 82, 93], ["metapneumovirus", "ORGANISM", 98, 113], ["coronavirus", "SPECIES", 82, 93], ["rhinovirus", "PROBLEM", 70, 80], ["coronavirus", "PROBLEM", 82, 93], ["metapneumovirus", "PROBLEM", 98, 113], ["metapneumovirus", "OBSERVATION", 98, 113]]], ["Even the measles virus has recently been isolated from the middle ear fluid in two patients [64] .BacteriaIn 70% of patients with AOM, bacteria can be found by culturing the middle ear fluid [35] .", [["middle ear fluid", "ANATOMY", 59, 75], ["middle ear fluid", "ANATOMY", 174, 190], ["AOM", "DISEASE", 130, 133], ["measles virus", "ORGANISM", 9, 22], ["ear", "ORGAN", 66, 69], ["fluid", "ORGANISM_SUBSTANCE", 70, 75], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 116, 124], ["ear", "ORGAN", 181, 184], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 116, 124], ["measles virus", "SPECIES", 9, 22], ["the measles virus", "PROBLEM", 5, 22], ["BacteriaIn", "TREATMENT", 98, 108], ["AOM", "PROBLEM", 130, 133], ["bacteria", "PROBLEM", 135, 143], ["culturing the middle ear fluid", "TEST", 160, 190], ["middle", "ANATOMY_MODIFIER", 59, 65], ["ear", "ANATOMY", 66, 69], ["fluid", "OBSERVATION", 70, 75], ["middle", "ANATOMY_MODIFIER", 174, 180], ["ear", "ANATOMY", 181, 184], ["fluid", "OBSERVATION", 185, 190]]], ["The most frequent species isolated are Haemophilus influenzae and Streptococcus pneumoniae [27] .", [["Haemophilus influenzae", "DISEASE", 39, 61], ["Haemophilus influenzae", "ORGANISM", 39, 61], ["Streptococcus pneumoniae", "ORGANISM", 66, 90], ["Haemophilus influenzae", "SPECIES", 39, 61], ["Streptococcus pneumoniae", "SPECIES", 66, 90], ["Haemophilus influenzae", "SPECIES", 39, 61], ["Streptococcus pneumoniae", "SPECIES", 66, 90], ["The most frequent species", "PROBLEM", 0, 25], ["Haemophilus influenzae", "PROBLEM", 39, 61], ["Streptococcus pneumoniae", "PROBLEM", 66, 90], ["Streptococcus pneumoniae", "OBSERVATION", 66, 90]]], ["Nasopharyngeal aspirate culture may give valuable information on the bacteria involved in AOM [28, 51, 55, 58] .", [["Nasopharyngeal aspirate", "ANATOMY", 0, 23], ["AOM", "DISEASE", 90, 93], ["Nasopharyngeal aspirate culture", "TEST", 0, 31], ["the bacteria", "TEST", 65, 77]]], ["The presence of conjunctivitis points to Haemophilus influenzae infection [4] .BacteriaHeikkinen et al. found Streptococcus pneumoniae in 25% of their patients, Haemophilus influenzae in 23% and Moraxella catarrhalis in 15% [21] .", [["conjunctivitis", "DISEASE", 16, 30], ["Haemophilus influenzae infection", "DISEASE", 41, 73], ["Streptococcus pneumoniae", "DISEASE", 110, 134], ["Haemophilus influenzae", "DISEASE", 161, 183], ["Moraxella catarrhalis", "DISEASE", 195, 216], ["Haemophilus influenzae", "ORGANISM", 41, 63], ["Streptococcus pneumoniae", "ORGANISM", 110, 134], ["patients", "ORGANISM", 151, 159], ["Haemophilus influenzae", "ORGANISM", 161, 183], ["Moraxella catarrhalis", "ORGANISM", 195, 216], ["Haemophilus influenzae", "SPECIES", 41, 63], ["Streptococcus pneumoniae", "SPECIES", 110, 134], ["patients", "SPECIES", 151, 159], ["Haemophilus influenzae", "SPECIES", 161, 183], ["Moraxella catarrhalis", "SPECIES", 195, 216], ["Haemophilus influenzae", "SPECIES", 41, 63], ["Streptococcus pneumoniae", "SPECIES", 110, 134], ["Haemophilus influenzae", "SPECIES", 161, 183], ["Moraxella catarrhalis", "SPECIES", 195, 216], ["conjunctivitis", "PROBLEM", 16, 30], ["Haemophilus influenzae infection", "PROBLEM", 41, 73], ["Streptococcus pneumoniae", "PROBLEM", 110, 134], ["Haemophilus influenzae", "TEST", 161, 183], ["Moraxella catarrhalis", "PROBLEM", 195, 216], ["conjunctivitis", "OBSERVATION", 16, 30], ["Haemophilus", "OBSERVATION_MODIFIER", 41, 52], ["influenzae", "OBSERVATION_MODIFIER", 53, 63], ["infection", "OBSERVATION", 64, 73], ["Streptococcus", "OBSERVATION_MODIFIER", 110, 123], ["pneumoniae", "OBSERVATION", 124, 134], ["Moraxella catarrhalis", "OBSERVATION", 195, 216]]], ["It has been demonstrated that recurrences of AOM are associated with positive bacterial culture in the nasopharynx [23] , even at the end of the antibiotic treatment [28] and in most cases the pathogen was Streptococcus pneumoniae [58] .", [["nasopharynx", "ANATOMY", 103, 114], ["AOM", "DISEASE", 45, 48], ["Streptococcus pneumoniae", "DISEASE", 206, 230], ["AOM", "PATHOLOGICAL_FORMATION", 45, 48], ["nasopharynx", "ORGAN", 103, 114], ["Streptococcus pneumoniae", "ORGANISM", 206, 230], ["Streptococcus pneumoniae", "SPECIES", 206, 230], ["Streptococcus pneumoniae", "SPECIES", 206, 230], ["AOM", "PROBLEM", 45, 48], ["positive bacterial culture in the nasopharynx", "PROBLEM", 69, 114], ["the antibiotic treatment", "TREATMENT", 141, 165], ["Streptococcus pneumoniae", "PROBLEM", 206, 230], ["recurrences", "OBSERVATION_MODIFIER", 30, 41], ["AOM", "OBSERVATION", 45, 48], ["positive", "OBSERVATION_MODIFIER", 69, 77], ["bacterial", "OBSERVATION_MODIFIER", 78, 87], ["culture", "OBSERVATION_MODIFIER", 88, 95], ["nasopharynx", "ANATOMY", 103, 114]]], ["However, recurrence more than 14 days after an initial AOM episode is mostly due to a new infection, i.e. not a true relapse [27] .", [["AOM", "DISEASE", 55, 58], ["infection", "DISEASE", 90, 99], ["recurrence", "PROBLEM", 9, 19], ["an initial AOM episode", "PROBLEM", 44, 66], ["a new infection", "PROBLEM", 84, 99], ["mostly due to", "UNCERTAINTY", 70, 83], ["new", "OBSERVATION_MODIFIER", 86, 89], ["infection", "OBSERVATION", 90, 99]]], ["In a most recent prospective study on purulent meningitis [11] , the association of AOM was found in half of the patients [14] .Bacteria and virusesBulut et al. performed both bacterial and viral testing in 120 children with AOM [8] .", [["meningitis", "DISEASE", 47, 57], ["AOM", "DISEASE", 84, 87], ["AOM", "DISEASE", 225, 228], ["AOM", "PATHOLOGICAL_FORMATION", 84, 87], ["patients", "ORGANISM", 113, 121], ["children", "ORGANISM", 211, 219], ["patients", "SPECIES", 113, 121], ["children", "SPECIES", 211, 219], ["purulent meningitis", "PROBLEM", 38, 57], ["AOM", "PROBLEM", 84, 87], ["Bacteria", "PROBLEM", 128, 136], ["viruses", "PROBLEM", 141, 148], ["viral testing", "TEST", 190, 203], ["AOM", "PROBLEM", 225, 228], ["purulent", "OBSERVATION_MODIFIER", 38, 46], ["meningitis", "OBSERVATION", 47, 57], ["AOM", "OBSERVATION", 84, 87], ["viruses", "OBSERVATION", 141, 148]]], ["These patients, aged between Fig. 3 The difference in the angle of the eustachian tube between infants and adults [5] Fig. 4 The tympanic membrane forms the lateral wall of the boxshaped middle ear.", [["eustachian tube", "ANATOMY", 71, 86], ["tympanic membrane", "ANATOMY", 129, 146], ["lateral wall", "ANATOMY", 157, 169], ["middle ear", "ANATOMY", 187, 197], ["patients", "ORGANISM", 6, 14], ["eustachian tube", "MULTI-TISSUE_STRUCTURE", 71, 86], ["infants", "ORGANISM", 95, 102], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 129, 146], ["lateral wall", "MULTI-TISSUE_STRUCTURE", 157, 169], ["ear", "ORGAN", 194, 197], ["patients", "SPECIES", 6, 14], ["infants", "SPECIES", 95, 102], ["the eustachian tube", "TREATMENT", 67, 86], ["The tympanic membrane", "TEST", 125, 146], ["eustachian tube", "OBSERVATION", 71, 86], ["tympanic membrane", "ANATOMY", 129, 146], ["lateral", "ANATOMY_MODIFIER", 157, 164], ["wall", "ANATOMY_MODIFIER", 165, 169], ["boxshaped middle ear", "ANATOMY", 177, 197]]], ["The function of the eustachian tube is to equilibrate middle ear pressure with that in the nasopharynx.", [["eustachian tube", "ANATOMY", 20, 35], ["ear", "ANATOMY", 61, 64], ["nasopharynx", "ANATOMY", 91, 102], ["eustachian tube", "TISSUE", 20, 35], ["ear", "ORGAN", 61, 64], ["nasopharynx", "ORGAN", 91, 102], ["the eustachian tube", "TREATMENT", 16, 35], ["eustachian tube", "OBSERVATION", 20, 35], ["middle ear", "ANATOMY", 54, 64], ["pressure", "OBSERVATION_MODIFIER", 65, 73], ["nasopharynx", "ANATOMY", 91, 102]]], ["Bacteria and viruses resident in the nasopharynx may reach the middle ear during pressure equilibration.", [["nasopharynx", "ANATOMY", 37, 48], ["middle ear", "ANATOMY", 63, 73], ["Bacteria", "CELL", 0, 8], ["nasopharynx", "ORGAN", 37, 48], ["ear", "ORGAN", 70, 73], ["Bacteria", "PROBLEM", 0, 8], ["viruses", "PROBLEM", 13, 20], ["pressure equilibration", "TREATMENT", 81, 103], ["viruses", "OBSERVATION", 13, 20], ["nasopharynx", "ANATOMY", 37, 48], ["middle ear", "ANATOMY", 63, 73], ["pressure equilibration", "OBSERVATION", 81, 103]]], ["One-third of the middle ear mucosa and the entire eustachian tube are lined with mucociliary epithelium to transport bacteria from the middle ear back to the nasopharynx.", [["middle ear mucosa", "ANATOMY", 17, 34], ["eustachian tube", "ANATOMY", 50, 65], ["mucociliary epithelium", "ANATOMY", 81, 103], ["ear", "ANATOMY", 142, 145], ["nasopharynx", "ANATOMY", 158, 169], ["ear mucosa", "MULTI-TISSUE_STRUCTURE", 24, 34], ["eustachian tube", "TISSUE", 50, 65], ["mucociliary epithelium", "TISSUE", 81, 103], ["ear", "ORGAN", 142, 145], ["nasopharynx", "ORGAN", 158, 169], ["mucociliary epithelium", "PROBLEM", 81, 103], ["transport bacteria", "PROBLEM", 107, 125], ["third", "ANATOMY_MODIFIER", 4, 9], ["middle", "ANATOMY_MODIFIER", 17, 23], ["ear mucosa", "ANATOMY", 24, 34], ["entire", "OBSERVATION_MODIFIER", 43, 49], ["eustachian tube", "OBSERVATION", 50, 65], ["mucociliary epithelium", "OBSERVATION", 81, 103], ["transport bacteria", "OBSERVATION", 107, 125], ["middle", "ANATOMY_MODIFIER", 135, 141], ["ear", "ANATOMY", 142, 145], ["nasopharynx", "ANATOMY", 158, 169]]], ["Air from the middle ear enters the mastoid air cells by way of the aditus 6 months and 12 years, did not receive an antibiotic for 2 weeks prior to the study.", [["middle ear", "ANATOMY", 13, 23], ["mastoid air cells", "ANATOMY", 35, 52], ["ear", "ORGAN", 20, 23], ["mastoid air cells", "CELL", 35, 52], ["mastoid air cells", "CELL_TYPE", 35, 52], ["an antibiotic", "TREATMENT", 113, 126], ["the study", "TEST", 148, 157], ["middle ear", "ANATOMY", 13, 23], ["mastoid", "ANATOMY", 35, 42], ["air cells", "OBSERVATION", 43, 52]]], ["A positive bacterial culture was obtained in 54% of the children and respiratory viruses were identified in 32% of them; combined viral and bacterial infection was demonstrated in 12% of the samples.Bacteria and virusesPersistent otitis was documented in about 50% of the children with combined viral and bacterial infection in a prospective study of 271 children because viral infections contribute to the ET dysfunction [12] .Other risk factorsThe immaturity of the immune system of young children makes them incapable of killing encapsulated bacteria.", [["samples", "ANATOMY", 191, 198], ["immune system", "ANATOMY", 468, 481], ["respiratory viruses", "DISEASE", 69, 88], ["viral and bacterial infection", "DISEASE", 130, 159], ["otitis", "DISEASE", 230, 236], ["viral and bacterial infection", "DISEASE", 295, 324], ["viral infections", "DISEASE", 372, 388], ["children", "ORGANISM", 56, 64], ["Bacteria", "CELL", 199, 207], ["children", "ORGANISM", 272, 280], ["children", "ORGANISM", 355, 363], ["immune system", "ANATOMICAL_SYSTEM", 468, 481], ["children", "ORGANISM", 491, 499], ["risk factors", "PROTEIN", 434, 446], ["children", "SPECIES", 56, 64], ["children", "SPECIES", 272, 280], ["children", "SPECIES", 355, 363], ["children", "SPECIES", 491, 499], ["A positive bacterial culture", "PROBLEM", 0, 28], ["respiratory viruses", "PROBLEM", 69, 88], ["combined viral and bacterial infection", "PROBLEM", 121, 159], ["the samples", "TEST", 187, 198], ["Bacteria", "PROBLEM", 199, 207], ["viruses", "PROBLEM", 212, 219], ["Persistent otitis", "PROBLEM", 219, 236], ["combined viral and bacterial infection", "PROBLEM", 286, 324], ["a prospective study", "TEST", 328, 347], ["viral infections", "PROBLEM", 372, 388], ["the ET dysfunction", "PROBLEM", 403, 421], ["Other risk factors", "PROBLEM", 428, 446], ["killing encapsulated bacteria", "PROBLEM", 524, 553], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["bacterial culture", "OBSERVATION", 11, 28], ["respiratory viruses", "ANATOMY", 69, 88], ["bacterial", "OBSERVATION_MODIFIER", 140, 149], ["infection", "OBSERVATION", 150, 159], ["viruses", "OBSERVATION", 212, 219], ["otitis", "OBSERVATION", 230, 236], ["bacterial", "OBSERVATION_MODIFIER", 305, 314], ["infection", "OBSERVATION", 315, 324], ["immaturity", "OBSERVATION", 450, 460]]], ["This, along with the ET dysfunction, explains the longlasting course of AOM as well as the high recurrence rate.", [["ET dysfunction", "DISEASE", 21, 35], ["AOM", "DISEASE", 72, 75], ["the ET dysfunction", "PROBLEM", 17, 35], ["AOM", "PROBLEM", 72, 75], ["the high recurrence rate", "PROBLEM", 87, 111], ["ET dysfunction", "OBSERVATION", 21, 35]]], ["This is particularly important for infants attending day care centres [37, 38] .", [["infants", "ORGANISM", 35, 42], ["infants", "SPECIES", 35, 42]]], ["It is sometimes necessary to withdraw these infants from these institutions during the winter to avoid recurrences.", [["infants", "ORGANISM", 44, 51], ["infants", "SPECIES", 44, 51], ["recurrences", "PROBLEM", 103, 114]]], ["Additional risk factors are passive smoking, young siblings going to school and siblings with previous AOM episodes.Other risk factorsThese factors were identified in a prospective study on 2,253 children aged 2 months to 2 years published in 1997 [37] .", [["smoking", "CHEMICAL", 36, 43], ["AOM", "DISEASE", 103, 106], ["children", "ORGANISM", 196, 204], ["risk factors", "PROTEIN", 122, 134], ["children", "SPECIES", 196, 204], ["previous AOM episodes", "PROBLEM", 94, 115], ["Other risk factors", "PROBLEM", 116, 134], ["a prospective study", "TEST", 167, 186]]], ["The proportion of patients developing at least one episode of OME was 79% at 12 months and 91% at 24 months.", [["OME", "DISEASE", 62, 65], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["OME", "PROBLEM", 62, 65]]], ["Breast feeding and exposure to tobacco smoke contributed little to the outcome, but a lower socioeconomic status and repeated exposure to other children at home or in day care centres were the most important risk factors.Other risk factorsChildren with cleft palate are particularly prone to otitis and should be treated by early tympanostomy tube insertion [60] .Complications: mastoiditisMastoiditis should be treated by antibiotics according to the bacterial resistance and by temporarily inserting tympanostomy tubes to improve drainage [65] because of the narrow calibre of the aditus ad antrum.", [["Breast", "ANATOMY", 0, 6], ["cleft palate", "ANATOMY", 253, 265], ["aditus", "ANATOMY", 583, 589], ["antrum", "ANATOMY", 593, 599], ["smoke", "CHEMICAL", 39, 44], ["cleft palate", "DISEASE", 253, 265], ["otitis", "DISEASE", 292, 298], ["mastoiditis", "DISEASE", 379, 390], ["Mastoiditis", "DISEASE", 390, 401], ["Breast", "ORGANISM_SUBDIVISION", 0, 6], ["tobacco", "ORGANISM", 31, 38], ["children", "ORGANISM", 144, 152], ["palate", "ORGAN", 259, 265], ["tube", "TISSUE", 343, 347], ["antrum", "MULTI-TISSUE_STRUCTURE", 593, 599], ["children", "SPECIES", 144, 152], ["Children", "SPECIES", 239, 247], ["tobacco", "SPECIES", 31, 38], ["cleft palate", "PROBLEM", 253, 265], ["otitis", "PROBLEM", 292, 298], ["early tympanostomy tube insertion", "TREATMENT", 324, 357], ["mastoiditisMastoiditis", "PROBLEM", 379, 401], ["antibiotics", "TREATMENT", 423, 434], ["the bacterial resistance", "TREATMENT", 448, 472], ["temporarily inserting tympanostomy tubes", "TREATMENT", 480, 520], ["drainage", "TREATMENT", 532, 540], ["cleft palate", "ANATOMY", 253, 265], ["otitis", "OBSERVATION", 292, 298], ["tympanostomy tube", "OBSERVATION", 330, 347], ["mastoiditis", "OBSERVATION", 379, 390], ["bacterial resistance", "OBSERVATION", 452, 472], ["tympanostomy tubes", "OBSERVATION", 502, 520], ["narrow", "OBSERVATION_MODIFIER", 561, 567], ["calibre", "OBSERVATION_MODIFIER", 568, 575], ["antrum", "ANATOMY", 593, 599]]], ["[22] (Fig. 4) .General considerationsA \"wait and see\" approach has been advocated in the treatment of AOM in children mainly because of the increased antimicrobial resistance of bacteria causing respiratory infections [13] .", [["respiratory", "ANATOMY", 195, 206], ["AOM", "DISEASE", 102, 105], ["respiratory infections", "DISEASE", 195, 217], ["children", "ORGANISM", 109, 117], ["children", "SPECIES", 109, 117], ["AOM", "PROBLEM", 102, 105], ["the increased antimicrobial resistance of bacteria", "PROBLEM", 136, 186], ["respiratory infections", "PROBLEM", 195, 217], ["antimicrobial resistance", "OBSERVATION", 150, 174]]], ["Indeed, a meta-analysis of 5,400 children, aged 6 months to 18 years, and collected from 33 randomized trials concluded that there was a significant but modest impact of antibiotics on the primary control of AOM [45] .", [["AOM", "DISEASE", 208, 211], ["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["antibiotics", "TREATMENT", 170, 181]]], ["Similar results emerged from a subsequent study published by Damoiseaux et al. in 2000 [15] .", [["a subsequent study", "TEST", 29, 47]]], ["This randomized double-blind prospective trial carried out by general practitioners in 240 children, aged 6 months to 2 years, showed that only 7 and maybe 8 of them needed antibiotics.", [["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["This randomized double-blind prospective trial", "TREATMENT", 0, 46], ["antibiotics", "TREATMENT", 173, 184]]], ["Both studies, however, suffer from major flaws; the absence of long-term data, in particular the recurrence rate of AOM, and OME not being considered an end point.", [["AOM", "DISEASE", 116, 119], ["OME", "DISEASE", 125, 128], ["Both studies", "TEST", 0, 12], ["long-term data", "PROBLEM", 63, 77], ["AOM", "PROBLEM", 116, 119], ["OME", "PROBLEM", 125, 128]]], ["Moreover, the former study included patients with a very large age range and therefore blunted the effect of the critical age group of the patients below the age of 2 years.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 139, 147], ["the former study", "TEST", 10, 26]]], ["Indeed, over 70% of AOM patients present their first attack during the first year of life and over 90% within 2 years of age [35] .", [["AOM", "DISEASE", 20, 23], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["The visualisation of the tympanum in this age group is not always easy especially when cerumen obstructs the narrow external ear channel.", [["tympanum", "ANATOMY", 25, 33], ["ear", "ANATOMY", 125, 128], ["tympanum", "ORGAN", 25, 33], ["ear", "ORGAN", 125, 128], ["cerumen obstructs the narrow external ear channel", "PROBLEM", 87, 136], ["tympanum", "ANATOMY", 25, 33], ["obstructs", "OBSERVATION", 95, 104], ["narrow", "OBSERVATION_MODIFIER", 109, 115], ["external ear channel", "ANATOMY", 116, 136]]], ["Yet, as already mentioned above, bulging and redness of the tympanic membrane are important diagnostic signs of bacterial AOM [27, 39] .Treatment of AOMThe crucial role of the first attack of AOM makes the immediate administration of antibiotics mandatory in all patients with AOM with redness and a bulging tympanum (Table 1 ) [26] .", [["tympanic membrane", "ANATOMY", 60, 77], ["AOM", "DISEASE", 122, 125], ["AOM", "DISEASE", 149, 152], ["AOM", "DISEASE", 192, 195], ["AOM", "DISEASE", 277, 280], ["redness", "DISEASE", 286, 293], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 60, 77], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 263, 271], ["bulging and redness of the tympanic membrane", "PROBLEM", 33, 77], ["bacterial AOM", "PROBLEM", 112, 125], ["AOM", "PROBLEM", 149, 152], ["AOM", "PROBLEM", 192, 195], ["antibiotics mandatory", "TREATMENT", 234, 255], ["AOM", "PROBLEM", 277, 280], ["redness", "PROBLEM", 286, 293], ["a bulging tympanum", "PROBLEM", 298, 316], ["bulging", "OBSERVATION", 33, 40], ["redness", "OBSERVATION", 45, 52], ["tympanic membrane", "ANATOMY", 60, 77], ["AOM", "OBSERVATION", 149, 152], ["AOM", "OBSERVATION", 192, 195], ["redness", "OBSERVATION", 286, 293], ["bulging", "OBSERVATION", 300, 307]]], ["A \"wait and see\" approach can only increase the inflammation and hence the ET dysfunction.", [["inflammation", "DISEASE", 48, 60], ["the inflammation", "PROBLEM", 44, 60], ["the ET dysfunction", "PROBLEM", 71, 89], ["inflammation", "OBSERVATION", 48, 60]]], ["The choice of the antibiotic must take into account the penetration in the middle ear and the type of bacteria involved.", [["middle ear", "ANATOMY", 75, 85], ["ear", "ORGAN", 82, 85], ["the antibiotic", "TREATMENT", 14, 28], ["the penetration in the middle ear", "PROBLEM", 52, 85], ["bacteria", "PROBLEM", 102, 110], ["middle ear", "ANATOMY", 75, 85], ["bacteria", "OBSERVATION", 102, 110]]], ["The penetration for amoxicillin-about 40% of the blood concentration-is much higher than for cephalosporins (about 20%) and macrolides (about 10%) but lower than for cotrimoxazole (60%) [31] .", [["blood", "ANATOMY", 49, 54], ["amoxicillin", "CHEMICAL", 20, 31], ["cephalosporins", "CHEMICAL", 93, 107], ["macrolides", "CHEMICAL", 124, 134], ["cotrimoxazole", "CHEMICAL", 166, 179], ["amoxicillin", "CHEMICAL", 20, 31], ["cephalosporins", "CHEMICAL", 93, 107], ["macrolides", "CHEMICAL", 124, 134], ["cotrimoxazole", "CHEMICAL", 166, 179], ["amoxicillin", "SIMPLE_CHEMICAL", 20, 31], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["cephalosporins", "SIMPLE_CHEMICAL", 93, 107], ["macrolides", "SIMPLE_CHEMICAL", 124, 134], ["cotrimoxazole", "SIMPLE_CHEMICAL", 166, 179], ["The penetration", "PROBLEM", 0, 15], ["amoxicillin", "TREATMENT", 20, 31], ["the blood concentration", "TEST", 45, 68], ["cephalosporins", "TREATMENT", 93, 107], ["macrolides", "TEST", 124, 134], ["cotrimoxazole", "TREATMENT", 166, 179]]], ["The penetration of amoxicillin is not changed by the addition of clavulanate to amoxicillin [10, 52] .", [["amoxicillin", "CHEMICAL", 19, 30], ["clavulanate", "CHEMICAL", 65, 76], ["amoxicillin", "CHEMICAL", 80, 91], ["amoxicillin", "CHEMICAL", 19, 30], ["clavulanate", "CHEMICAL", 65, 76], ["amoxicillin", "CHEMICAL", 80, 91], ["amoxicillin", "SIMPLE_CHEMICAL", 19, 30], ["clavulanate", "SIMPLE_CHEMICAL", 65, 76], ["amoxicillin", "SIMPLE_CHEMICAL", 80, 91], ["amoxicillin", "TREATMENT", 19, 30], ["clavulanate", "TREATMENT", 65, 76], ["amoxicillin", "TREATMENT", 80, 91]]], ["Because of the increased incidence of Streptococcus pneumoniae with intermediary resistance [57, 61] , the dosage of amoxicillin should be doubled, i.e. 90 mg/kg per day given in three administrations as recommended by the Centers for Disease Control and Prevention [3] .Treatment of AOMHaemophilus influenzae is more likely to become \u03b2lactamase positive after previous antibiotic administration [9] .", [["Streptococcus pneumoniae", "DISEASE", 38, 62], ["amoxicillin", "CHEMICAL", 117, 128], ["AOMHaemophilus influenzae", "DISEASE", 284, 309], ["amoxicillin", "CHEMICAL", 117, 128], ["Streptococcus pneumoniae", "ORGANISM", 38, 62], ["amoxicillin", "SIMPLE_CHEMICAL", 117, 128], ["AOMHaemophilus influenzae", "ORGANISM", 284, 309], ["\u03b2lactamase", "GENE_OR_GENE_PRODUCT", 335, 345], ["Streptococcus pneumoniae", "SPECIES", 38, 62], ["AOMHaemophilus influenzae", "SPECIES", 284, 309], ["Streptococcus pneumoniae", "SPECIES", 38, 62], ["AOMHaemophilus influenzae", "SPECIES", 284, 309], ["Streptococcus pneumoniae", "PROBLEM", 38, 62], ["amoxicillin", "TREATMENT", 117, 128], ["Disease Control", "TREATMENT", 235, 250], ["AOMHaemophilus influenzae", "PROBLEM", 284, 309], ["\u03b2lactamase positive", "PROBLEM", 335, 354], ["previous antibiotic administration", "TREATMENT", 361, 395], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["Streptococcus pneumoniae", "OBSERVATION", 38, 62], ["intermediary resistance", "OBSERVATION", 68, 91], ["influenzae", "OBSERVATION", 299, 309]]], ["Therefore, the addition of clavulanate-at a dose of 6.4 mg/kg per day-to amoxicillin makes sense.", [["clavulanate", "CHEMICAL", 27, 38], ["amoxicillin", "CHEMICAL", 73, 84], ["clavulanate", "CHEMICAL", 27, 38], ["amoxicillin", "CHEMICAL", 73, 84], ["clavulanate", "SIMPLE_CHEMICAL", 27, 38], ["amoxicillin", "SIMPLE_CHEMICAL", 73, 84], ["clavulanate", "TREATMENT", 27, 38], ["amoxicillin", "TREATMENT", 73, 84]]], ["Most Moraxella catarrhalis strains are nowadays also \u03b2-lactamase positive [42] .Treatment of AOMThe duration of the antibiotic treatment is a matter of discussion.", [["Moraxella catarrhalis", "ORGANISM", 5, 26], ["Moraxella catarrhalis", "SPECIES", 5, 26], ["Moraxella catarrhalis", "SPECIES", 5, 26], ["Most Moraxella catarrhalis strains", "PROBLEM", 0, 34], ["the antibiotic treatment", "TREATMENT", 112, 136], ["catarrhalis", "OBSERVATION", 15, 26]]], ["For children less than 2 years of age, a 10-day course is reasonable.", [["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12]]], ["Pneumo-otoscopy and tympanometry can help to appreciate the permeability of the ET.", [["Pneumo-otoscopy", "TREATMENT", 0, 15], ["tympanometry", "TEST", 20, 32]]], ["Careful follow-up is necessary.Treatment of AOMNasopharyngeal aspirate cultures may give valuable results and are highly recommended in children remaining in day care centres or with a history of previous AOM episodes [28, 51] .Treatment of AOMFor children more than 2 years of age the previously watchful guidelines can be maintained but some flexibility is recommended [22, 36] .Treatment of AOMTreatment of OME: tympanostomy tubes?Treatment of AOMThe approach to OME must take into account the natural history of spontaneous healing and the main complication which is temporary hearing impairment [1] .", [["AOMNasopharyngeal aspirate cultures", "ANATOMY", 44, 79], ["AOM", "DISEASE", 205, 208], ["OME", "DISEASE", 410, 413], ["OME", "DISEASE", 466, 469], ["hearing impairment", "DISEASE", 581, 599], ["AOMNasopharyngeal aspirate cultures", "CELL", 44, 79], ["children", "ORGANISM", 136, 144], ["children", "ORGANISM", 248, 256], ["AOMNasopharyngeal aspirate cultures", "CELL_LINE", 44, 79], ["children", "SPECIES", 136, 144], ["children", "SPECIES", 248, 256], ["AOMNasopharyngeal aspirate cultures", "TEST", 44, 79], ["previous AOM episodes", "PROBLEM", 196, 217], ["OME", "PROBLEM", 410, 413], ["tympanostomy tubes", "TREATMENT", 415, 433], ["Treatment of AOMThe approach", "TREATMENT", 434, 462], ["spontaneous healing", "PROBLEM", 516, 535], ["the main complication", "PROBLEM", 540, 561], ["temporary hearing impairment", "PROBLEM", 571, 599], ["tympanostomy tubes", "OBSERVATION", 415, 433], ["spontaneous", "OBSERVATION_MODIFIER", 516, 527], ["healing", "OBSERVATION_MODIFIER", 528, 535], ["main", "OBSERVATION_MODIFIER", 544, 548], ["complication", "OBSERVATION", 549, 561]]], ["The absence of spontaneous healing after 6 weeks to 2 months in children over 2 years of age is an indication for a 10-day antibiotic course according to the results of the nasopharyngeal aspirate cultures.", [["nasopharyngeal aspirate cultures", "ANATOMY", 173, 205], ["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["spontaneous healing", "PROBLEM", 15, 34], ["a 10-day antibiotic course", "TREATMENT", 114, 140], ["the nasopharyngeal aspirate cultures", "TEST", 169, 205], ["spontaneous", "OBSERVATION_MODIFIER", 15, 26], ["healing", "OBSERVATION_MODIFIER", 27, 34], ["nasopharyngeal", "ANATOMY", 173, 187]]], ["It is our experience that this approach has several advantages.", [["this approach", "TREATMENT", 26, 39]]], ["First, the effect even temporarily on the hearing defect is frequently successful.", [["the hearing defect", "PROBLEM", 38, 56], ["defect", "OBSERVATION", 50, 56]]], ["Second, it decreases the recurrence of AOM by improving the ET functions and third, it allows postponement or avoidance of tympanostomy tube insertion, because improved hearing points to improved permeability of the ET.Treatment of AOMThe delay of 6 weeks or 2 months before treatment of OME (Table 2) is based on the duration of OME.", [["tympanostomy tube", "ANATOMY", 123, 140], ["AOM", "DISEASE", 39, 42], ["OME", "DISEASE", 288, 291], ["OME", "DISEASE", 330, 333], ["AOM", "CANCER", 39, 42], ["tube", "TISSUE", 136, 140], ["AOM", "PROBLEM", 39, 42], ["tympanostomy tube insertion", "TREATMENT", 123, 150], ["improved hearing points", "PROBLEM", 160, 183], ["treatment", "TREATMENT", 275, 284], ["OME", "PROBLEM", 288, 291], ["OME", "PROBLEM", 330, 333], ["decreases", "OBSERVATION_MODIFIER", 11, 20], ["recurrence", "OBSERVATION_MODIFIER", 25, 35], ["AOM", "OBSERVATION", 39, 42], ["tympanostomy tube", "OBSERVATION", 123, 140]]], ["Indeed, in a prospective study by Renko et al. [43] of 90 children with AOM, 0.6-7 years of age, treated with amoxicillin or cefuroxime axetil for 10 days, the mean duration of OME was 10.2 days (range: 1-58 days); only 10 of 90 still had OME after 29-43 days.Treatment of AOMIn a long-term prospective study in 6,350 healthy infants treated according to specified guidelines, Paradise et al. [38] observed bilateral OME in only 5.6% of the 161 children who had not received tympanostomy tubes at the age of 4.Treatment of AOMThe indication to insert tubes is equivocal.", [["AOM", "DISEASE", 72, 75], ["amoxicillin", "CHEMICAL", 110, 121], ["cefuroxime axetil", "CHEMICAL", 125, 142], ["OME", "DISEASE", 177, 180], ["OME", "DISEASE", 239, 242], ["OME", "DISEASE", 417, 420], ["amoxicillin", "CHEMICAL", 110, 121], ["cefuroxime axetil", "CHEMICAL", 125, 142], ["children", "ORGANISM", 58, 66], ["amoxicillin", "SIMPLE_CHEMICAL", 110, 121], ["cefuroxime axetil", "SIMPLE_CHEMICAL", 125, 142], ["infants", "ORGANISM", 326, 333], ["children", "ORGANISM", 445, 453], ["AOMThe", "CANCER", 523, 529], ["children", "SPECIES", 58, 66], ["infants", "SPECIES", 326, 333], ["children", "SPECIES", 445, 453], ["a prospective study", "TEST", 11, 30], ["AOM", "PROBLEM", 72, 75], ["amoxicillin", "TREATMENT", 110, 121], ["cefuroxime axetil", "TREATMENT", 125, 142], ["a long-term prospective study", "TREATMENT", 279, 308], ["bilateral OME", "PROBLEM", 407, 420], ["tympanostomy tubes", "TREATMENT", 475, 493], ["insert tubes", "TREATMENT", 544, 556], ["bilateral", "ANATOMY_MODIFIER", 407, 416], ["tubes", "OBSERVATION", 488, 493], ["tubes", "OBSERVATION", 551, 556]]], ["The large prospective studies on 3,686 infants and young children by the Paradise group have shown the absence of or negligible effects of tympanostomies on developmental outcomes at 3-4 years [34, 37] .", [["tympanostomies", "DISEASE", 139, 153], ["infants", "ORGANISM", 39, 46], ["children", "ORGANISM", 57, 65], ["infants", "SPECIES", 39, 46], ["children", "SPECIES", 57, 65], ["The large prospective studies", "TEST", 0, 29], ["large", "OBSERVATION_MODIFIER", 4, 9]]], ["On the other hand, insertion of tympanostomy tubes during the first 3 years of life is associated with complications in at least 80% of the patients [63] .", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["insertion of tympanostomy tubes", "TREATMENT", 19, 50], ["complications", "PROBLEM", 103, 116], ["tympanostomy tubes", "OBSERVATION", 32, 50]]], ["Tympanostomy can be a source of bacterial infections [24] and of tympanosclerosis.Treatment of AOMExtensive reviews by Kubba et al. [25] , Rosenfeld et al. [46] , Rovers et al. [48] and the recent Cochrane Database by Lous et al. [30] concluded that there was only a small benefit of the conventional ventilation tube.", [["Tympanostomy", "DISEASE", 0, 12], ["bacterial infections", "DISEASE", 32, 52], ["tympanosclerosis", "DISEASE", 65, 81], ["tympanosclerosis", "CANCER", 65, 81], ["Tympanostomy", "TREATMENT", 0, 12], ["bacterial infections", "PROBLEM", 32, 52], ["tympanosclerosis", "PROBLEM", 65, 81], ["the conventional ventilation tube", "TREATMENT", 284, 317], ["bacterial", "OBSERVATION_MODIFIER", 32, 41], ["infections", "OBSERVATION", 42, 52], ["tympanosclerosis", "OBSERVATION", 65, 81], ["small", "OBSERVATION_MODIFIER", 267, 272], ["ventilation tube", "OBSERVATION", 301, 317]]], ["The main reason for the poor results of tympanostomy tubes is the absence of effects on the ET dysfunction.", [["tympanostomy tubes", "TREATMENT", 40, 58], ["the ET dysfunction", "PROBLEM", 88, 106], ["main", "OBSERVATION_MODIFIER", 4, 8], ["tympanostomy tubes", "OBSERVATION", 40, 58], ["ET dysfunction", "OBSERVATION", 92, 106]]], ["It has never been demonstrated that tympanostomy tubes improve the functions of the ET.Treatment of AOMThe recommendations by the American Academy of Pediatrics [1] are to insert tubes in conditions with persisting hearing loss of more than 40 dB particularly with posterosuperior retraction pockets, ossicular erosions and adhesive atelectasis because of the increase of structural damage with effusion duration.Treatment of AOMWatchful waiting for 3-6 months in the winter period seems advisable in children with mild hearing deficit.Treatment of AOMAdenoidectomy should be considered in children \u22653 years of age with nasopharyngeal obstruction and recurrent adenoiditis [45] .VaccinationThe effects of pneumococcal vaccination on recurrent AOM have been studied extensively.", [["ossicular", "ANATOMY", 301, 310], ["nasopharyngeal", "ANATOMY", 620, 634], ["hearing loss", "DISEASE", 215, 227], ["ossicular erosions", "DISEASE", 301, 319], ["atelectasis", "DISEASE", 333, 344], ["effusion", "DISEASE", 395, 403], ["hearing deficit", "DISEASE", 520, 535], ["AOMAdenoidectomy", "DISEASE", 549, 565], ["nasopharyngeal obstruction", "DISEASE", 620, 646], ["adenoiditis", "DISEASE", 661, 672], ["AOM", "DISEASE", 743, 746], ["children", "ORGANISM", 501, 509], ["children", "ORGANISM", 590, 598], ["nasopharyngeal", "ORGAN", 620, 634], ["pneumococcal", "ORGANISM", 705, 717], ["children", "SPECIES", 501, 509], ["children", "SPECIES", 590, 598], ["pneumococcal", "SPECIES", 705, 717], ["tympanostomy tubes", "TREATMENT", 36, 54], ["tubes", "TREATMENT", 179, 184], ["persisting hearing loss", "PROBLEM", 204, 227], ["posterosuperior retraction pockets", "PROBLEM", 265, 299], ["ossicular erosions", "PROBLEM", 301, 319], ["adhesive atelectasis", "PROBLEM", 324, 344], ["structural damage", "PROBLEM", 372, 389], ["effusion duration", "PROBLEM", 395, 412], ["mild hearing deficit", "PROBLEM", 515, 535], ["AOMAdenoidectomy", "TREATMENT", 549, 565], ["nasopharyngeal obstruction", "PROBLEM", 620, 646], ["recurrent adenoiditis", "PROBLEM", 651, 672], ["Vaccination", "TREATMENT", 679, 690], ["pneumococcal vaccination", "TREATMENT", 705, 729], ["recurrent AOM", "PROBLEM", 733, 746], ["tympanostomy tubes", "OBSERVATION", 36, 54], ["tubes", "OBSERVATION", 179, 184], ["retraction", "OBSERVATION", 281, 291], ["ossicular", "ANATOMY", 301, 310], ["erosions", "OBSERVATION", 311, 319], ["adhesive", "OBSERVATION_MODIFIER", 324, 332], ["atelectasis", "OBSERVATION", 333, 344], ["increase", "OBSERVATION_MODIFIER", 360, 368], ["structural", "OBSERVATION_MODIFIER", 372, 382], ["damage", "OBSERVATION", 383, 389], ["effusion", "OBSERVATION", 395, 403], ["AOMAdenoidectomy", "OBSERVATION", 549, 565], ["nasopharyngeal", "ANATOMY", 620, 634], ["obstruction", "OBSERVATION", 635, 646]]], ["In a randomized controlled trial by Brouwer et al. [6] in 383 children, aged 1-7 years, with recurrent AOM, the effects in 190 children treated with heptavalent pneumococcal vaccine were compared with 193 children receiving hepatitis A or B vaccines.", [["AOM", "DISEASE", 103, 106], ["hepatitis A or B", "CHEMICAL", 224, 240], ["children", "ORGANISM", 62, 70], ["children", "ORGANISM", 127, 135], ["children", "ORGANISM", 205, 213], ["B vaccines", "ORGANISM", 239, 249], ["children", "SPECIES", 62, 70], ["children", "SPECIES", 127, 135], ["children", "SPECIES", 205, 213], ["pneumococcal", "SPECIES", 161, 173], ["hepatitis A", "SPECIES", 224, 235], ["recurrent AOM", "PROBLEM", 93, 106], ["heptavalent pneumococcal vaccine", "TREATMENT", 149, 181], ["hepatitis A", "TREATMENT", 224, 235], ["B vaccines", "TREATMENT", 239, 249], ["AOM", "OBSERVATION", 103, 106]]], ["The study concluded that there was no beneficial effect.", [["The study", "TEST", 0, 9], ["beneficial effect", "PROBLEM", 38, 55], ["no", "UNCERTAINTY", 35, 37], ["beneficial", "OBSERVATION_MODIFIER", 38, 48]]], ["A similar conclusion was drawn from a study by Van Kempen et al. [62] in 74 children aged 1-7 years and in the Cochrane Database by Straetemans et al. [56] .VaccinationA shift of the causative pathogen has been observed from Streptococcus pneumoniae to Haemophilus influenzae or to other strains of pneumococci than the ones included in the vaccine [20, 59] .", [["Streptococcus pneumoniae", "DISEASE", 225, 249], ["Haemophilus influenzae", "DISEASE", 253, 275], ["pneumococci", "DISEASE", 299, 310], ["children", "ORGANISM", 76, 84], ["Streptococcus pneumoniae", "ORGANISM", 225, 249], ["Haemophilus influenzae", "ORGANISM", 253, 275], ["children", "SPECIES", 76, 84], ["Streptococcus pneumoniae", "SPECIES", 225, 249], ["Haemophilus influenzae", "SPECIES", 253, 275], ["Streptococcus pneumoniae", "SPECIES", 225, 249], ["Haemophilus influenzae", "SPECIES", 253, 275], ["a study", "TEST", 36, 43], ["the causative pathogen", "PROBLEM", 179, 201], ["Streptococcus pneumoniae", "PROBLEM", 225, 249], ["Haemophilus influenzae", "PROBLEM", 253, 275], ["pneumococci", "PROBLEM", 299, 310]]], ["A slight reduction of the incidence of AOM of 6-8% was observed in the USA [7] .Infants and prematuresA high incidence of OME has been observed in neonatal intensive care units due to the nasally placed tubes for ventilatory assistance.", [["AOM", "DISEASE", 39, 42], ["OME", "DISEASE", 122, 125], ["Infants", "ORGANISM", 80, 87], ["Infants", "SPECIES", 80, 87], ["A slight reduction", "PROBLEM", 0, 18], ["AOM", "PROBLEM", 39, 42], ["OME", "PROBLEM", 122, 125], ["the nasally placed tubes", "TREATMENT", 184, 208], ["ventilatory assistance", "TREATMENT", 213, 235], ["slight", "OBSERVATION_MODIFIER", 2, 8], ["reduction", "OBSERVATION_MODIFIER", 9, 18], ["incidence", "OBSERVATION_MODIFIER", 26, 35], ["AOM", "OBSERVATION_MODIFIER", 39, 42], ["tubes", "OBSERVATION", 203, 208]]], ["It has been suggested that immune immaturity with impaired neuromotor function predisposes to this complication [17] .", [["impaired neuromotor function", "DISEASE", 50, 78], ["immune immaturity", "PROBLEM", 27, 44], ["impaired neuromotor function", "PROBLEM", 50, 78], ["this complication", "PROBLEM", 94, 111]]], ["Vaccination with the heptavalent pneumococcal vaccine has been advocated in premature babies and neonates [19] , but this study does not provide information on the actual AOM prevalence in a control group receiving only hepatitis B vaccine.", [["AOM", "DISEASE", 171, 174], ["hepatitis B", "DISEASE", 220, 231], ["babies", "ORGANISM", 86, 92], ["hepatitis B", "ORGANISM", 220, 231], ["pneumococcal", "SPECIES", 33, 45], ["Vaccination", "TREATMENT", 0, 11], ["the heptavalent pneumococcal vaccine", "TREATMENT", 17, 53], ["this study", "TEST", 117, 127], ["hepatitis B vaccine", "TREATMENT", 220, 239]]], ["It should be remembered that meconium aspiration into the entry of the middle ear is associated with increased risk of AOM and therefore early nasopharyngeal suction is mandatory [29] .", [["meconium", "ANATOMY", 29, 37], ["middle ear", "ANATOMY", 71, 81], ["nasopharyngeal", "ANATOMY", 143, 157], ["AOM", "DISEASE", 119, 122], ["ear", "ORGAN", 78, 81], ["nasopharyngeal", "ORGAN", 143, 157], ["meconium aspiration", "PROBLEM", 29, 48], ["AOM", "PROBLEM", 119, 122], ["early nasopharyngeal suction", "TREATMENT", 137, 165], ["meconium", "OBSERVATION_MODIFIER", 29, 37], ["aspiration", "OBSERVATION", 38, 48], ["middle ear", "ANATOMY", 71, 81], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["AOM", "OBSERVATION", 119, 122], ["early", "OBSERVATION_MODIFIER", 137, 142], ["nasopharyngeal", "ANATOMY", 143, 157], ["suction", "OBSERVATION", 158, 165]]]], "fc818659e1af317faaff55c7646316662a49f67f": [["A call to action : the need for autopsies to determine the full extent of organ involvement associated with COVID-19 infections Letter to the Editor A call to action : the need for autopsies to determine the full extent of organ involvement associated with COVID-19 infections Xinyang Xu [1] ; Rolf F. Barth [2] ; L. Maximilian Buja [3] [1] Kansas City University of Medicine and Biosciences Kansas City, Missouri 64106 [2] The Ohio State University, Department of Pathology, Columbus, Ohio 43210 *Corresponding Author [3] The University of Texas Health Science Center at Houston, Department of Pathology, Houston, TX 77030", [["organ", "ANATOMY", 74, 79], ["organ", "ANATOMY", 223, 228], ["infections", "DISEASE", 117, 127], ["infections", "DISEASE", 266, 276], ["TX 77030", "CHEMICAL", 615, 623], ["organ", "ORGAN", 74, 79], ["organ", "ORGAN", 223, 228], ["autopsies", "TREATMENT", 32, 41], ["organ involvement", "PROBLEM", 74, 91], ["autopsies", "TREATMENT", 181, 190], ["organ involvement", "PROBLEM", 223, 240], ["COVID", "TEST", 257, 262]]]], "8175ae8fad46af47167fcb55b238f5f9dfc78e8d": [["Empfehlungen f\u00fcr ECMO bei COVID-19-Patienten Consensus Paper zur Extrakorporalen Membranoxygenierung der Medizinischen Universit\u00e4t WienHintergrund Die aktuelle COVID-19-Pandemie, die durch das SARS-CoV-2 ausgel\u00f6st wird, hat bereits in vielen betroffenen L\u00e4ndern zu gravierenden Ressourcenengp\u00e4ssen in den jeweiligen Gesundheitssystemen gef\u00fchrt [1] .Empfehlungen f\u00fcr ECMO bei COVID-19-Patienten Consensus Paper zur Extrakorporalen Membranoxygenierung der Medizinischen Universit\u00e4t WienObwohl sehr viele COVID-19-Patienten nur moderate Symptome zeigen, entwickelt eine Subgruppe ein schweres respiratorisches Versagen unter dem Bild eines Acute Respiratory Distress Syndrome (ARDS) [2, 3] .", [["Respiratory Distress Syndrome", "DISEASE", 643, 672], ["ARDS", "DISEASE", 674, 678], ["Empfehlungen f\u00fcr ECMO bei COVID-19-Patienten Consensus Paper zur Extrakorporalen Membranoxygenierung der Medizinischen Universit\u00e4t WienHintergrund", "SPECIES", 0, 146], ["Die aktuelle COVID-19-Pandemie, die durch das SARS-CoV-2 ausgel\u00f6st wird", "SPECIES", 147, 218], ["Empfehlungen f\u00fcr ECMO bei COVID-19-Patienten Consensus Paper zur Extrakorporalen Membranoxygenierung der Medizinischen Universit\u00e4t WienObwohl sehr viele COVID-19-Patienten nur moderate Symptome zeigen", "SPECIES", 349, 549], ["Empfehlungen", "TREATMENT", 0, 12], ["ECMO", "TEST", 17, 21], ["COVID", "TEST", 26, 31], ["vielen betroffenen", "TREATMENT", 235, 253], ["Empfehlungen", "TEST", 349, 361], ["ECMO", "TEST", 366, 370], ["COVID", "TEST", 375, 380], ["WienObwohl", "TEST", 480, 490], ["COVID", "TEST", 502, 507], ["moderate Symptome zeigen", "PROBLEM", 525, 549], ["Acute Respiratory Distress Syndrome", "PROBLEM", 637, 672], ["ARDS)", "PROBLEM", 674, 679], ["Acute", "OBSERVATION_MODIFIER", 637, 642], ["Respiratory Distress", "OBSERVATION", 643, 663]]], ["Ebenso wird eine kardiale Beteiligung mit fulminanter Myokarditis, Herzrhythmusst\u00f6rungen und Kreislaufversagen beschrieben [3, 4] .", [["Ebenso wird eine kardiale Beteiligung mit fulminanter Myokarditis, Herzrhythmusst\u00f6rungen und Kreislaufversagen beschrieben", "SPECIES", 0, 122], ["Ebenso", "TEST", 0, 6], ["Myokarditis", "PROBLEM", 54, 65]]], ["COVID-19-Patienten, die mechanisch beatmet werden m\u00fcssen, weisen eine hohe Mortalit\u00e4t auf.", [["COVID", "TEST", 0, 5]]], ["Trotz der Tat-Im Manuskript werden Personenbezeichnungen der besseren Lesbarkeit wegen in nur einer Form verwendet, beziehen sich jedoch auf beide Geschlechter.Empfehlungen f\u00fcr ECMO bei COVID-19-Patienten Consensus Paper zur Extrakorporalen Membranoxygenierung der Medizinischen Universit\u00e4t Wiensache, dass sowohl in China als auch in Italien (den L\u00e4ndern mit den zum Zeitpunkt der Manuskripterstellung h\u00f6chsten Zahlen an COVID-19-Patienten) die Anzahl an ECMO(Extrakorporale Membranoxygenierung)-Patienten unter den COVID-19-F\u00e4llen gering ist, erscheint es wichtig, sich in \u00d6sterreich bzw. in Wien mit diesem speziellen Szenario auseinanderzusetzen und Richtlinien f\u00fcr den ECMO-Einsatz in diesem speziellen Fall zu erstellen.Empfehlungen f\u00fcr ECMO bei COVID-19-Patienten Consensus Paper zur Extrakorporalen Membranoxygenierung der Medizinischen Universit\u00e4t WienGrunds\u00e4tzlich darf bei weiterf\u00fchren-denFragenaufdie rezente Stellungnahme der European Life Support Organization (ELSO) verwiesen werden [5] .AllokationGrundsatzfrage: Sollte eine ECMO-Therapie f\u00fcr COVID-19-Patienten in Betracht gezogen werden?AllokationDerzeit befinden wir uns in \u00d6sterreich noch in keiner Triagesituation, in der gewisse Patientengruppen grunds\u00e4tzlich von Therapien ausgeschlossen werden.", [["Empfehlungen f\u00fcr ECMO bei COVID-19-Patienten Consensus Paper zur Extrakorporalen Membranoxygenierung der Medizinischen Universit\u00e4t Wiensache, dass sowohl in China als auch in Italien (den L\u00e4ndern mit den zum Zeitpunkt der Manuskripterstellung h\u00f6chsten Zahlen an COVID-19-Patienten) die Anzahl an ECMO(Extrakorporale Membranoxygenierung)-Patienten unter den COVID-19-F\u00e4llen gering ist, erscheint es wichtig", "SPECIES", 160, 565], ["Wien mit diesem speziellen Szenario auseinanderzusetzen und Richtlinien f\u00fcr den ECMO-Einsatz in diesem speziellen Fall zu erstellen", "SPECIES", 594, 725], ["Empfehlungen f\u00fcr ECMO bei COVID-19-Patienten Consensus Paper zur Extrakorporalen Membranoxygenierung der Medizinischen Universit\u00e4t WienGrunds\u00e4tzlich darf bei weiterf\u00fchren-denFragenaufdie rezente", "SPECIES", 726, 920], ["Sollte eine ECMO-Therapie f\u00fcr COVID-19-Patienten", "SPECIES", 1029, 1077], ["Trotz der Tat", "TREATMENT", 0, 13], ["Empfehlungen", "TREATMENT", 160, 172], ["ECMO", "TEST", 177, 181], ["COVID", "TEST", 186, 191], ["an COVID", "TREATMENT", 419, 427], ["an ECMO(Extrakorporale Membranoxygenierung", "TREATMENT", 453, 495], ["ECMO", "TREATMENT", 674, 678], ["Einsatz", "TREATMENT", 679, 686], ["Empfehlungen", "TREATMENT", 726, 738], ["ECMO", "TEST", 743, 747], ["COVID", "TEST", 752, 757], ["darf bei weiterf\u00fchren", "TREATMENT", 875, 896], ["Sollte eine ECMO", "TREATMENT", 1029, 1045], ["COVID", "TEST", 1059, 1064]]], ["Dennoch muss eine Indikationsstellung zum ECMO-Support bei COVID-19 mit R\u00fccksichtnahme auf m\u00f6gliche zuk\u00fcnftige Ressourcenengp\u00e4sse restriktiv gestellt werden [6] .", [["Dennoch muss eine Indikationsstellung zum ECMO-Support bei COVID-19 mit R\u00fccksichtnahme auf m\u00f6gliche zuk\u00fcnftige Ressourcenengp\u00e4sse restriktiv gestellt werden", "SPECIES", 0, 156], ["ECMO", "TREATMENT", 42, 46], ["Support bei COVID", "TREATMENT", 47, 64]]], ["Dies bedeutet aber nicht, dass Covid-19-Patienten generell von einer ECMO-Therapie ausgeschlossen werden sollen.", [["Dies bedeutet aber nicht, dass Covid-19-Patienten generell von einer ECMO-Therapie ausgeschlossen werden sollen", "SPECIES", 0, 111], ["ECMO", "TREATMENT", 69, 73]]], ["Allerdings sind fortgeschrittenes Patientenalter, Komorbidit\u00e4ten und grunds\u00e4tzliche Prognoseeinsch\u00e4tzung wichtige Parameter, die bereits jetzt in die Entscheidung, COVID-19-Patienten mittels ECMO zu unterst\u00fctzen, einflie\u00dfen m\u00fcssen.AllokationSollte es in \u00d6sterreich zu einer Triagesituation \u00e4hnlich zu der derzeitigen Lage in Italien, Spanien und anderen L\u00e4ndern kommen, ist die Entscheidung zur ECMO an die jeweilige Triageentscheidung der Intensivstation bzw.", [["Komorbidit\u00e4ten und grunds\u00e4tzliche Prognoseeinsch\u00e4tzung wichtige Parameter, die bereits jetzt in die Entscheidung, COVID-19-Patienten mittels ECMO zu unterst\u00fctzen", "SPECIES", 50, 211], ["\u00d6sterreich zu einer Triagesituation \u00e4hnlich zu der derzeitigen Lage in Italien, Spanien und anderen L\u00e4ndern kommen, ist die Entscheidung zur ECMO an die jeweilige Triageentscheidung der Intensivstation bzw", "SPECIES", 254, 459], ["Komorbidit\u00e4ten und grunds\u00e4tzliche Prognoseeinsch\u00e4tzung wichtige Parameter", "TREATMENT", 50, 123], ["COVID", "TEST", 164, 169], ["ECMO", "TREATMENT", 191, 195], ["AllokationSollte es", "TREATMENT", 231, 250]]], ["Ressourcenkapazit\u00e4ten zu kn\u00fcpfen.AllokationAn diese Grundsatzdebatte ist die Frage anzuschlie\u00dfen, ob in der Pan-Vorgehen und Ausschlusskriterien bei COVID-19positiven ECMO-KandidatenWenn sich ein SARS-CoV-2-positiver Patient au\u00dferhalb des Allgemeinen Krankenhauses (AKH) Wien anhand der gegebenen Richtlinien f\u00fcr eine ECMO qualifiziert, ist eine fr\u00fchzeitige Kontaktaufnahme mit den intensivmedizinischen Koordinatoren des AKH Wien aus den Bereichen der An\u00e4sthesie oder Innere Medizin n\u00f6tig.Protektive Ma\u00dfnahmenF\u00fcr die entsprechenden Schutzma\u00dfnahmen bei der ECMO-Implantation bzw. generell w\u00e4hrend der Behandlung von Patienten mit COVID-19 gelten die Richtlinien des Wiener Krankenanstaltenverbunds [7] .", [["Patient", "SPECIES", 217, 224], ["Ressourcenkapazit\u00e4ten zu kn\u00fcpfen", "SPECIES", 0, 32], ["An diese Grundsatzdebatte ist die Frage anzuschlie\u00dfen, ob in der Pan-Vorgehen und Ausschlusskriterien bei COVID-19positiven ECMO-KandidatenWenn sich ein SARS-CoV-2-positiver Patient au\u00dferhalb des Allgemeinen Krankenhauses (AKH) Wien anhand der gegebenen Richtlinien f\u00fcr eine ECMO qualifiziert, ist eine fr\u00fchzeitige Kontaktaufnahme mit den intensivmedizinischen Koordinatoren des AKH Wien aus den Bereichen der An\u00e4sthesie oder Innere Medizin n\u00f6tig", "SPECIES", 43, 489], ["generell w\u00e4hrend der Behandlung von Patienten mit COVID-19 gelten die Richtlinien des Wiener Krankenanstaltenverbunds", "SPECIES", 580, 697], ["Ressourcenkapazit\u00e4ten", "TREATMENT", 0, 21], ["COVID", "TEST", 149, 154], ["ECMO", "TEST", 167, 171], ["CoV", "TEST", 201, 204], ["eine ECMO qualifiziert", "TREATMENT", 313, 335], ["ist eine fr\u00fchzeitige Kontaktaufnahme mit", "TREATMENT", 337, 377], ["Innere Medizin n\u00f6tig", "TREATMENT", 469, 489], ["Protektive Ma\u00dfnahmenF\u00fcr die", "TREATMENT", 490, 517], ["Schutzma\u00dfnahmen bei der ECMO", "TREATMENT", 533, 561], ["Implantation bzw", "TREATMENT", 562, 578]]], ["Zus\u00e4tzliche Empfehlung f\u00fcr den Operateur zur Vermeidung einer Wundkontamination ist eine FFP-2-oder FFP-3-Maske ohne Ventil.", [["Zus\u00e4tzliche Empfehlung f\u00fcr den Operateur zur Vermeidung einer Wundkontamination ist eine FFP-2-oder FFP-3-Maske ohne", "SPECIES", 0, 116], ["Zus\u00e4tzliche", "TREATMENT", 0, 11], ["ist eine FFP", "TREATMENT", 80, 92], ["FFP", "TREATMENT", 100, 103], ["Maske ohne Ventil", "TREATMENT", 106, 123]]], ["Alternativ kann auch eine FFP-2-oder FFP-3-Maske mit Ventil mit einer konventionellen Mund-Nasen-Maske kombiniert werden.Ausschlusskriterien f\u00fcr eine ECMO-Therapie bei COVID-19-PatientenAuf Basis der vorhandenen Ressourcen k\u00f6nnen sich die klinischen Ausschlusskriteriendynamisch\u00e4ndern. .", [["Ventil mit einer konventionellen Mund-Nasen-Maske kombiniert werden", "SPECIES", 53, 120], ["Ausschlusskriterien f\u00fcr eine ECMO-Therapie bei COVID-19-PatientenAuf Basis der vorhandenen Ressourcen k\u00f6nnen sich die klinischen", "SPECIES", 121, 249], ["Alternativ kann auch eine FFP", "TREATMENT", 0, 29], ["FFP", "TREATMENT", 37, 40], ["Ausschlusskriterien", "TREATMENT", 121, 140], ["eine ECMO", "TREATMENT", 145, 154], ["Therapie bei COVID", "TREATMENT", 155, 173]]], ["Tab.", [["Tab", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["1 fasst absolute und relative Kontraindikationen f\u00fcr einen ECMO-Support bei COVID-19-Patienten zusammen.", [["Kontraindikationen f\u00fcr einen ECMO-Support bei COVID-19-Patienten zusammen", "SPECIES", 30, 103], ["einen ECMO", "TREATMENT", 53, 63]]], ["Aus derzeitiger Sicht sollten Patienten mit diesen Kriterien f\u00fcr einen ECMO-Support ausgeschlossen oder zumindest sehr kritisch evaluiert werden.Venoven\u00f6se ECMO (\"respiratory ECMO\")Grundsatz.", [["Aus derzeitiger Sicht sollten Patienten mit diesen Kriterien f\u00fcr einen ECMO-Support ausgeschlossen oder zumindest sehr kritisch evaluiert werden", "SPECIES", 0, 144], ["einen ECMO", "TREATMENT", 65, 75], ["Venoven\u00f6se ECMO", "TREATMENT", 145, 160]]], ["ECMO bei COVID-19 ist eine Rescuetherapie, wenn die mechanische Beatmung den Gasaustausch nicht mehr gew\u00e4hrleisten kann, sodass eine lebens-oder organbedrohliche Hypoxie und/oder Hyperkapnie resultiert.Venoven\u00f6se ECMO (\"respiratory ECMO\")Eine ECMO-Therapie soll auch dann als indiziert angesehen werden, wenn die Invasivit\u00e4t und damit die negativen Effekte einer mechanischen Beatmung als zu hoch erachtet werden.", [["Venoven\u00f6se", "CHEMICAL", 202, 212], ["sodass eine lebens-oder organbedrohliche Hypoxie und/oder Hyperkapnie resultiert", "SPECIES", 121, 201], ["auch dann als indiziert angesehen werden, wenn die Invasivit\u00e4t und damit die negativen Effekte einer mechanischen Beatmung als zu hoch erachtet werden", "SPECIES", 262, 412], ["ECMO bei COVID", "TREATMENT", 0, 14], ["ist eine Rescuetherapie", "TREATMENT", 18, 41], ["Venoven\u00f6se ECMO", "TREATMENT", 202, 217], ["Eine ECMO", "TREATMENT", 238, 247]]], ["Hier ist besonders auf den rechtzeitigen Einsatz bzw. die rechtzeitige Vorstellung des Patienten hinzuweisen.Indikationen und KontraindikationenAls Grundlage f\u00fcr die Beurteilung, ob eine solche Situation vorliegt, kann der von der Extracorporeal Life Support Organization empfohlene Algorithmus unter den Bedingungen einer optimierten Be-atmungstherapie herangezogen werden (.", [["Hier ist besonders", "TREATMENT", 0, 18], ["kann der von der Extracorporeal Life Support", "TREATMENT", 214, 258], ["empfohlene Algorithmus", "TREATMENT", 272, 294]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["1; [5, 8]Schl\u00fcsselw\u00f6rterAkutes Atemnotsyndrom \u00b7 Empfehlungen \u00b7 Kriterien \u00b7 Indikationen \u00b7 Kan\u00fclierungBeatmungsstrategie unter VV ECMOUnter VV ECMO ist eine lungenprotektive Beatmungsstrategie unter Ber\u00fccksichtigung einer Reduktion von Tidalvolumen, \"driving pressure\" und Atemfrequenz zu empfehlen [9] [10] [11] .", [["Schl\u00fcsselw\u00f6rterAkutes Atemnotsyndrom \u00b7 Empfehlungen \u00b7 Kriterien \u00b7 Indikationen \u00b7 Kan\u00fclierung", "SPECIES", 9, 101], ["Beatmungsstrategie unter VV ECMOUnter VV ECMO ist eine lungenprotektive Beatmungsstrategie unter Ber\u00fccksichtigung einer Reduktion von Tidalvolumen", "SPECIES", 101, 247], ["Schl\u00fcsselw\u00f6rterAkutes", "TEST", 9, 30], ["Atemnotsyndrom", "TREATMENT", 31, 45], ["Empfehlungen", "TREATMENT", 48, 60], ["Kriterien", "TREATMENT", 63, 72], ["VV ECMO", "TREATMENT", 139, 146]]], ["Die PEEP-Titration sollte individuell entsprechend des Rekrutierungspotenzials erfolgen [12] .", [["PEEP", "TREATMENT", 4, 8], ["Titration sollte individuell entsprechend des", "TREATMENT", 9, 54]]], ["Aufgrund der Tatsache, dass die meisten COVID-19-Patienten eine respiratorische Beteiligung aufweisen, ist davon auszugehen, dass ein betr\u00e4chtlicher Anteil der Patienten aufgrund des Harlekin-Effektes eine ungen\u00fcgende Oxygenierung der oberen K\u00f6rperh\u00e4lfte aufweist [13] .", [["Aufgrund der Tatsache, dass die meisten COVID-19-Patienten eine respiratorische Beteiligung aufweisen, ist davon auszugehen, dass ein betr\u00e4chtlicher Anteil der Patienten aufgrund des Harlekin-Effektes eine ungen\u00fcgende Oxygenierung der oberen K\u00f6rperh\u00e4lfte aufweist", "SPECIES", 0, 263], ["COVID", "TEST", 40, 45], ["des Harlekin", "TREATMENT", 179, 191]]], ["Im Falle einer schlechten Oxygenierung ist fr\u00fchzeitig eine \u00c4nderung des ECMO Set-ups zu empfehlen.", [["Im Falle einer schlechten Oxygenierung ist fr\u00fchzeitig eine \u00c4nderung des ECMO Set-ups zu empfehlen", "SPECIES", 0, 97], ["Im Falle einer schlechten", "TREATMENT", 0, 25]]], ["Gerade bei CO-VID-19-Patienten ist, um ein potenzielles Infektionsrisiko so gering wie m\u00f6glich zu halten, ein \"upgrading\" auf eine V-VA ECMO die erste Variante.", [["Gerade bei CO-VID-19-Patienten ist, um ein potenzielles Infektionsrisiko so gering wie m\u00f6glich zu halten, ein \"upgrading\" auf eine V-VA ECMO die erste Variante", "SPECIES", 0, 159], ["Gerade bei CO", "TEST", 0, 13], ["VID", "TEST", 14, 17]]], ["Alternative ist die Umkan\u00fclierung von der arteriellen R\u00fcckf\u00fchrung von femoral auf die A. subclavia.", [["Alternative ist die", "TREATMENT", 0, 19], ["femoral", "ANATOMY", 70, 77], ["subclavia", "ANATOMY", 89, 98]]], ["Da hierf\u00fcr auch chirurgische Kapazit\u00e4ten ben\u00f6-tigt werden, ist diese Entscheidung auch an das Vorhandensein herzchirurgischer Operationskapazit\u00e4ten in der Pandemiezeit zu kn\u00fcpfen.Venoarterielle ECMO bei COVID-19-Patienten (\"cardiac ECMO\")Bez\u00fcglich der unterst\u00fctzenden Bildgebung bei der Implantation ist anzumerken, dass prinzipiell die trans\u00f6sophageale Echokardiographie die etablierteste und am h\u00e4ufigsten verwendete Methode ist.", [["cardiac", "ANATOMY", 224, 231], ["COVID-19-Patienten", "CHEMICAL", 203, 221], ["Venoarterielle", "TEST", 179, 193], ["ECMO", "TEST", 194, 198], ["COVID", "TEST", 203, 208], ["cardiac ECMO\"", "TREATMENT", 224, 237], ["Bez\u00fcglich der unterst\u00fctzenden Bildgebung bei der Implantation ist anzumerken", "TREATMENT", 238, 314], ["cardiac", "ANATOMY", 224, 231], ["ECMO", "OBSERVATION", 232, 236]]], ["Da das TEE eine aerosolbildende Ma\u00dfnahme darstellt, ist diese Entscheidung jedoch situationsabh\u00e4ngig zu f\u00e4llen und gegen ein potenzielles Infektionsrisiko abzuw\u00e4gen.", [["TEE", "TEST", 7, 10]]], ["Alternativ kann auf eine transthorakale bzw. abdominelle Ultraschallbildgebung zur\u00fcckgegriffen werden.", [["Alternativ", "TREATMENT", 0, 10], ["zur\u00fcckgegriffen werden", "OBSERVATION", 79, 101]]], ["Das Risiko einer Infektion des medizinischen Personals im eCPR-Setting ist als hoch einzusch\u00e4tzen (\"aerosol generating procedure\" [AEP]).", [["Das Risiko einer Infektion des medizinischen Personals im eCPR-Setting ist als hoch einzusch\u00e4tzen", "SPECIES", 0, 97], ["Das Risiko einer Infektion des medizinischen Personals im eCPR", "TREATMENT", 0, 62], ["Setting ist als hoch einzusch\u00e4tzen (\"aerosol generating procedure", "TREATMENT", 63, 128]]], ["Dies gilt f\u00fcr nachgewiesen SARS-CoV-2-positive Patienten wie auch f\u00fcr alle Verdachtsf\u00e4lle.Kreislaufversagen an der VV ECMOBei eCPR SARS-CoV-2-positiver Patienten ist dringend die fr\u00fchzeitige (pr\u00e4hospitale) Kontaktaufnahme mit dem Team der Notfallaufnahme einzufordern, damit eine Entscheidung \u00fcber die ECMO-Implantation noch vor Eintreffen der Patienten im Krankenhaus getroffen werden kann.", [["CoV", "TEST", 32, 35], ["Kreislaufversagen", "TEST", 90, 107], ["eCPR SARS", "TEST", 126, 135], ["CoV", "TEST", 136, 139], ["ECMO", "TREATMENT", 302, 306], ["Implantation noch vor", "TREATMENT", 307, 328]]], ["Es muss vermieden werden, SARS-CoV-2-positive Patienten f\u00fcr eCPR ins Zentrum zu bringen, um dann erst vor Ort festzustellen, dass sich diese nicht daf\u00fcr qualifizieren.", [["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34]]], ["Bez\u00fcglich der Schutzma\u00dfnahmen ist derzeit bei jeglichen unter laufender Reanimation kommenden Patienten mit unbekanntem SARS-CoV-2-Status so vorzugehen, als ob der Patient positiv w\u00e4re.Entscheidung \u00fcber Therapiebeendigung bzw. weiterf\u00fchrende TherapieWie bei allen ECMO-Patienten ist eine Evaluierung des Patientenzustandes auf t\u00e4glicher Basis notwendig.", [["weiterf\u00fchrende", "CHEMICAL", 227, 241], ["Bez\u00fcglich der Schutzma\u00dfnahmen ist derzeit bei jeglichen unter laufender Reanimation kommenden Patienten mit unbekanntem SARS-CoV-2-Status so vorzugehen, als ob der Patient positiv w\u00e4re", "SPECIES", 0, 184], ["Entscheidung \u00fcber Therapiebeendigung bzw", "SPECIES", 185, 225], ["Bez\u00fcglich der Schutzma\u00dfnahmen ist derzeit", "TREATMENT", 0, 41]]], ["Auch hier ist auf die protektiven Ma\u00dfnahmen f\u00fcr das medizinische Personal hinzuweisen.", [["Auch hier ist auf die protektiven Ma\u00dfnahmen f\u00fcr das medizinische Personal hinzuweisen", "SPECIES", 0, 85]]], ["Im Falle von pulmonaler und/oder kardialer Recovery ist ein entsprechendes Weaning-Protokoll einzuleiten.Entscheidung \u00fcber Therapiebeendigung bzw. weiterf\u00fchrende TherapieSollte es zu keiner Erholung kommen, muss auch bei COVID-19-Patienten eingesch\u00e4tzt werden, ob diese sich f\u00fcr weiterf\u00fchrende Therapien qualifizieren (VAD oder Transplantation).", [["Im Falle von pulmonaler und/oder kardialer Recovery ist ein entsprechendes Weaning-Protokoll einzuleiten", "SPECIES", 0, 104], ["Entscheidung \u00fcber Therapiebeendigung bzw", "SPECIES", 105, 145], ["weiterf\u00fchrende TherapieSollte es zu keiner Erholung kommen, muss auch bei COVID-19-Patienten eingesch\u00e4tzt werden", "SPECIES", 147, 259], ["Protokoll einzuleiten", "TREATMENT", 83, 104], ["VAD oder Transplantation", "TREATMENT", 319, 343]]], ["Aus derzeitiger Sicht ist zwar nicht davon auszugehen, dass dies auf einen gro\u00dfen Teil der Patienten zutrifft, allerdings sollte diese Option gerade bei jungen Patienten nicht von vornherein ausgeschlossen werden.Entscheidung \u00fcber Therapiebeendigung bzw. weiterf\u00fchrende TherapieAufgrund von wissenschaftlichen Vorarbeiten wissen wir, dass bereits ab dem 7.", [["Aus derzeitiger Sicht ist zwar nicht davon auszugehen, dass dies auf einen gro\u00dfen Teil der Patienten zutrifft, allerdings sollte diese Option gerade bei jungen Patienten nicht von vornherein ausgeschlossen werden", "SPECIES", 0, 212], ["Entscheidung \u00fcber Therapiebeendigung bzw", "SPECIES", 213, 253]]], ["Tag an der VA ECMO das \u00dcberleben der Patienten deutlich ab-nimmt.", [["Tag", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Tag jegliche ECMO-Therapie beendet werden sollte.", [["Tag", "GENE_OR_GENE_PRODUCT", 0, 3], ["Tag jegliche ECMO-Therapie beendet werden sollte", "SPECIES", 0, 48], ["Tag jegliche ECMO", "TREATMENT", 0, 17]]], ["Allerdings ist es n\u00f6tig, Therapieziele nach einer Woche Behandlungsdauer zu reevaluieren und Entscheidungen entsprechend anzupassen [15, 16] .Entscheidung \u00fcber Therapiebeendigung bzw. weiterf\u00fchrende TherapieIm Falle der nicht vorhandenen Optionen f\u00fcr eine weiterf\u00fchrende Therapie m\u00fcssen eine Weiterf\u00fchrung der ECMO-Therapie und der Therapieabbruch diskutiert werden.", [["Entscheidung \u00fcber Therapiebeendigung bzw", "SPECIES", 142, 182], ["Therapie m\u00fcssen eine Weiterf\u00fchrung der ECMO-Therapie und der Therapieabbruch diskutiert werden", "SPECIES", 271, 365]]], ["Bei respiratorischer Indikation (VV ECMO) gibt es eine Subgruppe von Patienten mit Recovery auch nach deutlich l\u00e4ngerer Zeit, sodass im Einzelfall (unter Ber\u00fccksichtigung des Verlaufes und zus\u00e4tzlicher Organversagen) entschieden werden muss, ob die Fortf\u00fchrung der ECMO-Therapie als zielf\u00fchrend erachtet werden kann [17, 18] .", [["Bei respiratorischer Indikation (VV ECMO) gibt es eine Subgruppe von Patienten mit Recovery auch nach deutlich l\u00e4ngerer Zeit, sodass im Einzelfall (unter Ber\u00fccksichtigung des Verlaufes und zus\u00e4tzlicher Organversagen) entschieden werden muss, ob die Fortf\u00fchrung der ECMO-Therapie als zielf\u00fchrend erachtet werden kann", "SPECIES", 0, 315], ["VV ECMO)", "TREATMENT", 33, 41], ["sodass im Einzelfall (unter Ber\u00fccksichtigung des Verlaufes und zus\u00e4tzlicher Organversagen", "TREATMENT", 126, 215], ["der ECMO", "TREATMENT", 261, 269], ["ob", "ANATOMY", 242, 244]]], ["Auch diese Entscheidungen werden abh\u00e4ngig von der Ressourcenverf\u00fcgbarkeit dynamisch beeinflusst werden.Entscheidung \u00fcber Therapiebeendigung bzw. weiterf\u00fchrende TherapieOpen Access.", [["Entscheidung \u00fcber Therapiebeendigung bzw", "SPECIES", 103, 143]]], ["Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz ver\u00f6ffentlicht, welche die Nutzung, Vervielf\u00e4ltigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die urspr\u00fcnglichen Autor(en) und die Quelle ordnungsgem\u00e4\u00df nennen, einen Link zur Creative Commons Lizenz beif\u00fcgen und angeben, ob \u00c4nderungen vorgenommen wurden.Entscheidung \u00fcber Therapiebeendigung bzw. weiterf\u00fchrende TherapieDie in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt.", [["Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz ver\u00f6ffentlicht, welche die Nutzung, Vervielf\u00e4ltigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die urspr\u00fcnglichen Autor(en) und die Quelle ordnungsgem\u00e4\u00df nennen, einen Link zur Creative Commons Lizenz beif\u00fcgen und angeben", "SPECIES", 0, 360], ["Entscheidung \u00fcber Therapiebeendigung bzw", "SPECIES", 395, 435], ["International Lizenz ver\u00f6ffentlicht", "TREATMENT", 65, 100], ["weiterf\u00fchrende TherapieDie", "TREATMENT", 437, 463], ["ob", "ANATOMY", 362, 364]]], ["Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist f\u00fcr die oben aufgef\u00fchrten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen.Entscheidung \u00fcber Therapiebeendigung bzw. weiterf\u00fchrende TherapieWeitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/ licenses/by/4.0/deed.de.", [["Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist f\u00fcr die oben aufgef\u00fchrten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen", "SPECIES", 0, 287], ["Entscheidung \u00fcber Therapiebeendigung bzw", "SPECIES", 288, 328]]]], "3ccaa465d3a20adea09d6fc496c7bd9cdd0fdd9a": [["IntroductionSevere acute respiratory syndrome coronavirus two (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, was discovered in Wuhan, China, in December 2019 [1] .", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["coronavirus disease", "DISEASE", 106, 125], ["COVID-19", "CHEMICAL", 132, 140], ["IntroductionSevere acute respiratory syndrome coronavirus", "ORGANISM", 0, 57], ["SARS-CoV-2", "ORGANISM", 63, 73], ["COVID-19", "ORGANISM", 132, 140], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 63, 73], ["coronavirus disease 2019 (COVID-19", "SPECIES", 106, 140], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["the virus", "PROBLEM", 76, 85], ["the coronavirus disease", "PROBLEM", 102, 125], ["COVID", "TEST", 132, 137], ["pandemic", "PROBLEM", 142, 150], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["coronavirus disease", "OBSERVATION", 106, 125]]], ["SARS-CoV-2 is a member of the betacoronaviruses, a genus of enveloped positive-sense single-stranded RNA viruses.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 30, 47], ["SARS-CoV", "SPECIES", 0, 8], ["stranded RNA viruses", "PROBLEM", 92, 112], ["RNA viruses", "OBSERVATION", 101, 112]]], ["The symptom profile of COVID-19 infections vary, with a dry cough and fever most often reported [2] and resulting in a mild illness in most cases.", [["infections", "DISEASE", 32, 42], ["dry cough", "DISEASE", 56, 65], ["fever", "DISEASE", 70, 75], ["illness", "DISEASE", 124, 131], ["COVID-19", "ORGANISM", 23, 31], ["COVID-19", "SPECIES", 23, 31], ["COVID", "TEST", 23, 28], ["19 infections", "PROBLEM", 29, 42], ["a dry cough", "PROBLEM", 54, 65], ["fever", "PROBLEM", 70, 75], ["a mild illness in most cases", "PROBLEM", 117, 145], ["cough", "OBSERVATION", 60, 65], ["mild", "OBSERVATION_MODIFIER", 119, 123], ["illness", "OBSERVATION", 124, 131]]], ["However, severe illness has been reported as occurring in as many as 20% of laboratory-confirmed infections [3] , depending on population demographics and country-specific testing protocols, with symptoms including acute myocardial injury [4] and acute kidney injury [5] .", [["myocardial", "ANATOMY", 221, 231], ["kidney", "ANATOMY", 253, 259], ["illness", "DISEASE", 16, 23], ["infections", "DISEASE", 97, 107], ["acute myocardial injury", "DISEASE", 215, 238], ["acute kidney injury", "DISEASE", 247, 266], ["myocardial", "MULTI-TISSUE_STRUCTURE", 221, 231], ["kidney", "ORGAN", 253, 259], ["severe illness", "PROBLEM", 9, 23], ["infections", "PROBLEM", 97, 107], ["specific testing protocols", "TEST", 163, 189], ["symptoms", "PROBLEM", 196, 204], ["acute myocardial injury", "PROBLEM", 215, 238], ["acute kidney injury", "PROBLEM", 247, 266], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["illness", "OBSERVATION", 16, 23], ["infections", "OBSERVATION", 97, 107], ["acute", "OBSERVATION_MODIFIER", 215, 220], ["myocardial", "ANATOMY", 221, 231], ["injury", "OBSERVATION", 232, 238], ["acute", "OBSERVATION_MODIFIER", 247, 252], ["kidney", "ANATOMY", 253, 259], ["injury", "OBSERVATION", 260, 266]]], ["Two other highly pathogenic coronaviruses are known [6] : Unlike SARS-CoV-1 and MERS-CoV, however, SARS-CoV-2 is widely reported to cause asymptomatic carriage [7] in some individuals, which has contributed to the rapid, global spread [8] , and subsequent radical, world-wide restrictions on daily life to control transmission.", [["SARS", "DISEASE", 99, 103], ["coronaviruses", "ORGANISM", 28, 41], ["SARS-CoV-1", "ORGANISM", 65, 75], ["MERS-CoV", "ORGANISM", 80, 88], ["SARS-CoV-2", "ORGANISM", 99, 109], ["CoV-1", "SPECIES", 70, 75], ["SARS-CoV-1", "SPECIES", 65, 75], ["MERS-CoV", "SPECIES", 80, 88], ["SARS-CoV", "SPECIES", 99, 107], ["Two other highly pathogenic coronaviruses", "PROBLEM", 0, 41], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["MERS", "TEST", 80, 84], ["SARS", "PROBLEM", 99, 103], ["asymptomatic carriage", "PROBLEM", 138, 159], ["the rapid, global spread", "PROBLEM", 210, 234], ["highly", "OBSERVATION_MODIFIER", 10, 16], ["pathogenic", "OBSERVATION_MODIFIER", 17, 27], ["coronaviruses", "OBSERVATION", 28, 41]]], ["The disease now represents an unprecedented global health challenge.Mechanism of infectionUnderstanding of the mechanism of pathogenesis is a piecemeal process.", [["infection", "DISEASE", 81, 90], ["The disease", "PROBLEM", 0, 11], ["infection", "PROBLEM", 81, 90], ["pathogenesis", "PROBLEM", 124, 136], ["a piecemeal process", "PROBLEM", 140, 159], ["disease", "OBSERVATION", 4, 11], ["unprecedented", "OBSERVATION_MODIFIER", 30, 43], ["global", "OBSERVATION_MODIFIER", 44, 50], ["health", "OBSERVATION_MODIFIER", 51, 57], ["infection", "OBSERVATION", 81, 90], ["piecemeal", "OBSERVATION", 142, 151]]], ["One process that is particularly well understood is the entry of SARS-CoV-2 into human cells, which occurs via two major methods: TMPRSS2-dependent entry and TMPRSS2-independent entry [9] .", [["cells", "ANATOMY", 87, 92], ["SARS", "DISEASE", 65, 69], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 65, 75], ["human", "ORGANISM", 81, 86], ["cells", "CELL", 87, 92], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 130, 137], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 158, 165], ["human cells", "CELL_TYPE", 81, 92], ["TMPRSS2", "PROTEIN", 130, 137], ["TMPRSS2", "PROTEIN", 158, 165], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["CoV", "TEST", 70, 73], ["human cells", "ANATOMY", 81, 92]]], ["The first method relies on two human transmembrane proteins, ACE2 and TMPRSS2.", [["transmembrane", "ANATOMY", 37, 50], ["human", "ORGANISM", 31, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 70, 77], ["human transmembrane proteins", "PROTEIN", 31, 59], ["ACE2", "PROTEIN", 61, 65], ["TMPRSS2", "PROTEIN", 70, 77], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["TMPRSS2", "TEST", 70, 77]]], ["The spike proteins of SARS-CoV-2, which mediate coronavirus entry to human cells, have been shown to have strong affinity for the human protein ACE2, which is highly expressed on the surface of different cell types, including lung epithelial cells and type II alveolar cells [10] .", [["cells", "ANATOMY", 75, 80], ["surface", "ANATOMY", 183, 190], ["cell", "ANATOMY", 204, 208], ["lung epithelial cells", "ANATOMY", 226, 247], ["type II alveolar cells", "ANATOMY", 252, 274], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["coronavirus", "ORGANISM", 48, 59], ["human", "ORGANISM", 69, 74], ["cells", "CELL", 75, 80], ["human", "ORGANISM", 130, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 144, 148], ["surface", "CELLULAR_COMPONENT", 183, 190], ["cell", "CELL", 204, 208], ["lung epithelial cells", "CELL", 226, 247], ["type II alveolar cells", "CELL", 252, 274], ["spike proteins", "PROTEIN", 4, 18], ["human cells", "CELL_TYPE", 69, 80], ["human protein ACE2", "PROTEIN", 130, 148], ["lung epithelial cells", "CELL_TYPE", 226, 247], ["type II alveolar cells", "CELL_TYPE", 252, 274], ["coronavirus", "SPECIES", 48, 59], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 130, 135], ["SARS-CoV", "SPECIES", 22, 30], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 130, 135], ["SARS", "PROBLEM", 22, 26], ["CoV", "TEST", 27, 30], ["the human protein ACE2", "TEST", 126, 148], ["lung epithelial cells", "PROBLEM", 226, 247], ["type II alveolar cells", "PROBLEM", 252, 274], ["different cell types", "OBSERVATION", 194, 214], ["lung", "ANATOMY", 226, 230], ["epithelial cells", "OBSERVATION", 231, 247], ["alveolar cells", "OBSERVATION", 260, 274]]], ["Once the viral spike proteins have bound to ACE2, localised TMPRSS2 can activate the viral spike proteins and cleave the cytoplasm-facing domain of ACE2.", [["cytoplasm", "ANATOMY", 121, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 60, 67], ["cytoplasm", "ORGANISM_SUBSTANCE", 121, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["viral spike proteins", "PROTEIN", 9, 29], ["ACE2", "PROTEIN", 44, 48], ["TMPRSS2", "PROTEIN", 60, 67], ["viral spike proteins", "PROTEIN", 85, 105], ["cytoplasm-facing domain", "PROTEIN", 121, 144], ["ACE2", "PROTEIN", 148, 152], ["the viral spike proteins", "PROBLEM", 5, 29], ["ACE2", "TEST", 44, 48], ["localised TMPRSS2", "PROBLEM", 50, 67], ["the viral spike proteins", "PROBLEM", 81, 105], ["ACE2", "TEST", 148, 152], ["viral spike", "OBSERVATION", 85, 96]]], ["This mechanism causes the virus' membrane to fuse with the human cell's membrane, allowing the viral genomic RNA to enter the cell, where it can replicate and facilitate the production of new virions.Mechanism of infectionIn the absence of localised TMPRSS2, SARS-CoV-2 can enter human cells expressing ACE2 via another mechanism.", [["membrane", "ANATOMY", 33, 41], ["cell", "ANATOMY", 65, 69], ["membrane", "ANATOMY", 72, 80], ["cell", "ANATOMY", 126, 130], ["virions", "ANATOMY", 192, 199], ["cells", "ANATOMY", 286, 291], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["human", "ORGANISM", 59, 64], ["cell's membrane", "CELLULAR_COMPONENT", 65, 80], ["cell", "CELL", 126, 130], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 250, 257], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 259, 269], ["human", "ORGANISM", 280, 285], ["cells", "CELL", 286, 291], ["ACE2", "GENE_OR_GENE_PRODUCT", 303, 307], ["viral genomic RNA", "RNA", 95, 112], ["TMPRSS2", "PROTEIN", 250, 257], ["human cells", "CELL_TYPE", 280, 291], ["ACE2", "PROTEIN", 303, 307], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 280, 285], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 280, 285], ["the virus' membrane", "PROBLEM", 22, 41], ["the human cell's membrane", "TREATMENT", 55, 80], ["the viral genomic RNA", "PROBLEM", 91, 112], ["new virions", "PROBLEM", 188, 199], ["infectionIn", "PROBLEM", 213, 224], ["localised TMPRSS2", "PROBLEM", 240, 257], ["SARS", "PROBLEM", 259, 263], ["CoV", "TEST", 264, 267], ["virus", "OBSERVATION", 26, 31], ["human cell", "OBSERVATION", 59, 69], ["viral genomic RNA", "OBSERVATION", 95, 112], ["new", "OBSERVATION_MODIFIER", 188, 191], ["virions", "OBSERVATION", 192, 199]]], ["In this process, the viral spike proteins bind to ACE2 and the ACE2 receptor protein recruits clathrin, which initiates endocytosis of the virus.", [["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["clathrin", "GENE_OR_GENE_PRODUCT", 94, 102], ["viral spike proteins", "PROTEIN", 21, 41], ["ACE2", "PROTEIN", 50, 54], ["ACE2 receptor protein", "PROTEIN", 63, 84], ["clathrin", "PROTEIN", 94, 102], ["the viral spike proteins bind", "PROBLEM", 17, 46], ["ACE2", "TEST", 50, 54], ["the ACE2 receptor protein recruits clathrin", "TREATMENT", 59, 102], ["the virus", "PROBLEM", 135, 144], ["viral spike", "OBSERVATION", 21, 32]]], ["Usually, following endocytosis, proton pumps transport H + ions into endosomes, lowering the internal pH, allowing the endosome to begin the process of becoming an endolysosome and breaking down anything within.", [["endosomes", "ANATOMY", 69, 78], ["endosome", "ANATOMY", 119, 127], ["endolysosome", "ANATOMY", 164, 176], ["H", "CHEMICAL", 55, 56], ["H +", "CHEMICAL", 55, 58], ["H +", "SIMPLE_CHEMICAL", 55, 58], ["endosomes", "CELLULAR_COMPONENT", 69, 78], ["endosome", "CELLULAR_COMPONENT", 119, 127], ["proton pumps transport H + ions into endosomes", "TREATMENT", 32, 78], ["an endolysosome", "PROBLEM", 161, 176], ["endolysosome", "OBSERVATION", 164, 176]]], ["However, the pH-dependent enzyme cathepsin L present in endosomes are used by SARS-CoV-2 to activate the viral spike proteins, which allow the virus to fuse with the endosomal membrane and release its genomic RNA into the host cell in preparation for replication and production of more virions.Mechanism of infectionRepurposing drugs for the treatment of COVID-19Mechanism of infectionDue to the rapid increase in COVID-19 cases, a large amount of research into the disease pathogenesis and potential treatment has been carried out in a short space of time.", [["endosomes", "ANATOMY", 56, 65], ["endosomal membrane", "ANATOMY", 166, 184], ["cell", "ANATOMY", 227, 231], ["virions", "ANATOMY", 286, 293], ["COVID-19Mechanism", "CHEMICAL", 355, 372], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 33, 44], ["endosomes", "CELLULAR_COMPONENT", 56, 65], ["SARS-CoV-2", "ORGANISM", 78, 88], ["endosomal membrane", "CELLULAR_COMPONENT", 166, 184], ["host cell", "CELL", 222, 231], ["pH-dependent enzyme", "PROTEIN", 13, 32], ["cathepsin L", "PROTEIN", 33, 44], ["viral spike proteins", "PROTEIN", 105, 125], ["genomic RNA", "RNA", 201, 212], ["the pH", "TEST", 9, 15], ["dependent enzyme cathepsin", "PROBLEM", 16, 42], ["CoV", "TEST", 83, 86], ["the viral spike proteins", "PROBLEM", 101, 125], ["the virus", "PROBLEM", 139, 148], ["the endosomal membrane", "TREATMENT", 162, 184], ["replication", "TREATMENT", 251, 262], ["more virions", "PROBLEM", 281, 293], ["infectionRepurposing drugs", "TREATMENT", 307, 333], ["the treatment", "TREATMENT", 338, 351], ["COVID", "TREATMENT", 355, 360], ["infectionDue", "PROBLEM", 376, 388], ["COVID", "TEST", 414, 419], ["the disease pathogenesis", "PROBLEM", 462, 486], ["potential treatment", "TREATMENT", 491, 510], ["viral spike", "OBSERVATION", 105, 116], ["endosomal membrane", "OBSERVATION", 166, 184], ["host cell", "OBSERVATION", 222, 231], ["infectionRepurposing drugs", "OBSERVATION", 307, 333], ["rapid", "OBSERVATION_MODIFIER", 396, 401], ["increase", "OBSERVATION_MODIFIER", 402, 410], ["large", "OBSERVATION_MODIFIER", 432, 437], ["amount", "OBSERVATION_MODIFIER", 438, 444], ["disease", "OBSERVATION", 466, 473]]], ["Given the rapid onset of the pandemic, there is an urgent need to identify new drugs that are able to treat the disease and improve patient outcomes [11, 12] .", [["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 132, 139], ["new drugs", "TREATMENT", 75, 84], ["the disease", "PROBLEM", 108, 119]]], ["Developing novel drugs and taking them to market typically takes many years, so the traditional pathways are unlikely to provide a timely treatment for the current pandemic.", [["novel drugs", "TREATMENT", 11, 22], ["a timely treatment", "TREATMENT", 129, 147], ["drugs", "OBSERVATION", 17, 22]]], ["The time pressures for new treatments make drug repurposing particularly attractive.", [["The time pressures", "TEST", 0, 18], ["new treatments", "TREATMENT", 23, 37], ["drug repurposing", "TREATMENT", 43, 59]]], ["Drugs approved for one indication (disease) may also happen to be efficacious for another.", [["Drugs", "TREATMENT", 0, 5]]], ["If likely candidates for repurposing can be identified, the time to approval for a drug can be reduced to just a few months by drawing from the pool of the many thousands of drugs that have already been through the regulatory approval process, and are therefore well-characterised.", [["drugs", "TREATMENT", 174, 179]]], ["Identifying high quality drug repurposing candidates is challenging.", [["high", "OBSERVATION_MODIFIER", 12, 16]]], ["However, with the advent of network approaches to studying biology at a systems level, new computational approaches have emerged that allow a more systematic approach to drug repurposing [14] [15] [16] .", [["[14] [15] [16]", "SIMPLE_CHEMICAL", 187, 201]]], ["Networks are a convenient method to represent drugs, genes, proteins, diseases, etc., and the relationships between them.", [["diseases", "PROBLEM", 70, 78], ["diseases", "OBSERVATION", 70, 78]]], ["They support human investigation through visual exploration, while at the same time being amenable to computational analysis, enabling automated and systematic analysis.Mechanism of infectionDrug repurposing algorithms derive new relationships between drugs, targets, diseases, genes etc., based on existing knowledge of these relationships [15] , These new relationships can lead to hypotheses about novel repurposing opportunities and the evidence for them can be reviewed and then hypotheses tested in the laboratory and clinic.", [["infection", "DISEASE", 182, 191], ["human", "ORGANISM", 13, 18], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["human investigation", "TEST", 13, 32], ["visual exploration", "TEST", 41, 59], ["computational analysis", "TEST", 102, 124], ["systematic analysis", "TEST", 149, 168], ["infection", "PROBLEM", 182, 191], ["diseases", "PROBLEM", 268, 276], ["infection", "OBSERVATION", 182, 191]]], ["Computational drug repurposing prediction and human curation both require the availability of a variety of data sources that describe the molecular processes in a cell and their interaction with drugs.Mechanism of infectionThese data are typically distributed in a range of different data sources and databases and may be integrated after they have been represented as networks to form an integrated network or knowledge graph [17] [18] [19] .", [["cell", "ANATOMY", 163, 167], ["infection", "DISEASE", 214, 223], ["human", "ORGANISM", 46, 51], ["cell", "CELL", 163, 167], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["Computational drug repurposing prediction", "TREATMENT", 0, 41], ["infection", "PROBLEM", 214, 223], ["infection", "OBSERVATION", 214, 223]]], ["Repurposing algorithms that operate over the data can vary from simple pattern matching or network module analysis, through to the application of artificial intelligence [20] [21] [22] [23] [24] .", [["20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 171, 194], ["Repurposing algorithms", "TREATMENT", 0, 22], ["network module analysis", "TEST", 91, 114], ["artificial intelligence", "TEST", 146, 169]]], ["The output of these algorithms are systematic computational predictions and therefore need human curation, with a range of expertise, to assess their value.", [["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["these algorithms", "TEST", 14, 30], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["Therefore, the computational prediction of repurposable drugs is usually applied in an iterative fashion, coupled with the input of a human expert who is able to verify and generate hypotheses about new repurposing opportunities.Mechanism of infectionThe need for new drugs to treat COVID-19 has resulted in a large number of recent studies [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .", [["infection", "DISEASE", 242, 251], ["COVID-19", "CHEMICAL", 283, 291], ["COVID-19", "CHEMICAL", 283, 291], ["human", "ORGANISM", 134, 139], ["[25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41]", "SIMPLE_CHEMICAL", 341, 425], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["repurposable drugs", "TREATMENT", 43, 61], ["Mechanism of infection", "PROBLEM", 229, 251], ["new drugs", "TREATMENT", 264, 273], ["COVID", "TEST", 283, 288], ["recent studies", "TEST", 326, 340], ["infection", "OBSERVATION", 242, 251], ["large", "OBSERVATION_MODIFIER", 310, 315]]], ["Antiviral drugs have been the most obvious target since some of these have been shown to be active against SARS.", [["SARS", "DISEASE", 107, 111], ["Antiviral drugs", "TREATMENT", 0, 15], ["SARS", "PROBLEM", 107, 111], ["most obvious", "OBSERVATION_MODIFIER", 30, 42]]], ["For example, drugs such as Elbasvir are under scrutiny to this effect [42] .", [["Elbasvir", "CHEMICAL", 27, 35], ["Elbasvir", "CHEMICAL", 27, 35], ["Elbasvir", "SIMPLE_CHEMICAL", 27, 35], ["drugs", "TREATMENT", 13, 18], ["Elbasvir", "TREATMENT", 27, 35]]], ["Other antiviral drugs, such as Remdesivir, originally employed for the treatment of Ebola, have recently been approved for the treatment of COVID-19 [43] .Mechanism of infectionHowever, there is still a pressing need for more candidate drugs, especially those addressing the abnormal immune response seen in some patients [43, 44] .", [["Remdesivir", "CHEMICAL", 31, 41], ["Ebola", "DISEASE", 84, 89], ["infection", "DISEASE", 168, 177], ["Remdesivir", "CHEMICAL", 31, 41], ["COVID-19", "CHEMICAL", 140, 148], ["Remdesivir", "SIMPLE_CHEMICAL", 31, 41], ["Ebola", "ORGANISM", 84, 89], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 313, 321], ["Other antiviral drugs", "TREATMENT", 0, 21], ["Remdesivir", "TREATMENT", 31, 41], ["Ebola", "PROBLEM", 84, 89], ["COVID", "TEST", 140, 145], ["infection", "PROBLEM", 168, 177], ["more candidate drugs", "TREATMENT", 221, 241], ["the abnormal immune response", "PROBLEM", 271, 299], ["antiviral drugs", "OBSERVATION", 6, 21], ["Ebola", "OBSERVATION", 84, 89], ["infection", "OBSERVATION", 168, 177], ["immune response", "OBSERVATION", 284, 299]]], ["The wider search for repurposable drugs remains a field under active development.", [["repurposable drugs", "TREATMENT", 21, 39], ["active", "OBSERVATION", 62, 68]]], ["Most of these studies are computational in nature and have resulted in many potential new drug candidates.", [["these studies", "TEST", 8, 21]]], ["These studies have employed a variety of strategies including network based analyses.", [["These studies", "TEST", 0, 13], ["network based analyses", "TEST", 62, 84]]], ["Some of these candidates are now undergoing clinical trials to test their effectiveness [34] .Mechanism of infectionIn this work we used a combination of network algorithms and human curation to search integrated knowledge graphs for drug repurposing opportunities for COVID-19.", [["infection", "DISEASE", 107, 116], ["COVID-19", "CHEMICAL", 269, 277], ["human", "ORGANISM", 177, 182], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 177, 182], ["clinical trials", "TREATMENT", 44, 59], ["Mechanism of infection", "PROBLEM", 94, 116], ["network algorithms", "TREATMENT", 154, 172], ["COVID", "TEST", 269, 274], ["infection", "OBSERVATION", 107, 116]]], ["We aimed to highlight potential repurposing opportunities that are possibly novel in comparison to those published so far.", [["potential repurposing opportunities", "TREATMENT", 22, 57]]], ["We also introduce some newer features to our analytical process in an effort to improve accuracy by incorporating measures, which take data quality into account, and to speed up data verification by facilitating multiple curation.Mechanism of infectionMany studies, for example that of Kumar 2020 [36] , have employed protein interaction networks to study the relationships between COVID-19 proteins, the proteins they interact with, and the molecular interaction networks in the cell.", [["cell", "ANATOMY", 480, 484], ["infection", "DISEASE", 243, 252], ["COVID-19", "GENE_OR_GENE_PRODUCT", 382, 390], ["cell", "CELL", 480, 484], ["protein interaction networks", "PROTEIN", 318, 346], ["COVID-19 proteins", "PROTEIN", 382, 399], ["Mechanism of infection", "PROBLEM", 230, 252], ["COVID", "TEST", 382, 387], ["infection", "OBSERVATION", 243, 252]]], ["Instead of using a standard protein interaction graph, we developed a probabilistic functional interaction network for human proteins that uses highly curated interactions from BioGrid as a gold standard to produce a weighted protein interaction network, where the weight indicates the confidence of a functional interaction.", [["human", "ORGANISM", 119, 124], ["human proteins", "PROTEIN", 119, 133], ["BioGrid", "PROTEIN", 177, 184], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["a standard protein interaction graph", "TREATMENT", 17, 53], ["human proteins", "TREATMENT", 119, 133]]], ["We then mapped onto this human probabilistic function integrated network (PFIN) the interactions with COVID-19 proteins, discovered experimentally in Gordon et al ., 2020 [27] .Mechanism of infectionThe process of curating computational predictions, or manually analysing networks for new opportunities is a large-scale, time consuming task.", [["infection", "DISEASE", 190, 199], ["human", "ORGANISM", 25, 30], ["COVID-19", "GENE_OR_GENE_PRODUCT", 102, 110], ["PFIN", "DNA", 74, 78], ["COVID-19 proteins", "PROTEIN", 102, 119], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["infection", "PROBLEM", 190, 199], ["infection", "OBSERVATION", 190, 199]]], ["The division of labour through network partitioning and crowdsourcing are promising approaches to more rapid verification of results [45, 46] .", [["network", "MULTI-TISSUE_STRUCTURE", 31, 38]]], ["However, one of the challenges facing this approach is the assignment of appropriate sections of a complex network to each curator.", [["sections", "ANATOMY", 85, 93]]], ["Those subgraphs containing COVID-19 protein interactors were then enriched with information from previously integrated networks to add relationships to drugs, diseases, genes, pathways and so on.Mechanism of infectionEach subgraph then represents a unit of the network that was systematically assigned to a curator for analysis.", [["COVID-19 protein interactors", "PROTEIN", 27, 55], ["Those subgraphs", "TEST", 0, 15], ["COVID", "TEST", 27, 32], ["drugs", "TREATMENT", 152, 157], ["diseases", "PROBLEM", 159, 167], ["Mechanism of infectionEach subgraph", "PROBLEM", 195, 230], ["analysis", "TEST", 319, 327], ["infectionEach subgraph", "OBSERVATION", 208, 230]]], ["In this fashion, a large scale task is broken down and becomes faster with more curators participating in the exercise.", [["a large scale task", "TREATMENT", 17, 35], ["large", "OBSERVATION_MODIFIER", 19, 24], ["scale", "OBSERVATION_MODIFIER", 25, 30]]], ["Here we present details of our approach to the development and partitioning of the knowledge network and the resulting predictions for potentially repurposable drugs.MethodsThis work extends approaches developed by Mullen et al .", [["repurposable drugs", "TREATMENT", 147, 165]]], ["In brief, a semantic knowledge graph was constructed in Neo4j, comprising data about existing, approved drugs.MethodsThe data sources contributing to the knowledge graph are shown in Table 1 . between genes in the gold-standard, and absent from the gold-standard, respectively, and, P(L) and~P(L) represent the prior expectation of linkages between genes in the gold-standard, and absent from the gold-standard, respectively.Data sourceDatasets with a LLS of 0 or lower were discarded, and the remaining datasets were sorted in order of LLS, and integrated using the following formula:Data sourcewhere, L 1 is the highest LLS score and L n that with the lowest of a set of n datasets.", [["Data sourceDatasets", "TEST", 425, 444], ["a LLS", "TEST", 450, 455], ["Data sourcewhere", "TEST", 585, 601]]], ["For visualisation purposes, functional interaction relationships were omitted if the confidence score was lower than 4.336.Data sourceThe PFIN was clustered using a weighted MCL algorithm with the default parameters and viewed in Cytoscape [58, 59] .", [["PFIN", "GENE_OR_GENE_PRODUCT", 138, 142], ["PFIN", "DNA", 138, 142], ["visualisation purposes", "TEST", 4, 26], ["the confidence score", "TEST", 81, 101], ["The PFIN", "TREATMENT", 134, 142], ["a weighted MCL algorithm", "TEST", 163, 187], ["the default parameters", "TEST", 193, 215], ["Cytoscape", "TEST", 230, 239]]], ["Next, for the set of Homo sapiens proteins identified as interacting with SARS-CoV-2 proteins by Gordon et al. [60] , clusters from the PFIN containing genes that encode at least one of these proteins were extracted, decorated with edges and nodes from the knowledge base (Fig 1) , and returned.", [["Homo sapiens", "ORGANISM", 21, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 74, 84], ["PFIN", "GENE_OR_GENE_PRODUCT", 136, 140], ["Homo sapiens proteins", "PROTEIN", 21, 42], ["SARS-CoV-2 proteins", "PROTEIN", 74, 93], ["PFIN", "DNA", 136, 140], ["Homo sapiens", "SPECIES", 21, 33], ["Homo sapiens", "SPECIES", 21, 33], ["Homo sapiens proteins", "PROBLEM", 21, 42], ["CoV", "TEST", 79, 82], ["these proteins", "PROBLEM", 186, 200], ["nodes", "OBSERVATION", 242, 247]]], ["Theophylline Theophylline (IUPAC name: 1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione) is a methylxanthine drug with activities including smooth muscle relaxation and bronchial dilation.Data sourceIndicated for conditions such as chronic obstructive pulmonary disorder (COPD) and asthma, theophylline exerts its activity through competitive inhibition of type III and IV phosphodiesterase [61] .", [["smooth muscle", "ANATOMY", 143, 156], ["bronchial", "ANATOMY", 172, 181], ["pulmonary", "ANATOMY", 255, 264], ["Theophylline", "CHEMICAL", 0, 12], ["Theophylline", "CHEMICAL", 13, 25], ["IUPAC", "CHEMICAL", 27, 32], ["1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione", "CHEMICAL", 39, 90], ["methylxanthine", "CHEMICAL", 97, 111], ["chronic obstructive pulmonary disorder", "DISEASE", 235, 273], ["COPD", "DISEASE", 275, 279], ["asthma", "DISEASE", 285, 291], ["theophylline", "CHEMICAL", 293, 305], ["Theophylline", "CHEMICAL", 0, 12], ["Theophylline", "CHEMICAL", 13, 25], ["IUPAC", "CHEMICAL", 27, 32], ["1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione", "CHEMICAL", 39, 90], ["methylxanthine", "CHEMICAL", 97, 111], ["theophylline", "CHEMICAL", 293, 305], ["Theophylline", "SIMPLE_CHEMICAL", 0, 12], ["Theophylline", "SIMPLE_CHEMICAL", 13, 25], ["1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione", "SIMPLE_CHEMICAL", 39, 90], ["methylxanthine", "SIMPLE_CHEMICAL", 97, 111], ["smooth muscle", "TISSUE", 143, 156], ["bronchial", "MULTI-TISSUE_STRUCTURE", 172, 181], ["pulmonary", "ORGAN", 255, 264], ["theophylline", "SIMPLE_CHEMICAL", 293, 305], ["type III and IV phosphodiesterase", "GENE_OR_GENE_PRODUCT", 360, 393], ["Theophylline Theophylline", "TREATMENT", 0, 25], ["dimethyl", "TREATMENT", 43, 51], ["tetrahydro-1H-purine", "TREATMENT", 60, 80], ["a methylxanthine drug", "TREATMENT", 95, 116], ["smooth muscle relaxation", "TREATMENT", 143, 167], ["bronchial dilation", "TREATMENT", 172, 190], ["conditions", "PROBLEM", 216, 226], ["chronic obstructive pulmonary disorder", "PROBLEM", 235, 273], ["COPD)", "PROBLEM", 275, 280], ["asthma", "PROBLEM", 285, 291], ["theophylline", "TREATMENT", 293, 305], ["type III and IV phosphodiesterase", "TREATMENT", 360, 393], ["smooth muscle", "ANATOMY", 143, 156], ["bronchial", "ANATOMY", 172, 181], ["dilation", "OBSERVATION", 182, 190], ["chronic", "OBSERVATION_MODIFIER", 235, 242], ["obstructive", "OBSERVATION_MODIFIER", 243, 254], ["pulmonary", "ANATOMY", 255, 264], ["disorder", "OBSERVATION", 265, 273], ["COPD", "OBSERVATION", 275, 279], ["asthma", "OBSERVATION", 285, 291]]], ["Clustering of the PFIN revealed a cluster of genes, one of which, DNAJC11 , encodes the DNA J homolog subfamily C member 11 protein (Q9NVH1), whichData sourceGordon et al. [27] reported as interacting with the SARS-CoV-2 E protein.", [["PFIN", "GENE_OR_GENE_PRODUCT", 18, 22], ["DNAJC11", "GENE_OR_GENE_PRODUCT", 66, 73], ["DNA J homolog subfamily C member 11", "GENE_OR_GENE_PRODUCT", 88, 123], ["SARS-CoV-2 E", "GENE_OR_GENE_PRODUCT", 210, 222], ["PFIN", "DNA", 18, 22], ["DNAJC11", "DNA", 66, 73], ["DNA J homolog subfamily C member 11 protein", "PROTEIN", 88, 131], ["Q9NVH1", "PROTEIN", 133, 139], ["SARS-CoV-2 E protein", "PROTEIN", 210, 230], ["the PFIN", "TEST", 14, 22], ["the SARS", "TEST", 206, 214], ["cluster", "OBSERVATION_MODIFIER", 34, 41]]], ["SARS-Cov2 E encodes the envelope protein, E, which plays a role in the structure and maturation of the virus [62] .", [["SARS", "DISEASE", 0, 4], ["E", "GENE_OR_GENE_PRODUCT", 42, 43], ["E", "DNA", 10, 11], ["envelope protein", "PROTEIN", 24, 40], ["E", "PROTEIN", 42, 43], ["the virus", "PROBLEM", 99, 108]]], ["DNAJC11 is a mitochondrial protein which is required for mitochondrial inner membrane organization which associates with the mitochondrial contact site and cristae organizing system (MICOS) complex [62, 63] .", [["mitochondrial", "ANATOMY", 13, 26], ["mitochondrial inner membrane", "ANATOMY", 57, 85], ["mitochondrial contact site", "ANATOMY", 125, 151], ["cristae", "ANATOMY", 156, 163], ["DNAJC11", "GENE_OR_GENE_PRODUCT", 0, 7], ["mitochondrial", "CELLULAR_COMPONENT", 13, 26], ["mitochondrial", "CELLULAR_COMPONENT", 57, 70], ["inner membrane", "CELLULAR_COMPONENT", 71, 85], ["mitochondrial", "CELLULAR_COMPONENT", 125, 138], ["cristae", "CELLULAR_COMPONENT", 156, 163], ["DNAJC11", "PROTEIN", 0, 7], ["mitochondrial protein", "PROTEIN", 13, 34], ["mitochondrial contact site", "PROTEIN", 125, 151], ["a mitochondrial protein", "PROBLEM", 11, 34], ["mitochondrial inner membrane organization", "TREATMENT", 57, 98], ["mitochondrial protein", "OBSERVATION", 13, 34], ["inner membrane organization", "OBSERVATION", 71, 98], ["mitochondrial contact", "OBSERVATION", 125, 146]]], ["The PFIN suggests that DNAJC11 has a high likelihood of being functionally related to RIC3 , which encodes the protein RIC3 (Q7Z5B4) -a protein target of theophylline (Fig 2) [64] .", [["DNAJC11", "CHEMICAL", 23, 30], ["theophylline", "CHEMICAL", 154, 166], ["theophylline", "CHEMICAL", 154, 166], ["PFIN", "GENE_OR_GENE_PRODUCT", 4, 8], ["DNAJC11", "GENE_OR_GENE_PRODUCT", 23, 30], ["RIC3", "GENE_OR_GENE_PRODUCT", 86, 90], ["RIC3", "GENE_OR_GENE_PRODUCT", 119, 123], ["Q7Z5B4", "GENE_OR_GENE_PRODUCT", 125, 131], ["theophylline", "SIMPLE_CHEMICAL", 154, 166], ["PFIN", "PROTEIN", 4, 8], ["DNAJC11", "PROTEIN", 23, 30], ["RIC3", "PROTEIN", 86, 90], ["RIC3", "PROTEIN", 119, 123], ["Q7Z5B4", "PROTEIN", 125, 131], ["the protein RIC3", "TEST", 107, 123], ["theophylline (Fig", "TREATMENT", 154, 171], ["high", "OBSERVATION_MODIFIER", 37, 41]]], ["RIC3 promotes functional expression of homomeric alpha-7 and alpha-8 nicotinic acetylcholine receptors at the cell surface and is found in endoplasmic reticulum and the golgi apparatus [65] .", [["cell surface", "ANATOMY", 110, 122], ["endoplasmic reticulum", "ANATOMY", 139, 160], ["acetylcholine", "CHEMICAL", 79, 92], ["acetylcholine", "CHEMICAL", 79, 92], ["RIC3", "GENE_OR_GENE_PRODUCT", 0, 4], ["alpha-7", "GENE_OR_GENE_PRODUCT", 49, 56], ["alpha-8 nicotinic acetylcholine receptors", "GENE_OR_GENE_PRODUCT", 61, 102], ["cell surface", "CELLULAR_COMPONENT", 110, 122], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 139, 160], ["golgi apparatus", "CELLULAR_COMPONENT", 169, 184], ["RIC3", "PROTEIN", 0, 4], ["homomeric alpha-7 and alpha-8 nicotinic acetylcholine receptors", "PROTEIN", 39, 102], ["homomeric alpha", "TEST", 39, 54], ["alpha", "TEST", 61, 66], ["nicotinic acetylcholine receptors", "TREATMENT", 69, 102], ["the golgi apparatus", "TEST", 165, 184], ["endoplasmic reticulum", "OBSERVATION", 139, 160]]], ["The relevance of the functional relationship between DNAJC11 and RIC3 is unclear, however the interaction was identified by Affinity Capture-Mass Spectroscopy, which implies a physical binding.", [["DNAJC11", "GENE_OR_GENE_PRODUCT", 53, 60], ["RIC3", "GENE_OR_GENE_PRODUCT", 65, 69], ["DNAJC11", "PROTEIN", 53, 60], ["RIC3", "PROTEIN", 65, 69], ["Mass Spectroscopy", "TEST", 141, 158], ["a physical binding", "PROBLEM", 174, 192]]], ["It is possible, therefore, that RIC3 complexes with DNAJC11 (although current evidence has them expressed in different organelles) and theophylline could block the binding of DNAJC11 by SARS-CoV-2 E. Interestingly, DNAJC11 has well-conserved orthologues in other species, such as mouse, rat, and dog [66] .Calmodulin inhibitorsCalmodulin is a ubiquitous calcium binding protein which binds to transmembrane proteins such as ACE [67] .", [["organelles", "ANATOMY", 119, 129], ["transmembrane", "ANATOMY", 393, 406], ["theophylline", "CHEMICAL", 135, 147], ["DNAJC11", "CHEMICAL", 215, 222], ["calcium", "CHEMICAL", 354, 361], ["theophylline", "CHEMICAL", 135, 147], ["calcium", "CHEMICAL", 354, 361], ["RIC3", "GENE_OR_GENE_PRODUCT", 32, 36], ["DNAJC11", "GENE_OR_GENE_PRODUCT", 52, 59], ["organelles", "CELLULAR_COMPONENT", 119, 129], ["theophylline", "SIMPLE_CHEMICAL", 135, 147], ["DNAJC11", "GENE_OR_GENE_PRODUCT", 175, 182], ["SARS-CoV-2 E.", "ORGANISM", 186, 199], ["DNAJC11", "GENE_OR_GENE_PRODUCT", 215, 222], ["mouse", "ORGANISM", 280, 285], ["rat", "ORGANISM", 287, 290], ["Calmodulin", "GENE_OR_GENE_PRODUCT", 306, 316], ["Calmodulin", "GENE_OR_GENE_PRODUCT", 327, 337], ["calcium", "SIMPLE_CHEMICAL", 354, 361], ["transmembrane", "CELLULAR_COMPONENT", 393, 406], ["ACE [67]", "GENE_OR_GENE_PRODUCT", 424, 432], ["RIC3 complexes", "PROTEIN", 32, 46], ["DNAJC11", "PROTEIN", 52, 59], ["DNAJC11", "PROTEIN", 175, 182], ["DNAJC11", "PROTEIN", 215, 222], ["Calmodulin", "PROTEIN", 327, 337], ["ubiquitous calcium binding protein", "PROTEIN", 343, 377], ["transmembrane proteins", "PROTEIN", 393, 415], ["ACE", "PROTEIN", 424, 427], ["mouse", "SPECIES", 280, 285], ["rat", "SPECIES", 287, 290], ["dog", "SPECIES", 296, 299], ["mouse", "SPECIES", 280, 285], ["rat", "SPECIES", 287, 290], ["DNAJC11", "TREATMENT", 52, 59], ["theophylline", "TREATMENT", 135, 147], ["CoV", "TEST", 191, 194], ["Calmodulin inhibitorsCalmodulin", "TREATMENT", 306, 337], ["a ubiquitous calcium binding protein", "TREATMENT", 341, 377], ["transmembrane proteins", "TEST", 393, 415], ["ACE", "TEST", 424, 427]]], ["As described in the introduction, ACE transmembrane proteins have a distinct role in Covid-19 infection [9] .", [["infection", "DISEASE", 94, 103], ["ACE", "GENE_OR_GENE_PRODUCT", 34, 37], ["Covid-19", "GENE_OR_GENE_PRODUCT", 85, 93], ["ACE transmembrane proteins", "PROTEIN", 34, 60], ["ACE transmembrane proteins", "TREATMENT", 34, 60], ["Covid", "TEST", 85, 90], ["infection", "PROBLEM", 94, 103]]], ["Calmodulin plays a crucial role in regulating ACE2Calmodulin inhibitorspresence on the cell surface by binding to the cytoplasmic tail of ACE2 [68] .", [["cell surface", "ANATOMY", 87, 99], ["cytoplasmic tail", "ANATOMY", 118, 134], ["Calmodulin", "GENE_OR_GENE_PRODUCT", 0, 10], ["ACE2Calmodulin", "GENE_OR_GENE_PRODUCT", 46, 60], ["cell surface", "CELLULAR_COMPONENT", 87, 99], ["cytoplasmic", "ORGANISM_SUBSTANCE", 118, 129], ["ACE2", "GENE_OR_GENE_PRODUCT", 138, 142], ["Calmodulin", "PROTEIN", 0, 10], ["ACE2Calmodulin", "PROTEIN", 46, 60], ["cytoplasmic tail", "PROTEIN", 118, 134], ["ACE2", "PROTEIN", 138, 142], ["Calmodulin", "TREATMENT", 0, 10]]], ["A potential target for decreasing infection and viral loading could, therefore, be the use of calmodulin inhibitors, acting to decrease the association of the two proteins.", [["infection", "DISEASE", 34, 43], ["calmodulin", "GENE_OR_GENE_PRODUCT", 94, 104], ["calmodulin", "PROTEIN", 94, 104], ["decreasing infection", "PROBLEM", 23, 43], ["viral loading", "PROBLEM", 48, 61], ["calmodulin inhibitors", "TREATMENT", 94, 115], ["the two proteins", "PROBLEM", 155, 171], ["decreasing", "OBSERVATION_MODIFIER", 23, 33], ["infection", "OBSERVATION", 34, 43], ["viral loading", "OBSERVATION", 48, 61]]], ["Without the binding of calmodulin to ACE2, the cells start to shed the ectodomain of ACE2, leading to decreased expression and catalytic activity [67] .", [["cells", "ANATOMY", 47, 52], ["calmodulin", "GENE_OR_GENE_PRODUCT", 23, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["cells", "CELL", 47, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["calmodulin", "PROTEIN", 23, 33], ["ACE2", "PROTEIN", 37, 41], ["ACE2", "PROTEIN", 85, 89], ["the cells", "TREATMENT", 43, 52]]], ["Querying our knowledge graph for approved drugs that inhibit CALM1 (P0DP23), we identified 10 existing, approved drugs that are labelled as inhibitors of calmodulin, indicated for a range of conditions including hypertension, seasonal allergies, and antidepressants (full list in Table S1 ).Angiotensin IIAngiotensinogen is a small peptide hormone which, as part of the renin-angiotensin-aldosterone system (RAAS), is involved in the regulation of blood pressure [69] .", [["blood", "ANATOMY", 448, 453], ["hypertension", "DISEASE", 212, 224], ["seasonal allergies", "DISEASE", 226, 244], ["antidepressants", "CHEMICAL", 250, 265], ["Angiotensin", "CHEMICAL", 291, 302], ["angiotensin", "CHEMICAL", 376, 387], ["aldosterone", "CHEMICAL", 388, 399], ["aldosterone", "CHEMICAL", 388, 399], ["CALM1", "GENE_OR_GENE_PRODUCT", 61, 66], ["P0DP23", "GENE_OR_GENE_PRODUCT", 68, 74], ["calmodulin", "GENE_OR_GENE_PRODUCT", 154, 164], ["Angiotensin IIAngiotensinogen", "GENE_OR_GENE_PRODUCT", 291, 320], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 370, 399], ["RAAS", "GENE_OR_GENE_PRODUCT", 408, 412], ["blood", "ORGANISM_SUBSTANCE", 448, 453], ["CALM1", "PROTEIN", 61, 66], ["P0DP23", "PROTEIN", 68, 74], ["calmodulin", "PROTEIN", 154, 164], ["renin", "PROTEIN", 370, 375], ["drugs", "TREATMENT", 113, 118], ["calmodulin", "TREATMENT", 154, 164], ["hypertension", "PROBLEM", 212, 224], ["seasonal allergies", "PROBLEM", 226, 244], ["antidepressants", "TREATMENT", 250, 265], ["Angiotensin IIAngiotensinogen", "TREATMENT", 291, 320], ["a small peptide hormone", "PROBLEM", 324, 347], ["the renin", "TEST", 366, 375], ["angiotensin-aldosterone system", "TREATMENT", 376, 406], ["blood pressure", "TEST", 448, 462], ["hypertension", "OBSERVATION", 212, 224], ["small", "OBSERVATION_MODIFIER", 326, 331]]], ["Via the action of renin, angiotensinogen is converted into angiotensin I. In turn, angiotensin I, via the action of angiotensin converting enzyme (ACE), is converted into angiotensin II.", [["angiotensin", "CHEMICAL", 59, 70], ["angiotensin I", "CHEMICAL", 83, 96], ["angiotensin", "CHEMICAL", 116, 127], ["angiotensin II", "CHEMICAL", 171, 185], ["renin", "GENE_OR_GENE_PRODUCT", 18, 23], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 25, 40], ["angiotensin I.", "GENE_OR_GENE_PRODUCT", 59, 73], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 83, 96], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 116, 145], ["ACE", "GENE_OR_GENE_PRODUCT", 147, 150], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 171, 185], ["renin", "PROTEIN", 18, 23], ["angiotensinogen", "PROTEIN", 25, 40], ["angiotensin I", "PROTEIN", 83, 96], ["angiotensin converting enzyme", "PROTEIN", 116, 145], ["ACE", "PROTEIN", 147, 150], ["angiotensin II", "PROTEIN", 171, 185], ["renin", "TREATMENT", 18, 23], ["angiotensinogen", "TREATMENT", 25, 40], ["angiotensin I.", "TREATMENT", 59, 73], ["angiotensin I", "TREATMENT", 83, 96], ["angiotensin converting enzyme (ACE)", "TREATMENT", 116, 151]]], ["Critically, ACE2 converts angiotensin II into angiotensin (1-7), an effector of nitric oxide-dependent vasodilation which has been implicated in attenuating acute lung injury [70] .", [["lung", "ANATOMY", 163, 167], ["angiotensin II", "CHEMICAL", 26, 40], ["angiotensin (1-7)", "CHEMICAL", 46, 63], ["nitric oxide", "CHEMICAL", 80, 92], ["acute lung injury", "DISEASE", 157, 174], ["nitric oxide", "CHEMICAL", 80, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 26, 40], ["angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 46, 62], ["nitric oxide", "SIMPLE_CHEMICAL", 80, 92], ["lung", "ORGAN", 163, 167], ["ACE2", "PROTEIN", 12, 16], ["angiotensin II", "PROTEIN", 26, 40], ["angiotensin II into angiotensin", "TREATMENT", 26, 57], ["nitric oxide", "TREATMENT", 80, 92], ["dependent vasodilation", "PROBLEM", 93, 115], ["attenuating acute lung injury", "PROBLEM", 145, 174], ["dependent vasodilation", "OBSERVATION", 93, 115], ["attenuating", "OBSERVATION_MODIFIER", 145, 156], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["lung", "ANATOMY", 163, 167], ["injury", "OBSERVATION", 168, 174]]], ["The role of drugs which inhibit the RAAS, such as commonly prescribed antihypertensive agents (e.g., ACE inhibitors and angiotensin receptor blockers) is controversial, with arguments proposed for both harmful and protective effects [71] [72] [73] .Angiotensin IIGiven that angiotensin II is, itself, an approved drug, it may have a therapeutic use in COVID-19 via the actions of angiotensin (1-7).", [["angiotensin", "CHEMICAL", 120, 131], ["Angiotensin", "CHEMICAL", 249, 260], ["angiotensin II", "CHEMICAL", 274, 288], ["COVID-19", "CHEMICAL", 352, 360], ["angiotensin (1-7)", "CHEMICAL", 380, 397], ["COVID-19", "CHEMICAL", 352, 360], ["RAAS", "GENE_OR_GENE_PRODUCT", 36, 40], ["ACE", "GENE_OR_GENE_PRODUCT", 101, 104], ["angiotensin receptor blockers", "GENE_OR_GENE_PRODUCT", 120, 149], ["Angiotensin IIGiven", "GENE_OR_GENE_PRODUCT", 249, 268], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 274, 288], ["angiotensin", "SIMPLE_CHEMICAL", 380, 391], ["drugs", "TREATMENT", 12, 17], ["the RAAS", "TREATMENT", 32, 40], ["antihypertensive agents", "TREATMENT", 70, 93], ["ACE inhibitors", "TREATMENT", 101, 115], ["angiotensin receptor blockers", "TREATMENT", 120, 149], ["Angiotensin", "TREATMENT", 249, 260], ["COVID", "TEST", 352, 357], ["angiotensin", "TREATMENT", 380, 391], ["therapeutic", "OBSERVATION_MODIFIER", 333, 344]]], ["Angiotensin II has already been suggested as a possible therapeutic agent, and is currently being investigated (NCT04332666).Cathepsin L and TMPRSS2 synergistic targetsWhilst inhibition of the ACE2 receptor may seem an ideal target for treating COVID-19, as it is required for both major mechanisms of viral entry into host cells, it has been shown that ACE2 is essential for repairing damage to lung tissues.", [["cells", "ANATOMY", 324, 329], ["lung tissues", "ANATOMY", 396, 408], ["Angiotensin II", "CHEMICAL", 0, 14], ["COVID-19", "CHEMICAL", 245, 253], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 0, 14], ["Cathepsin L", "GENE_OR_GENE_PRODUCT", 125, 136], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 141, 148], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 193, 206], ["COVID-19", "CELL", 245, 253], ["host cells", "CELL", 319, 329], ["ACE2", "GENE_OR_GENE_PRODUCT", 354, 358], ["lung tissues", "TISSUE", 396, 408], ["Angiotensin II", "PROTEIN", 0, 14], ["Cathepsin L", "PROTEIN", 125, 136], ["TMPRSS2", "PROTEIN", 141, 148], ["ACE2 receptor", "PROTEIN", 193, 206], ["host cells", "CELL_TYPE", 319, 329], ["ACE2", "PROTEIN", 354, 358], ["Angiotensin II", "TREATMENT", 0, 14], ["therapeutic agent", "TREATMENT", 56, 73], ["Cathepsin L and TMPRSS2 synergistic targets", "TREATMENT", 125, 168], ["the ACE2 receptor", "TREATMENT", 189, 206], ["COVID", "TEST", 245, 250], ["ACE2", "TEST", 354, 358], ["repairing damage to lung tissues", "PROBLEM", 376, 408], ["lung", "ANATOMY", 396, 400]]], ["Instead, it may be possible to inhibit TMPRSS2, which could lead to most virus particles entering the host cell via endosomes.", [["cell", "ANATOMY", 107, 111], ["endosomes", "ANATOMY", 116, 125], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 39, 46], ["cell", "CELL", 107, 111], ["endosomes", "CELLULAR_COMPONENT", 116, 125], ["TMPRSS2", "PROTEIN", 39, 46], ["TMPRSS2", "PROBLEM", 39, 46], ["most virus particles", "PROBLEM", 68, 88], ["may be possible", "UNCERTAINTY", 12, 27], ["host cell", "OBSERVATION", 102, 111]]], ["If cathepsin L is also inhibited, the endosome-enclosed viruses will be unable to escape, allowing the endosomes to progress fully to endolysosomes and destroy the virus particles.Cathepsin L and TMPRSS2 synergistic targetsIn this way, it may be possible to not only prevent entry into the host cell and subsequent replication, but also reduce overall viral load by enabling the body to destroy SARS-CoV-2.", [["endosome", "ANATOMY", 38, 46], ["endosomes", "ANATOMY", 103, 112], ["endolysosomes", "ANATOMY", 134, 147], ["cell", "ANATOMY", 295, 299], ["body", "ANATOMY", 379, 383], ["SARS", "DISEASE", 395, 399], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 3, 14], ["endosome", "CELLULAR_COMPONENT", 38, 46], ["endosomes", "CELLULAR_COMPONENT", 103, 112], ["Cathepsin L", "GENE_OR_GENE_PRODUCT", 180, 191], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 196, 203], ["host cell", "CELL", 290, 299], ["body", "ORGANISM_SUBDIVISION", 379, 383], ["SARS-CoV-2", "ORGANISM", 395, 405], ["cathepsin L", "PROTEIN", 3, 14], ["Cathepsin L", "PROTEIN", 180, 191], ["TMPRSS2", "PROTEIN", 196, 203], ["SARS-CoV", "SPECIES", 395, 403], ["cathepsin L", "PROBLEM", 3, 14], ["the endosome-enclosed viruses", "PROBLEM", 34, 63], ["endolysosomes", "TREATMENT", 134, 147], ["the virus particles", "PROBLEM", 160, 179], ["Cathepsin L and TMPRSS2 synergistic targets", "TREATMENT", 180, 223], ["overall viral load", "PROBLEM", 344, 362], ["viruses", "OBSERVATION", 56, 63], ["host cell", "OBSERVATION", 290, 299], ["viral load", "OBSERVATION", 352, 362]]], ["Previous studies have suggested that an already approved drug, camostat mesylate, could be used as a TMPRSS2 inhibitor [74] .", [["camostat mesylate", "CHEMICAL", 63, 80], ["camostat mesylate", "CHEMICAL", 63, 80], ["camostat mesylate", "SIMPLE_CHEMICAL", 63, 80], ["TMPRSS2", "SIMPLE_CHEMICAL", 101, 108], ["Previous studies", "TEST", 0, 16], ["camostat mesylate", "TREATMENT", 63, 80], ["a TMPRSS2 inhibitor", "TREATMENT", 99, 118]]], ["In this study, through rational querying of the knowledge graph, drug candidates for putative cathepsin L inhibitors have been identified (Table 2) .", [["cathepsin L", "GENE_OR_GENE_PRODUCT", 94, 105], ["cathepsin L", "PROTEIN", 94, 105], ["this study", "TEST", 3, 13], ["putative cathepsin L inhibitors", "TREATMENT", 85, 116]]], ["Two of these drugs, telaprevir and boceprevir, have been used previously to help treat chronic hepatitis C infections; however, both have since been discontinued due to common side effects such as severe rashes, anemia, decreased neutrophils, and fatigue.", [["neutrophils", "ANATOMY", 230, 241], ["telaprevir", "CHEMICAL", 20, 30], ["boceprevir", "CHEMICAL", 35, 45], ["chronic hepatitis C infections", "DISEASE", 87, 117], ["rashes", "DISEASE", 204, 210], ["anemia", "DISEASE", 212, 218], ["decreased neutrophils", "DISEASE", 220, 241], ["fatigue", "DISEASE", 247, 254], ["telaprevir", "CHEMICAL", 20, 30], ["boceprevir", "CHEMICAL", 35, 45], ["telaprevir", "SIMPLE_CHEMICAL", 20, 30], ["boceprevir", "SIMPLE_CHEMICAL", 35, 45], ["neutrophils", "CELL", 230, 241], ["neutrophils", "CELL_TYPE", 230, 241], ["these drugs", "TREATMENT", 7, 18], ["telaprevir", "TREATMENT", 20, 30], ["boceprevir", "TREATMENT", 35, 45], ["chronic hepatitis C infections", "PROBLEM", 87, 117], ["common side effects", "PROBLEM", 169, 188], ["severe rashes", "PROBLEM", 197, 210], ["anemia", "PROBLEM", 212, 218], ["decreased neutrophils", "PROBLEM", 220, 241], ["fatigue", "PROBLEM", 247, 254], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["hepatitis", "OBSERVATION", 95, 104], ["infections", "OBSERVATION", 107, 117], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["rashes", "OBSERVATION", 204, 210], ["anemia", "OBSERVATION", 212, 218], ["decreased neutrophils", "OBSERVATION", 220, 241], ["fatigue", "OBSERVATION_MODIFIER", 247, 254]]], ["Sodium aurothiomalate is a gold-containing compound approved for use treating rheumatoid arthritis.", [["Sodium aurothiomalate", "CHEMICAL", 0, 21], ["rheumatoid arthritis", "DISEASE", 78, 98], ["Sodium aurothiomalate", "CHEMICAL", 0, 21], ["Sodium aurothiomalate", "SIMPLE_CHEMICAL", 0, 21], ["gold", "SIMPLE_CHEMICAL", 27, 31], ["Sodium aurothiomalate", "PROBLEM", 0, 21], ["a gold-containing compound", "PROBLEM", 25, 51], ["rheumatoid arthritis", "PROBLEM", 78, 98], ["aurothiomalate", "OBSERVATION", 7, 21], ["gold", "OBSERVATION_MODIFIER", 27, 31], ["rheumatoid arthritis", "OBSERVATION", 78, 98]]], ["This drug is not currently commonly sold due to a difficulty in sourcing sodium aurothiomalate.", [["sodium aurothiomalate", "CHEMICAL", 73, 94], ["sodium aurothiomalate", "CHEMICAL", 73, 94], ["sodium aurothiomalate", "SIMPLE_CHEMICAL", 73, 94], ["sodium aurothiomalate", "TREATMENT", 73, 94]]], ["The final potential cathepsin L inhibitor identified in this study is fostamatinib, which is approved for use against chronic immune thrombocytopenia.", [["fostamatinib", "CHEMICAL", 70, 82], ["immune thrombocytopenia", "DISEASE", 126, 149], ["fostamatinib", "CHEMICAL", 70, 82], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 20, 31], ["fostamatinib", "SIMPLE_CHEMICAL", 70, 82], ["cathepsin L inhibitor", "TREATMENT", 20, 41], ["this study", "TEST", 56, 66], ["fostamatinib", "PROBLEM", 70, 82], ["chronic immune thrombocytopenia", "PROBLEM", 118, 149], ["thrombocytopenia", "OBSERVATION", 133, 149]]], ["Other drug repurposing studies for COVID-19 have also identified this drug as a potential candidate, but as an ACE2 inhibitor [75] .", [["COVID-19", "CHEMICAL", 35, 43], ["COVID-19", "SIMPLE_CHEMICAL", 35, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 111, 115], ["ACE2", "PROTEIN", 111, 115], ["COVID", "TEST", 35, 40], ["an ACE2 inhibitor", "TREATMENT", 108, 125]]], ["These same studies, however, did not evaluate it as a cathepsin L inhibitor.", [["cathepsin L", "GENE_OR_GENE_PRODUCT", 54, 65], ["These same studies", "TEST", 0, 18], ["a cathepsin L inhibitor", "TREATMENT", 52, 75]]], ["Based on this and previous studies, it is therefore possible that a combined therapy of camostat mesylate and fostamatinib may aid in treating COVID-19.Cathepsin L and TMPRSS2 synergistic targetsInterestingly, fostamatinib was separately identified as a drug candidate via the PFIN clustering approach (Fig 3) .", [["camostat mesylate", "CHEMICAL", 88, 105], ["fostamatinib", "CHEMICAL", 110, 122], ["fostamatinib", "CHEMICAL", 210, 222], ["camostat mesylate", "CHEMICAL", 88, 105], ["fostamatinib", "CHEMICAL", 110, 122], ["COVID-19", "CHEMICAL", 143, 151], ["fostamatinib", "CHEMICAL", 210, 222], ["camostat mesylate", "SIMPLE_CHEMICAL", 88, 105], ["fostamatinib", "SIMPLE_CHEMICAL", 110, 122], ["Cathepsin L", "GENE_OR_GENE_PRODUCT", 152, 163], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 168, 175], ["fostamatinib", "SIMPLE_CHEMICAL", 210, 222], ["Cathepsin L", "PROTEIN", 152, 163], ["TMPRSS2", "PROTEIN", 168, 175], ["previous studies", "TEST", 18, 34], ["a combined therapy of camostat mesylate", "TREATMENT", 66, 105], ["fostamatinib", "TREATMENT", 110, 122], ["COVID", "TEST", 143, 148], ["Cathepsin L and TMPRSS2 synergistic targets", "TREATMENT", 152, 195], ["the PFIN clustering approach", "TREATMENT", 273, 301]]], ["Fostamatinib has serine/threonine-protein kinase TBK1Cathepsin L and TMPRSS2 synergistic targets(Q9UHD2) as a drug target, which was also identified by Gordon et al. [27] as being a protein that interacts with a SARS-CoV-2 protein.", [["Fostamatinib", "CHEMICAL", 0, 12], ["SARS", "DISEASE", 212, 216], ["Fostamatinib", "CHEMICAL", 0, 12], ["serine", "CHEMICAL", 17, 23], ["threonine", "CHEMICAL", 24, 33], ["Fostamatinib", "SIMPLE_CHEMICAL", 0, 12], ["serine", "AMINO_ACID", 17, 23], ["threonine", "AMINO_ACID", 24, 33], ["TBK1Cathepsin L", "GENE_OR_GENE_PRODUCT", 49, 64], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 69, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 212, 222], ["serine/threonine-protein kinase", "PROTEIN", 17, 48], ["TBK1Cathepsin L", "PROTEIN", 49, 64], ["TMPRSS2", "PROTEIN", 69, 76], ["Q9UHD2", "DNA", 97, 103], ["SARS-CoV-2 protein", "PROTEIN", 212, 230], ["serine/threonine", "TREATMENT", 17, 33], ["protein kinase", "TREATMENT", 34, 48], ["TBK", "TEST", 49, 52], ["1Cathepsin L and TMPRSS2 synergistic targets", "TREATMENT", 52, 96], ["a SARS", "TEST", 210, 216]]], ["However, the relevance of this interaction, if any, is unclear to us.Potential antiviral modulators of inflammationSevere COVID-19 disease often includes an exaggerated inflammatory response.", [["inflammation", "DISEASE", 103, 115], ["inflammationSevere COVID-19 disease", "PROBLEM", 103, 138], ["an exaggerated inflammatory response", "PROBLEM", 154, 190], ["antiviral modulators", "OBSERVATION", 79, 99], ["inflammation", "OBSERVATION_MODIFIER", 103, 115], ["Severe", "OBSERVATION_MODIFIER", 115, 121], ["19 disease", "OBSERVATION", 128, 138], ["exaggerated", "OBSERVATION_MODIFIER", 157, 168], ["inflammatory response", "OBSERVATION", 169, 190]]], ["Stebbing et al. suggested that combining antiviral and anti-inflammatory treatments is a possible means of reducing disease severity [76] .", [["combining antiviral and anti-inflammatory treatments", "TREATMENT", 31, 83], ["reducing disease severity", "PROBLEM", 107, 132]]], ["In their study, they examined the affinity between antiviral drugs (in particular, through inhibition of numb-associated kinases (NAKs)) and drug targets that may be useful in attenuating inflammation (e.g. through inhibition of Janus Kinases (JAKs)).", [["inflammation", "DISEASE", 188, 200], ["numb-associated kinases", "GENE_OR_GENE_PRODUCT", 105, 128], ["NAKs", "GENE_OR_GENE_PRODUCT", 130, 134], ["Janus Kinases", "GENE_OR_GENE_PRODUCT", 229, 242], ["JAKs", "GENE_OR_GENE_PRODUCT", 244, 248], ["numb-associated kinases", "PROTEIN", 105, 128], ["NAKs", "PROTEIN", 130, 134], ["Janus Kinases", "PROTEIN", 229, 242], ["JAKs", "PROTEIN", 244, 248], ["their study", "TEST", 3, 14], ["antiviral drugs", "TREATMENT", 51, 66], ["drug targets", "PROBLEM", 141, 153], ["attenuating inflammation", "PROBLEM", 176, 200], ["attenuating", "OBSERVATION_MODIFIER", 176, 187], ["inflammation", "OBSERVATION", 188, 200]]], ["As a result of the study, Stebbing et al. identified and discussed a range of drugs, including baricitinib, tofacitinib, and ruxolitinib.Potential antiviral modulators of inflammationTo determine whether there were any additional drug candidates not discussed by Stebbing et al. [76] , we queried our dataset for drugs targeting the NAKs and JAKs identified in the paper.", [["baricitinib", "CHEMICAL", 95, 106], ["tofacitinib", "CHEMICAL", 108, 119], ["ruxolitinib", "CHEMICAL", 125, 136], ["inflammation", "DISEASE", 171, 183], ["baricitinib", "CHEMICAL", 95, 106], ["tofacitinib", "CHEMICAL", 108, 119], ["ruxolitinib", "CHEMICAL", 125, 136], ["baricitinib", "SIMPLE_CHEMICAL", 95, 106], ["tofacitinib", "SIMPLE_CHEMICAL", 108, 119], ["ruxolitinib", "SIMPLE_CHEMICAL", 125, 136], ["NAKs", "GENE_OR_GENE_PRODUCT", 333, 337], ["JAKs", "GENE_OR_GENE_PRODUCT", 342, 346], ["NAKs", "PROTEIN", 333, 337], ["JAKs", "PROTEIN", 342, 346], ["the study", "TEST", 15, 24], ["drugs", "TREATMENT", 78, 83], ["baricitinib", "TREATMENT", 95, 106], ["tofacitinib", "TREATMENT", 108, 119], ["ruxolitinib", "TREATMENT", 125, 136], ["inflammation", "PROBLEM", 171, 183], ["drugs", "TREATMENT", 313, 318], ["antiviral modulators", "OBSERVATION", 147, 167], ["inflammation", "OBSERVATION", 171, 183]]], ["These proteins were as follows: AAK1 (Q2M2I8), BIKE (Q9NSY1), GAK (O14976), JAK1 (P23458), JAK2 (O60674), JAK3 (P52333), and TYK2 (P29597).", [["AAK1", "GENE_OR_GENE_PRODUCT", 32, 36], ["Q2M2I8", "GENE_OR_GENE_PRODUCT", 38, 44], ["BIKE", "GENE_OR_GENE_PRODUCT", 47, 51], ["GAK", "GENE_OR_GENE_PRODUCT", 62, 65], ["JAK1", "GENE_OR_GENE_PRODUCT", 76, 80], ["JAK2", "GENE_OR_GENE_PRODUCT", 91, 95], ["JAK3", "GENE_OR_GENE_PRODUCT", 106, 110], ["TYK2", "GENE_OR_GENE_PRODUCT", 125, 129], ["AAK1", "PROTEIN", 32, 36], ["Q2M2I8", "PROTEIN", 38, 44], ["BIKE", "PROTEIN", 47, 51], ["Q9NSY1", "PROTEIN", 53, 59], ["GAK", "PROTEIN", 62, 65], ["O14976", "PROTEIN", 67, 73], ["JAK1", "PROTEIN", 76, 80], ["P23458", "PROTEIN", 82, 88], ["JAK2", "PROTEIN", 91, 95], ["O60674", "PROTEIN", 97, 103], ["JAK3", "PROTEIN", 106, 110], ["P52333", "PROTEIN", 112, 118], ["TYK2", "PROTEIN", 125, 129], ["These proteins", "TEST", 0, 14], ["AAK1", "TEST", 32, 36], ["GAK", "TEST", 62, 65], ["JAK1", "TEST", 76, 80], ["JAK2", "TEST", 91, 95], ["JAK3", "TEST", 106, 110], ["TYK2", "TEST", 125, 129]]], ["In addition to baricitinib, tofacitinib, and ruxolitinib, we also identified fostamatinib as a potential drug candidate.", [["baricitinib", "CHEMICAL", 15, 26], ["tofacitinib", "CHEMICAL", 28, 39], ["ruxolitinib", "CHEMICAL", 45, 56], ["fostamatinib", "CHEMICAL", 77, 89], ["baricitinib", "CHEMICAL", 15, 26], ["tofacitinib", "CHEMICAL", 28, 39], ["ruxolitinib", "CHEMICAL", 45, 56], ["fostamatinib", "CHEMICAL", 77, 89], ["baricitinib", "SIMPLE_CHEMICAL", 15, 26], ["tofacitinib", "SIMPLE_CHEMICAL", 28, 39], ["ruxolitinib", "SIMPLE_CHEMICAL", 45, 56], ["fostamatinib", "SIMPLE_CHEMICAL", 77, 89], ["baricitinib", "TREATMENT", 15, 26], ["tofacitinib", "TREATMENT", 28, 39], ["ruxolitinib", "TREATMENT", 45, 56]]], ["In fact, in our knowledge graph, fostamatinib was the only drug recorded as having all the aforementioned proteins as drug targets.Potential antiviral modulators of inflammationEpidermal growth factor receptor (EGFR) inhibitors EGFR (P00533) is a protein implicated in tissue fibrosis, due to its role in TGF-\u03b21 dependent fibroblast-myofibroblast differentiation.", [["tissue", "ANATOMY", 269, 275], ["fibroblast-myofibroblast", "ANATOMY", 322, 346], ["fostamatinib", "CHEMICAL", 33, 45], ["inflammation", "DISEASE", 165, 177], ["fibrosis", "DISEASE", 276, 284], ["fostamatinib", "CHEMICAL", 33, 45], ["fostamatinib", "SIMPLE_CHEMICAL", 33, 45], ["Epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 177, 209], ["EGFR", "GENE_OR_GENE_PRODUCT", 211, 215], ["EGFR", "GENE_OR_GENE_PRODUCT", 228, 232], ["P00533", "GENE_OR_GENE_PRODUCT", 234, 240], ["tissue", "TISSUE", 269, 275], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 305, 311], ["fibroblast", "CELL", 322, 332], ["myofibroblast", "CELL", 333, 346], ["EGFR", "PROTEIN", 211, 215], ["EGFR", "PROTEIN", 228, 232], ["P00533", "PROTEIN", 234, 240], ["TGF", "PROTEIN", 305, 308], ["Potential antiviral modulators", "TREATMENT", 131, 161], ["inflammation", "PROBLEM", 165, 177], ["Epidermal growth factor receptor (EGFR) inhibitors", "TEST", 177, 227], ["EGFR", "TEST", 228, 232], ["a protein implicated in tissue fibrosis", "PROBLEM", 245, 284], ["TGF", "TEST", 305, 308], ["antiviral modulators", "OBSERVATION", 141, 161], ["inflammation", "OBSERVATION_MODIFIER", 165, 177], ["tissue", "ANATOMY", 269, 275], ["fibrosis", "OBSERVATION", 276, 284], ["myofibroblast differentiation", "OBSERVATION", 333, 362]]], ["Venkataraman and Frieman, 2017 [77] , suggested that inhibiting EGFR signalling prevents excessive fibrotic responses and, thus, lung damage, during SARS infections.Potential antiviral modulators of inflammationRunning the query in Fig 4 identified eight approved drugs that were possible EGFR inhibitors --brigatinib, afatinib, osimertinib, fostamatinib, dacomitinib, neratinib, vandetanib, and panitumumab.Lobeline, Nicotine and GalantamineTwo COVID proteins -ORF9c and NSP4 -have interactions with mitochondria-related human proteins ZNT6 (Q6NXT4, encoded by the SLC30A6 gene, transmembrane zinc transporter located in the golgi apparatus) and TIM29 (Q9BSF4, encoded by the TIMM29 gene, inner mitochondrial membrane translocase), respectively [27] .", [["lung", "ANATOMY", 129, 133], ["mitochondria", "ANATOMY", 501, 513], ["transmembrane", "ANATOMY", 580, 593], ["golgi apparatus", "ANATOMY", 626, 641], ["mitochondrial membrane", "ANATOMY", 696, 718], ["Venkataraman", "CHEMICAL", 0, 12], ["lung damage", "DISEASE", 129, 140], ["SARS infections", "DISEASE", 149, 164], ["inflammation", "DISEASE", 199, 211], ["brigatinib", "CHEMICAL", 307, 317], ["afatinib", "CHEMICAL", 319, 327], ["osimertinib", "CHEMICAL", 329, 340], ["fostamatinib", "CHEMICAL", 342, 354], ["dacomitinib", "CHEMICAL", 356, 367], ["neratinib", "CHEMICAL", 369, 378], ["vandetanib", "CHEMICAL", 380, 390], ["panitumumab", "CHEMICAL", 396, 407], ["Lobeline", "CHEMICAL", 408, 416], ["Nicotine", "CHEMICAL", 418, 426], ["brigatinib", "CHEMICAL", 307, 317], ["afatinib", "CHEMICAL", 319, 327], ["osimertinib", "CHEMICAL", 329, 340], ["fostamatinib", "CHEMICAL", 342, 354], ["dacomitinib", "CHEMICAL", 356, 367], ["neratinib", "CHEMICAL", 369, 378], ["vandetanib", "CHEMICAL", 380, 390], ["panitumumab", "CHEMICAL", 396, 407], ["Lobeline", "CHEMICAL", 408, 416], ["Nicotine", "CHEMICAL", 418, 426], ["zinc", "CHEMICAL", 594, 598], ["EGFR", "GENE_OR_GENE_PRODUCT", 64, 68], ["lung", "ORGAN", 129, 133], ["EGFR", "GENE_OR_GENE_PRODUCT", 289, 293], ["brigatinib", "SIMPLE_CHEMICAL", 307, 317], ["afatinib", "SIMPLE_CHEMICAL", 319, 327], ["osimertinib", "SIMPLE_CHEMICAL", 329, 340], ["fostamatinib", "SIMPLE_CHEMICAL", 342, 354], ["dacomitinib", "SIMPLE_CHEMICAL", 356, 367], ["neratinib", "SIMPLE_CHEMICAL", 369, 378], ["vandetanib", "SIMPLE_CHEMICAL", 380, 390], ["panitumumab", "SIMPLE_CHEMICAL", 396, 407], ["Lobeline", "SIMPLE_CHEMICAL", 408, 416], ["Nicotine", "SIMPLE_CHEMICAL", 418, 426], ["GalantamineTwo COVID", "GENE_OR_GENE_PRODUCT", 431, 451], ["ORF9c", "GENE_OR_GENE_PRODUCT", 462, 467], ["NSP4", "GENE_OR_GENE_PRODUCT", 472, 476], ["mitochondria", "CELLULAR_COMPONENT", 501, 513], ["human", "ORGANISM", 522, 527], ["ZNT6", "GENE_OR_GENE_PRODUCT", 537, 541], ["Q6NXT4", "GENE_OR_GENE_PRODUCT", 543, 549], ["SLC30A6", "GENE_OR_GENE_PRODUCT", 566, 573], ["transmembrane", "CELLULAR_COMPONENT", 580, 593], ["golgi apparatus", "CELLULAR_COMPONENT", 626, 641], ["TIM29", "GENE_OR_GENE_PRODUCT", 647, 652], ["Q9BSF4", "GENE_OR_GENE_PRODUCT", 654, 660], ["TIMM29", "GENE_OR_GENE_PRODUCT", 677, 683], ["inner", "CELLULAR_COMPONENT", 690, 695], ["mitochondrial membrane", "CELLULAR_COMPONENT", 696, 718], ["translocase", "CELLULAR_COMPONENT", 719, 730], ["EGFR", "PROTEIN", 64, 68], ["EGFR", "PROTEIN", 289, 293], ["GalantamineTwo COVID proteins", "PROTEIN", 431, 460], ["ORF9c", "PROTEIN", 462, 467], ["NSP4", "PROTEIN", 472, 476], ["human proteins", "PROTEIN", 522, 536], ["ZNT6", "PROTEIN", 537, 541], ["Q6NXT4", "PROTEIN", 543, 549], ["SLC30A6 gene", "DNA", 566, 578], ["transmembrane zinc transporter", "PROTEIN", 580, 610], ["TIM29", "PROTEIN", 647, 652], ["Q9BSF4", "PROTEIN", 654, 660], ["TIMM29 gene", "DNA", 677, 688], ["inner mitochondrial membrane translocase", "PROTEIN", 690, 730], ["human", "SPECIES", 522, 527], ["human", "SPECIES", 522, 527], ["excessive fibrotic responses", "PROBLEM", 89, 117], ["lung damage", "PROBLEM", 129, 140], ["SARS infections", "PROBLEM", 149, 164], ["inflammation", "PROBLEM", 199, 211], ["drugs", "TREATMENT", 264, 269], ["EGFR inhibitors", "TREATMENT", 289, 304], ["brigatinib", "TREATMENT", 307, 317], ["afatinib", "TREATMENT", 319, 327], ["osimertinib", "TREATMENT", 329, 340], ["fostamatinib", "TREATMENT", 342, 354], ["dacomitinib", "TREATMENT", 356, 367], ["neratinib", "TREATMENT", 369, 378], ["vandetanib", "TREATMENT", 380, 390], ["panitumumab", "TREATMENT", 396, 407], ["Lobeline", "TREATMENT", 408, 416], ["Nicotine", "TREATMENT", 418, 426], ["GalantamineTwo COVID proteins", "TREATMENT", 431, 460], ["NSP4", "PROBLEM", 472, 476], ["mitochondria", "TREATMENT", 501, 513], ["human proteins ZNT6", "TREATMENT", 522, 541], ["transmembrane zinc transporter", "TREATMENT", 580, 610], ["inner mitochondrial membrane translocase", "TREATMENT", 690, 730], ["excessive", "OBSERVATION_MODIFIER", 89, 98], ["fibrotic", "OBSERVATION", 99, 107], ["lung", "ANATOMY", 129, 133], ["damage", "OBSERVATION", 134, 140], ["antiviral modulators", "OBSERVATION", 175, 195], ["inflammation", "OBSERVATION", 199, 211]]], ["The genes encoding these proteins were both identified as having a high-confidence functional interaction with the neuronal acetylcholine receptor subunit alpha-9 (NACHR9) protein (Q9UGM1, gene name CHRNA9) [78, 79] .", [["neuronal", "ANATOMY", 115, 123], ["acetylcholine", "CHEMICAL", 124, 137], ["acetylcholine", "CHEMICAL", 124, 137], ["neuronal acetylcholine receptor subunit alpha-9", "GENE_OR_GENE_PRODUCT", 115, 162], ["NACHR9", "GENE_OR_GENE_PRODUCT", 164, 170], ["Q9UGM1", "GENE_OR_GENE_PRODUCT", 181, 187], ["neuronal acetylcholine receptor subunit alpha-9 (NACHR9) protein", "PROTEIN", 115, 179], ["Q9UGM1", "PROTEIN", 181, 187], ["CHRNA9", "PROTEIN", 199, 205], ["a high-confidence functional interaction", "PROBLEM", 65, 105], ["the neuronal acetylcholine receptor subunit alpha", "TREATMENT", 111, 160]]], ["NACHR9 is a is part of the ligand-gated ionic channel and nicotinic acetylcholine receptor superfamilies, and forms homo-or hetero-oligomeric divalent cation channels in the plasma membrane [80] .", [["plasma membrane", "ANATOMY", 174, 189], ["NACHR9", "CHEMICAL", 0, 6], ["acetylcholine", "CHEMICAL", 68, 81], ["acetylcholine", "CHEMICAL", 68, 81], ["NACHR9", "GENE_OR_GENE_PRODUCT", 0, 6], ["nicotinic acetylcholine receptor", "GENE_OR_GENE_PRODUCT", 58, 90], ["cation", "SIMPLE_CHEMICAL", 151, 157], ["plasma membrane", "CELLULAR_COMPONENT", 174, 189], ["NACHR9", "PROTEIN", 0, 6], ["ligand-gated ionic channel", "PROTEIN", 27, 53], ["nicotinic acetylcholine receptor superfamilies", "PROTEIN", 58, 104], ["hetero-oligomeric divalent cation channels", "PROTEIN", 124, 166], ["the ligand-gated ionic channel", "TREATMENT", 23, 53], ["nicotinic acetylcholine receptor superfamilies", "TREATMENT", 58, 104], ["hetero-oligomeric divalent cation channels", "TREATMENT", 124, 166]]], ["According to DrugBank, NACHR9 is targeted by the following small molecules: lobeline; galantamine; nicotine; tetraethylammonium; RPI-78M and, ATG003.", [["lobeline", "CHEMICAL", 76, 84], ["galantamine", "CHEMICAL", 86, 97], ["nicotine", "CHEMICAL", 99, 107], ["tetraethylammonium", "CHEMICAL", 109, 127], ["RPI-78M", "CHEMICAL", 129, 136], ["ATG003", "CHEMICAL", 142, 148], ["lobeline", "CHEMICAL", 76, 84], ["galantamine", "CHEMICAL", 86, 97], ["nicotine", "CHEMICAL", 99, 107], ["tetraethylammonium", "CHEMICAL", 109, 127], ["RPI-78M", "CHEMICAL", 129, 136], ["ATG003", "CHEMICAL", 142, 148], ["NACHR9", "GENE_OR_GENE_PRODUCT", 23, 29], ["lobeline", "SIMPLE_CHEMICAL", 76, 84], ["galantamine", "SIMPLE_CHEMICAL", 86, 97], ["nicotine", "SIMPLE_CHEMICAL", 99, 107], ["tetraethylammonium", "SIMPLE_CHEMICAL", 109, 127], ["RPI-78M", "SIMPLE_CHEMICAL", 129, 136], ["ATG003", "SIMPLE_CHEMICAL", 142, 148], ["NACHR9", "DNA", 23, 29], ["lobeline", "TREATMENT", 76, 84], ["galantamine", "TREATMENT", 86, 97], ["nicotine", "TREATMENT", 99, 107], ["tetraethylammonium", "TREATMENT", 109, 127], ["RPI", "TEST", 129, 132], ["ATG003", "TREATMENT", 142, 148]]], ["Lobeline, in its natural form from plants in the Lobelia genus, has been proposed and applied for therapeutic uses including respiratory disorders (such as asthma) as a stimulant to treat wheezing, uncontrollable coughing and chest tightness [81] , and has been reported to improve acute lung injury in cell lines [82] .", [["respiratory", "ANATOMY", 125, 136], ["chest", "ANATOMY", 226, 231], ["lung", "ANATOMY", 288, 292], ["cell lines", "ANATOMY", 303, 313], ["Lobeline", "CHEMICAL", 0, 8], ["respiratory disorders", "DISEASE", 125, 146], ["asthma", "DISEASE", 156, 162], ["wheezing", "DISEASE", 188, 196], ["coughing", "DISEASE", 213, 221], ["chest tightness", "DISEASE", 226, 241], ["acute lung injury", "DISEASE", 282, 299], ["lung", "ORGAN", 288, 292], ["cell lines", "CELL", 303, 313], ["cell lines", "CELL_LINE", 303, 313], ["Lobeline", "TREATMENT", 0, 8], ["respiratory disorders", "PROBLEM", 125, 146], ["asthma", "PROBLEM", 156, 162], ["a stimulant", "TREATMENT", 167, 178], ["wheezing", "PROBLEM", 188, 196], ["uncontrollable coughing", "PROBLEM", 198, 221], ["chest tightness", "PROBLEM", 226, 241], ["acute lung injury in cell lines", "PROBLEM", 282, 313], ["plants", "OBSERVATION", 35, 41], ["Lobelia genus", "ANATOMY", 49, 62], ["chest", "ANATOMY", 226, 231], ["acute", "OBSERVATION_MODIFIER", 282, 287], ["lung", "ANATOMY", 288, 292], ["injury", "OBSERVATION", 293, 299], ["cell lines", "OBSERVATION", 303, 313]]], ["There have been promising studies carried out on mice where lobeline helped to treat acute lung injury [83] , but human studies are still required.", [["lung", "ANATOMY", 91, 95], ["lobeline", "CHEMICAL", 60, 68], ["acute lung injury", "DISEASE", 85, 102], ["mice", "ORGANISM", 49, 53], ["lung", "ORGAN", 91, 95], ["human", "ORGANISM", 114, 119], ["mice", "SPECIES", 49, 53], ["human", "SPECIES", 114, 119], ["mice", "SPECIES", 49, 53], ["human", "SPECIES", 114, 119], ["promising studies", "TEST", 16, 33], ["lobeline", "TREATMENT", 60, 68], ["acute lung injury", "PROBLEM", 85, 102], ["human studies", "TEST", 114, 127], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["lung", "ANATOMY", 91, 95], ["injury", "OBSERVATION", 96, 102]]], ["Nicotine induces ACE2 overexpression in Human Bronchial Epithelial Cells (HBEpC) via alpha7-nicotinic receptor (\u02517-nAChR) [84] , a paralog of NACHR9.", [["Bronchial Epithelial Cells", "ANATOMY", 46, 72], ["HBEpC", "ANATOMY", 74, 79], ["Nicotine", "CHEMICAL", 0, 8], ["Nicotine", "CHEMICAL", 0, 8], ["Nicotine", "SIMPLE_CHEMICAL", 0, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["Human", "ORGANISM", 40, 45], ["Bronchial Epithelial Cells", "CELL", 46, 72], ["HBEpC", "CELL", 74, 79], ["alpha7-nicotinic receptor", "GENE_OR_GENE_PRODUCT", 85, 110], ["\u02517-nAChR", "GENE_OR_GENE_PRODUCT", 112, 120], ["NACHR9", "GENE_OR_GENE_PRODUCT", 142, 148], ["ACE2", "PROTEIN", 17, 21], ["Human Bronchial Epithelial Cells", "CELL_TYPE", 40, 72], ["alpha7", "PROTEIN", 85, 91], ["nicotinic receptor", "PROTEIN", 92, 110], ["\u02517-nAChR", "PROTEIN", 112, 120], ["NACHR9", "PROTEIN", 142, 148], ["Human", "SPECIES", 40, 45], ["Human", "SPECIES", 40, 45], ["Nicotine", "TREATMENT", 0, 8], ["ACE2 overexpression in Human Bronchial Epithelial Cells", "PROBLEM", 17, 72], ["HBEpC", "TEST", 74, 79], ["alpha7-nicotinic receptor", "TREATMENT", 85, 110], ["a paralog of NACHR9", "TREATMENT", 129, 148], ["ACE2 overexpression", "OBSERVATION", 17, 36], ["Bronchial Epithelial Cells", "OBSERVATION", 46, 72], ["alpha7", "ANATOMY", 85, 91]]], ["Galantamine is a reversible, competitive inhibitor of acetylcholinesterase (AChE), which catalyses the breakdown of ACE, and is an allosteric modulator of nAChRs.", [["Galantamine", "CHEMICAL", 0, 11], ["Galantamine", "CHEMICAL", 0, 11], ["Galantamine", "SIMPLE_CHEMICAL", 0, 11], ["acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 54, 74], ["AChE", "GENE_OR_GENE_PRODUCT", 76, 80], ["ACE", "GENE_OR_GENE_PRODUCT", 116, 119], ["acetylcholinesterase", "PROTEIN", 54, 74], ["AChE", "PROTEIN", 76, 80], ["ACE", "PROTEIN", 116, 119], ["nAChRs", "PROTEIN", 155, 161], ["Galantamine", "TREATMENT", 0, 11], ["acetylcholinesterase (AChE)", "TREATMENT", 54, 81], ["ACE", "TREATMENT", 116, 119], ["reversible", "OBSERVATION_MODIFIER", 17, 27], ["breakdown", "OBSERVATION_MODIFIER", 103, 112]]], ["It is currently approved for mild to moderate dementia and Alzheimer's.QuercetinQuercetin is a polyphenol flavonoid found in many plants [85] and has been reported as having anti-inflammatory and anti-viral properties [86, 87] .", [["dementia", "DISEASE", 46, 54], ["Alzheimer", "DISEASE", 59, 68], ["QuercetinQuercetin", "CHEMICAL", 71, 89], ["polyphenol flavonoid", "CHEMICAL", 95, 115], ["QuercetinQuercetin", "CHEMICAL", 71, 89], ["polyphenol", "CHEMICAL", 95, 105], ["flavonoid", "CHEMICAL", 106, 115], ["QuercetinQuercetin", "SIMPLE_CHEMICAL", 71, 89], ["polyphenol", "SIMPLE_CHEMICAL", 95, 105], ["mild to moderate dementia", "PROBLEM", 29, 54], ["Alzheimer's", "PROBLEM", 59, 70], ["QuercetinQuercetin", "TREATMENT", 71, 89], ["a polyphenol flavonoid", "TREATMENT", 93, 115], ["anti-inflammatory and anti-viral properties", "TREATMENT", 174, 217], ["moderate", "OBSERVATION_MODIFIER", 37, 45], ["dementia", "OBSERVATION", 46, 54], ["Alzheimer", "OBSERVATION", 59, 68], ["polyphenol flavonoid", "OBSERVATION", 95, 115]]], ["In one of the PFIN clusters, quercetin was identified as targeting the human protein casein kinase II subunit beta (CK2-beta) protein (P67870, localised throughout the cell), which Gordon et al. reported as being a high-confidence interactor of the SARS-CoV-2 N protein [27] .", [["cell", "ANATOMY", 168, 172], ["quercetin", "CHEMICAL", 29, 38], ["SARS", "DISEASE", 249, 253], ["PFIN", "CHEMICAL", 14, 18], ["quercetin", "CHEMICAL", 29, 38], ["quercetin", "SIMPLE_CHEMICAL", 29, 38], ["human", "ORGANISM", 71, 76], ["casein kinase II subunit beta", "GENE_OR_GENE_PRODUCT", 85, 114], ["CK2-beta", "GENE_OR_GENE_PRODUCT", 116, 124], ["cell", "CELL", 168, 172], ["human protein casein kinase II subunit beta (CK2-beta) protein", "PROTEIN", 71, 133], ["P67870", "PROTEIN", 135, 141], ["SARS-CoV-2 N protein", "PROTEIN", 249, 269], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["quercetin", "TREATMENT", 29, 38], ["the human protein casein kinase", "TEST", 67, 98], ["subunit beta (CK2-beta) protein", "TEST", 102, 133], ["the SARS", "TEST", 245, 253], ["CoV", "TEST", 254, 257]]], ["Two CK2-beta molecules, together with a single alpha and alpha' subunit together form the tetramer casein kinases II (CK2).", [["CK2-beta", "GENE_OR_GENE_PRODUCT", 4, 12], ["alpha' subunit", "GENE_OR_GENE_PRODUCT", 57, 71], ["casein kinases II", "GENE_OR_GENE_PRODUCT", 99, 116], ["CK2", "GENE_OR_GENE_PRODUCT", 118, 121], ["CK2-beta molecules", "PROTEIN", 4, 22], ["alpha and alpha' subunit", "PROTEIN", 47, 71], ["tetramer casein kinases II", "PROTEIN", 90, 116], ["CK2", "PROTEIN", 118, 121], ["Two CK2", "TEST", 0, 7], ["a single alpha and alpha' subunit", "TREATMENT", 38, 71], ["beta molecules", "OBSERVATION_MODIFIER", 8, 22]]], ["CK2 acts as a serine/threonine-selective protein kinase, involved in cell cycle regulation, and is implicated in disorders of cell proliferation (e.g. tumours) [88] .QuercetinInterestingly, CK2 has been found to be stimulated in other viral infections [89] , and has various roles in the infection cycles of different viruses [90, 91] .", [["cell", "ANATOMY", 69, 73], ["cell", "ANATOMY", 126, 130], ["tumours", "ANATOMY", 151, 158], ["QuercetinInterestingly", "CHEMICAL", 166, 188], ["viral infections", "DISEASE", 235, 251], ["infection", "DISEASE", 288, 297], ["serine", "CHEMICAL", 14, 20], ["threonine", "CHEMICAL", 21, 30], ["CK2", "GENE_OR_GENE_PRODUCT", 0, 3], ["serine", "AMINO_ACID", 14, 20], ["threonine", "AMINO_ACID", 21, 30], ["cell", "CELL", 69, 73], ["cell", "CELL", 126, 130], ["tumours", "CANCER", 151, 158], ["CK2", "GENE_OR_GENE_PRODUCT", 190, 193], ["CK2", "PROTEIN", 0, 3], ["serine/threonine-selective protein kinase", "PROTEIN", 14, 55], ["CK2", "PROTEIN", 190, 193], ["CK2 acts", "TEST", 0, 8], ["a serine/threonine", "TEST", 12, 30], ["selective protein kinase", "TEST", 31, 55], ["cell proliferation", "PROBLEM", 126, 144], ["other viral infections", "PROBLEM", 229, 251], ["the infection cycles of different viruses", "PROBLEM", 284, 325], ["cell cycle", "OBSERVATION", 69, 79], ["cell proliferation", "OBSERVATION", 126, 144], ["viral", "OBSERVATION_MODIFIER", 235, 240], ["infections", "OBSERVATION", 241, 251], ["infection", "OBSERVATION", 288, 297]]], ["Further, Gordon et al.Quercetinsuggested CK2 inhibition as a possible therapeutic approach for COVID-19 [60] , as CK2Quercetindownregulates stress granule formation [92] which is associated with enhanced viral replication in other coronavirus infections [93] .", [["stress granule", "ANATOMY", 140, 154], ["COVID-19 [60]", "CHEMICAL", 95, 108], ["coronavirus infections", "DISEASE", 231, 253], ["COVID-19", "CHEMICAL", 95, 103], ["CK2", "GENE_OR_GENE_PRODUCT", 41, 44], ["CK2Quercetindownregulates", "SIMPLE_CHEMICAL", 114, 139], ["stress granule", "CELLULAR_COMPONENT", 140, 154], ["coronavirus", "ORGANISM", 231, 242], ["CK2", "PROTEIN", 41, 44], ["CK2 inhibition", "TREATMENT", 41, 55], ["COVID", "TEST", 95, 100], ["CK2Quercetindownregulates stress granule formation", "PROBLEM", 114, 164], ["enhanced viral replication in other coronavirus infections", "PROBLEM", 195, 253], ["viral replication", "OBSERVATION", 204, 221]]], ["Thus, depending on the nature of the interaction between quercetin and CK2, it may be of benefit.QuercetinQuercetin has already been suggested as a possible therapeutic to mitigate the severity of SARS-CoV-2 infection, as quercetin alters the expression of 30% of the human proteins that are targets of SARS-CoV-2 proteins [94] .DiscussionIn summary, this study aimed to build on existing studies that have used knowledge frameworks to generate hypotheses about drug repurposing opportunities for COVID-19.", [["quercetin", "CHEMICAL", 57, 66], ["QuercetinQuercetin", "CHEMICAL", 97, 115], ["SARS", "DISEASE", 197, 201], ["infection", "DISEASE", 208, 217], ["quercetin", "CHEMICAL", 222, 231], ["quercetin", "CHEMICAL", 57, 66], ["QuercetinQuercetin", "CHEMICAL", 97, 115], ["quercetin", "CHEMICAL", 222, 231], ["COVID-19", "CHEMICAL", 497, 505], ["quercetin", "SIMPLE_CHEMICAL", 57, 66], ["CK2", "GENE_OR_GENE_PRODUCT", 71, 74], ["QuercetinQuercetin", "SIMPLE_CHEMICAL", 97, 115], ["SARS-CoV-2", "ORGANISM", 197, 207], ["quercetin", "SIMPLE_CHEMICAL", 222, 231], ["human", "ORGANISM", 268, 273], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 303, 313], ["CK2", "PROTEIN", 71, 74], ["human proteins", "PROTEIN", 268, 282], ["SARS-CoV-2 proteins", "PROTEIN", 303, 322], ["human", "SPECIES", 268, 273], ["SARS-CoV-2", "SPECIES", 197, 207], ["human", "SPECIES", 268, 273], ["quercetin and CK2", "TREATMENT", 57, 74], ["QuercetinQuercetin", "TREATMENT", 97, 115], ["SARS", "PROBLEM", 197, 201], ["CoV", "PROBLEM", 202, 205], ["2 infection", "PROBLEM", 206, 217], ["quercetin", "TREATMENT", 222, 231], ["the human proteins", "TEST", 264, 282], ["SARS", "TEST", 303, 307], ["CoV", "TEST", 308, 311], ["this study", "TEST", 351, 361], ["existing studies", "TEST", 380, 396], ["COVID", "TEST", 497, 502], ["SARS", "OBSERVATION", 197, 201], ["infection", "OBSERVATION", 208, 217]]], ["As in other studies, an integrated dataset was developed, extending a drug repurposing framework developed by Mullen et al. [47] .", [["other studies", "TEST", 6, 19]]], ["We aimed to enhance the knowledge network approach through the use of PFINs to act as a framework to guide the hypothesis generation process.", [["PFINs", "SIMPLE_CHEMICAL", 70, 75], ["PFINs", "TREATMENT", 70, 75], ["the hypothesis generation process", "PROBLEM", 107, 140]]], ["The use of PFINs allowed us to scale the data curation process in a systematic fashion, exploiting the combined effort of multiple curators.", [["PFINs", "TREATMENT", 11, 16], ["multiple curators", "TREATMENT", 122, 139]]], ["Our approach could act as a template for future studies, with richer knowledge graphs, the incorporation of algorithmic predictions for drug repurposing and a much larger set of curators.", [["future studies", "TEST", 41, 55], ["drug repurposing", "TREATMENT", 136, 152]]], ["The drugs we identified for repurposing are illustrative of the value of our approach.", [["The drugs", "TREATMENT", 0, 9]]], ["Due to the rapidly developing nature of studies on SARS-CoV-2 and COVID-19, it is difficult to identify which candidates are truly novel, however, even in instances where candidates have already been suggested by other studies, our approach can still provide additional supporting (or refuting) evidence.DiscussionThe results presented in this study are grouped by drug class.", [["SARS", "DISEASE", 51, 55], ["COVID-19", "CELL", 66, 74], ["SARS-CoV", "SPECIES", 51, 59], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["COVID", "TEST", 66, 71], ["this study", "TEST", 339, 349]]], ["Where possible, we have tried to avoid suggesting specific instances of drugs (and focused on classes instead), in part because we recognise that our database is not complete.", [["drugs", "TREATMENT", 72, 77]]], ["However, there are some noteworthy cases where focusing on specific drugs within a class is necessary.DiscussionFor example, fostamatinib has emerged as a drug candidate in a number of different contexts as an anti-inflammatory agent, as an EGFR inhibitor, and as a cathepsin L inhibitor, establishing it as a promising candidate.DiscussionOne limitation of in silico drug repurposing studies is that, depending on the algorithms employed, many drug repurposing candidates can be suggested.", [["fostamatinib", "CHEMICAL", 125, 137], ["fostamatinib", "CHEMICAL", 125, 137], ["fostamatinib", "SIMPLE_CHEMICAL", 125, 137], ["EGFR", "GENE_OR_GENE_PRODUCT", 241, 245], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 266, 277], ["specific drugs", "TREATMENT", 59, 73], ["an anti-inflammatory agent", "TREATMENT", 207, 233], ["an EGFR inhibitor", "TREATMENT", 238, 255], ["a cathepsin L inhibitor", "TREATMENT", 264, 287], ["some", "OBSERVATION_MODIFIER", 19, 23], ["noteworthy", "OBSERVATION_MODIFIER", 24, 34], ["cases", "OBSERVATION", 35, 40]]], ["Refinement of a large set of drug candidates often requires many person-hours of time to curate, particularly when including time taken to understand the mechanisms / pathways involved.", [["large", "OBSERVATION_MODIFIER", 16, 21]]], ["By (1) leveraging a PFIN-based clustering approach and (2) focusing on clusters containing high-confidence interactors with SARS-CoV-2 proteins, we were able to reduce the drug candidate search space significantly.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 124, 134], ["SARS-CoV-2 proteins", "PROTEIN", 124, 143], ["a PFIN", "TEST", 18, 24], ["high-confidence interactors", "PROBLEM", 91, 118], ["SARS", "PROBLEM", 124, 128]]], ["Using a crowd-sourcing approach to analyse the clusters allowed individuals to curate sets of drug candidates that were likely to be mechanistically related, providing a logical partitioning of work.", [["a crowd-sourcing approach", "TREATMENT", 6, 31], ["drug candidates", "TREATMENT", 94, 109]]], ["Curation allowed us to focus on drugs with additional context (e.g., pharmacological, biological) evidence to support or refute the drugs discussed, thus providing a balanced perspective on the drugs discussed.", [["drugs", "TREATMENT", 32, 37], ["the drugs", "TREATMENT", 128, 137], ["the drugs", "TREATMENT", 190, 199]]], ["In future studies, it might be interesting to research systematic and computational approaches to integrating and ranking the findings of curators, perhaps building on larger systems for data sharing and integration such as FAIRDOMHub [95] .DiscussionThere are a number of caveats to this research which need to be addressed to ensure results are taken in an appropriate context.", [["future studies", "TEST", 3, 17]]], ["Firstly, the data sources contributing to our integrated semantic network are limited in scope and could be expanded.", [["could be", "UNCERTAINTY", 99, 107], ["expanded", "OBSERVATION", 108, 116]]], ["For example, the graph includes connections between drugs and their protein targets, but the nature (e.g.Discussion\"inhibitory\", \"stimulatory\", \"suppressor\") is not always recorded.", [["drugs", "TREATMENT", 52, 57]]], ["Secondly, computational prediction can only ever generate suggestions or hypotheses based on the analysis of the limited data available.", [["the analysis", "TEST", 93, 105]]], ["Thus, for any drug repurposing candidates suggested, it is critical that these are manually curated by experts in medicine, pharmacology, and human biology.", [["human", "ORGANISM", 142, 147], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147]]], ["Due to recent concerns over the potential for harm in COVID-19 preprints, we want to stress that this research should not be used to inform clinical practice, nor should people change their behaviour on the basis of it [96] .DiscussionSupporting information S1", [["people", "ORGANISM", 170, 176], ["people", "SPECIES", 170, 176]]]]}